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Abstract 
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maze 
Phencyclidine (PCP) is a non-competitive NMDA receptor antagonist that has been 
shown to induce schizophrenia-like psychotic symptoms that are clinically 
indistinguishable from schizophrenia in patients. When administered to rodents, PCP 
produces an array of behaviours that are characteristic of schizophrenia. 
Schizophrenia is associated with continual and treatment resistant cognitive deficits 
which are now recognised as a core feature of the disease.   
The aim of the studies reported in chapter 3 were to establish a set of objects with 
equal preference in the NOR (novel object recognition) test. Furthermore, the inter-
trial-interval (ITI) of the NOR test was investigated in an attempt to elucidate the 
effects of time and location of the rats during the ITI on the cognitive impairments 
following sub-chronic PCP treatment. The experiments in chapter 4 were designed to 
compare the performance of male and female rats in the NOR test following 
treatment with acute d-amphetamine (d-amph), PCP and sub-chronic PCP treatment. 
In chapter 5, validation of the cognitive deficits induced by sub-chronic PCP 
treatment was assessed using carefully selected pharmacological agents. The aim of 
the studies in chapter 6 was to determine the effects of isolation rearing on cognitive 
performance in the NOR test following increasing ITIs. Additionally, the sensitivity 
of isolation reared rats compared to social controls following acute administration of 
PCP and d-amph was assessed using the NOR test. Studies in chapter 8 utilised the 
16-holeboard maze to determine the effects of acute treatment with d-amphetamine, 
PCP and scopolamine on working memory in the rat. 
NOR is a visual learning and memory test that measures recognition memory which 
is impaired in patients with schizophrenia. Studies presented in this thesis 
demonstrate the importance of careful pilot studies when selecting objects for use in 
the NOR test. Initial studies in sub-chronic PCP (2 mg/kg for 7 days followed by 7 
days drug free) treated female hooded-Lister rats revealed a preference of the rats for 
the wooden cone object; subsequently this object was eliminated from further NOR 
experiments. 
Sub-chronic PCP treated rats were found to be highly susceptible to the disruptive 
influence of distraction during the short 1 min inter-trial-interval (ITI) in the NOR 
test. These results are consistent with clinical findings of the effects of distraction on 
cognition in schizophrenia patients. Following the initial validation experiments, a 1 
min ITI in the home cage was selected for all subsequent NOR studies. Further 
experiments provided evidence to confirm that information presented in the 
acquisition trial is encoded but not retained in the retention trial of the NOR test by 
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PCP-treated rats. Male rats were less sensitive to the recognition memory deficits 
induced by acute treatment with PCP and d-amphetamine compared with females. 
Following sub-chronic PCP treatment, both males and females showed object 
recognition deficits, however, the impairments were more robust in female rats.  
Female rats were therefore selected for all subsequent experiments. 
Pharmacological validation was carried out using carefully selected agents which 
were assessed for their ability to restore the sub-chronic PCP induced cognitive 
deficit in the object recognition test. It was found that the classical antipsychotic 
agents haloperidol and fluphenazine, the benzodiazepine anxiolytic chlordiazepoxide 
and the SSRI antidepressant fluoxetine were ineffective. Further studies showed that 
the atypical antipsychotic agents, clozapine and risperidone, the analeptic agent 
modafinil, the nAChR full agonist nicotine, and full agonist and positive allosteric 
modulator of the α7 nAChR (PNU-282987 and PNU120596 respectively) reversed 
the recognition memory deficit induced by sub-chronic  PCP treatment in the NOR 
test. 
Isolation rearing of rats at weaning is an environmental stressor that has relevance 
for modelling the symptomatology and pathology of schizophrenia. Isolates had a 
significantly increased locomotor activity (LMA) response to a novel environment 
and enhanced sensitivity to time delay-induced recognition memory deficits, 
compared with their socially reared counterparts. Isolates were less sensitive to an 
acute PCP-induced recognition memory deficit but more sensitive to an acute d-
amphetamine induced recognition memory deficit in the NOR test compared to 
social controls.  
Preliminary results from the 16-holeboard maze experiments reveal that acute 
administration of the mAChR antagonist scopolamine, d-amphetamine, PCP and 
sub-chronic PCP treatment reduced working memory scores compared to vehicle 
treated controls.  
Taken together, these findings suggest that sub-chronic treatment with PCP induces 
cognitive deficits in behavioural tests of relevance to cognition associated with 
schizophrenia. This may allow the detection of novel pharmacotherapies to alleviate 
these cognitive deficits and exploration of the nature of cognitive disturbances in 
these patients. 
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1.1 General Introduction 
1.1.1 Symptomology 
Schizophrenia is a psychiatric disease that is chronic, severe and highly debilitating 
to the patients that are inflicted. It is a highly complex clinical disorder, displaying a 
huge variety of incapacitating symptoms. The current worldwide morbidity of 
schizophrenia is almost 1% of the population (Trivedi & Jarbe, 2011) and reports 
have suggested that schizophrenia costs the NHS more than any other mental illness, 
consuming more than 5% of the total budget  (Hargreaves, 2003). Schizophrenia was 
termed demense precose (dementia praecox), a Latin phrase meaning "mental 
deterioration at an early age", a syndrome affecting teenagers and young adults by 
Benedict Morel in 1853. In 1887, Dr. Emile Kraepelin classified the symptoms of 
dementia praecox, with emphasis on the early age of onset and the deteriorating 
course of the illness as defining criteria.  
In 1908, Eugen Bleuler was the first to use the term schizophrenia “the breaking up 
or splitting of psychic functioning”,; he rejected Kraepelins emphasis on the early 
onset and deteriorating course of the disease. Bleuler went on to describe 
schizophrenia as a group of disorders, patients with mild and severe forms, acute and 
chronic with both poor and encouraging outcomes. 
Schizophrenia symptoms are currently divided into positive, negative and cognitive 
symptoms. 
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1.1.1.1 Positive Symptoms 
The diagnostic and statistical manual of mental disorders, 4
th
 edition text revision 
(DSM–IV TR) is currently used by clinicians and psychiatrists in the US to diagnose 
psychiatric illnesses.  For schizophrenia to be diagnosed, patients need to exhibit at 
least 1-month duration of two or more of the positive or negative symptoms. The 
positive symptoms are usually satisfactorily treated with antipsychotic medication 
(Feldman et al, 1997). The symptoms include: 
Delusions: False beliefs that are strongly held despite evidence to suggest otherwise. 
The delusions can be subdivided into paranoid delusions, delusions of reference, 
somatic delusions and delusions of grandeur. 
Hallucinations: Mainly auditory, visual, tactile, olfactory and gustatory. 
Disorganised speech: Moving swiftly through multiple topics, confused and 
repetitive speech and use of unrelated words without meaning. 
Catatonic behaviour: Physical immobility, excessive mobility, extreme resistance 
and peculiar movements (DSM–IV TR). 
1.1.1.2 Negative Symptoms 
The negative symptoms are feelings, thoughts and behaviours that are normally 
present that are absent or diminished in patients suffering from schizophrenia. The 
negative symptoms are often more difficult to diagnose than the positive symptoms 
because they represent a lesser degree of normal, rather than the presence of 
undesirable or bizarre behaviours. The negative symptoms not only arise from the 
pathology of the disease but can also develop as secondary negative symptoms 
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related to antipsychotic medication.  It has been reported that both classical and 
atypical antipsychotic agents have been shown to induce negative symptoms in 
healthy controls (Artaloytia et al, 2006) and exacerbate the primary negative 
symptoms in patients with schizophrenia. Conversely, atypical antipsychotics have 
also been shown to improve the negative symptoms of schizophrenia in certain 
patients (Meltzer, 1999). The negative symptoms include: 
Affective flattening: Reduction in the range and intensity of emotional expression, 
including facial expression, voice tone, eye contact, and body language. 
Alogia: Lessening of speech fluency and productivity, thought to reflect slowing or 
blocked thoughts, and often manifested as laconic, empty replies to questions. 
Avolition: Reduction, difficulty, or inability to initiate and persist in goal-directed 
behaviour; it is often mistaken for apparent disinterest. (Source DSM IV and ICD-10, 
2010). 
1.1.1.3 Cognitive Symptoms 
Since 1851 when the term ‘dementia praecox’ was used, impairments in cognitive 
function have been recognised and described as a core feature of the disease.  
Patients with schizophrenia show deficits in a variety of cognitive domains.  The 
cognitive symptoms refer to difficulties with concentration and memory. These may 
include the following; disorganised thinking, slow thinking, difficulty understanding, 
poor concentration, poor memory, difficulty expressing thoughts, difficulty 
integrating thoughts, feelings and behaviour. 
There is increasing evidence suggesting that cognitive deficits, particularly 
attentional deficits (Byrne et al, 1999; Lewis, 2004), verbal memory impairments 
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(Whyte et al, 2006) and other cognitive impairments (Niemi et al, 2003) are already 
present and detectable in adolescents, prior to the onset of illness, in subjects with 
high susceptibility to schizophrenia and in first-episode schizophrenia patients. 
Furthermore, many studies over the past 25 years have demonstrated that first degree 
relatives compared to second degree relatives of patients with schizophrenia exhibit 
greater cognitive deficits (see review by Snitz et al, 2006). Schizophrenia patients 
demonstrate cognitive impairments within various cognitive domains, which include 
memory and language, executive function and attention. 
Working memory has been described as the temporary “online” storage and the 
subsequent retrieval and manipulation of information (Baddelay & Hitch, 1974). 
This domain of memory has an important functional role in briefly retaining 
information and allowing it to be used rapidly.  Working memory dysfunction is 
increasingly recognised as a core feature in patients with schizophrenia (Thormodsen 
et al, 2011) 
The cognitive aspect of schizophrenia has huge implications on lifestyle and impacts 
on ability to function within the community, at school, work and to form and 
maintain relationships. The cognitive impairments observed in schizophrenia are 
shown to be associated with functional outcome and studies have shown that 
cognitive deficits are the most reliable predictor of this outcome (Green et al, 2000). 
Patients vary in the types of cognitive dysfunctions they exhibit; however, the level 
of cognitive impairment generally remains stable over time and throughout the 
course of the disease. 
Cognition is becoming the main target for schizophrenia therapy and recently the 
National Institute of Mental Health (NIMH) introduced the Measurement and 
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Treatment Research to Improve Cognition in Schizophrenia, known as the 
MATRICS Initiative. The MATRICS initiative’s aim was to identify the worst 
affected cognitive domains and develop a clinical test battery targeting these 
domains. The MATRICS Consensus Cognitive Battery (MCCB) is intended to 
provide a relatively brief evaluation of the key cognitive domains (see table 1) 
relevant to schizophrenia and related disorders, and was designed to facilitate the 
research and development of novel pharmacological approaches for treating the 
cognitive impairments associated with schizophrenia (http://www.matrics.ucla.edu).  
Tests used to measure Cognitive Performance in adults with Schizophrenia and related 
disorders 
Cognitive 
Domain 
Test Description 
Speed of 
Processing 
Brief Assessment of Cognition in 
Schizophrenia (BACS): 
Symbol-Coding 
Timed paper and pencil test in which respondent uses a key to 
write digits that correspond to nonsense symbols 
Category Fluency: Animal Naming 
Oral test in which respondent names as many animals as he/she 
can in one minute. 
Trail Making Test: Part A 
Timed paper and pencil test in which the respondent draws a 
line to connect consecutively numbered circle placed 
irregularly on a sheet of paper. 
Attention / 
Vigilance 
Continuous Performance Test - 
Identical Pairs (CPT-IP) 
Computer administered measure of sustained attention in 
which respondent presses a response button to consecutive 
matching numbers. 
Working 
Memory 
(Nonverbal) 
(verbal) 
Wechsler Memory Scale - 3
rd
 Ed. Using a board on which ten cubes are irregularly spaced, 
respondent taps cubes in same (or reverse) sequence as test 
administrator. (WMS-III): Spatial Span 
Letter-Number Span 
Orally administered test in which respondent mentally reorders 
strings of numbers and letters and repeats them to 
administrator. 
Verbal 
Learning 
Hopkins Verbal Learning Test - 
Revised (HVLT-R) 
Orally administered test in which a list of twelve words from 
three taxonomic categories is presented and the respondent is 
asked to recall as many as possible after each of three learning 
trials. 
Visual 
Learning 
Brief Visuospatial Memory Test - 
Revised (BVMT-R) 
A test that involves reproducing six geometric figures from 
memory. 
Reasoning 
and Problem 
Solving 
Neuropsychological Assessment 
Battery (NAB): Mazes 
Seven timed paper and pencil mazes of increasing difficulty 
that measure foresight and planning. 
Social 
Cognition 
Mayer-Solovey-Caruso Emotional 
Intelligence Test (MSCEIT): 
Managing Emotions 
Paper and pencil multiple choice test that assesses how people 
manage their emotions 
 
Table 1 The key cognitive domains as outlined by the MATRICS initiative to test and assess 
performance (www.matrics.ucla.edu). 
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1.1.2 Aetiology of Schizophrenia 
Schizophrenia is a highly complex disorder and likely to be derived from an 
interaction between genetic, behavioural and developmental components. 
1.1.2.1 Genetics 
There have been numerous epidemiological studies into schizophrenia, looking at 
family, twin and adoption studies, showing overwhelming evidence to suggest that 
pre-disposition to developing the illness is significantly increased in relatives of 
individuals who are already suffering from schizophrenia, thus depicting a strong 
genetic link (Pedersen & Mortensen, 2001; Owen et al, 2005; Mortensen et al, 2010). 
The data from monozygotic twin studies have shown a 41-65% presence of 
schizophrenia in both pairs of twins compared to 0-28% in dizygotic twins, with 
heritability estimates at approximately 85%, which means schizophrenia is one of the 
most hereditable medical disorders (Craddock et al, 2005). Furthermore, the risk of 
schizophrenia in progeny of both the affected and unaffected monozygotic twins is 
similar, which means that the unaffected twin carries the hereditable genetic material 
for developing the illness without expressing schizophrenia themselves (Kety et al, 
1994). 
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Figure 1 Percentage rates of developing schizophrenia when there is a family history of the 
disease (taken from Gottesman, 1991). 
Experiments using linkage analysis and quantitative trait locus analysis have shown 
numerous chromosomal regions with nucleotide sequences that relate to phenotypes. 
These findings have led to detailed mapping studies of linked regions with the 
association of specific predisposing genes for schizophrenia. In the review by Owen 
(2005), the genes with the most information available and implicated in 
schizophrenia are those that encode dysbindin (DTNBP1), neuregulin1 (NRG1), D-
amino-acid oxidase activator (DAOA; which was known as G72) and regulator of G-
protein signalling 4 (RGS4), Dysbindin, catechol-O-methyltransferase (COMT), 
proline dehydrogenase (PRODH), Asp-His-His-Cys (DHHC), disrupted in 
schizophrenia DISC1 and DISC2, metabotropic glutamate receptor-3 (GRM3; 
mGluR3). Many of the susceptibility genes that have been identified for 
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schizophrenia are known to regulate neuronal connectivity, synaptogenesis, and N-
methyl-D-aspartate (NMDA) glutamate receptor functions. Hypothetically, 
converging molecular abnormalities expressed by defective versions of these genes 
could cause dysregulation of NMDA receptors and NMDA synapses, leading to 
vulnerability for schizophrenia due to inefficient information processing at glutamate 
synapses (Stahl, 2007). 
1.1.2.2 Neurodevelopment 
Clearly genetic risk factors play an important role in the aetiology of schizophrenia, 
however there is a vast amount of literature available describing a non-genetic basis 
for schizophrenia.  
Studies have shown that the possibility of developing schizophrenia seems to begin 
as early as the first trimester (0-90 days) of pregnancy, with a 7-fold increase in the 
risk of developing schizophrenia and schizophrenia spectrum disorders following the 
exposure to influenza (Brown et al, 2004), whereas the second and third trimester of 
pregnancy showed no increased susceptibility (Opler & Susser, 2005). Other 
researchers have indicated that the second trimester of pregnancy confirms the 
greatest risk for schizophrenia (Sullivan et al, 2006). Brown and colleagues (2001) 
also demonstrated a 20.4% increase in the susceptibility to schizophrenia following 
early prenatal exposure to the rubella virus. However the rubella virus has been 
shown to be active up to 18 months following birth, which could mean that the pro-
schizophrenia risk caused by the rubella virus could actually be a postnatal effect 
(South & Sever, 1985). Subsequent studies have shown a large increase in subjects 
which were recently diagnosed with schizophrenia, 28.6% compared to 5% of 
chronic patients that test positively for the retroviral polymerase genes in the cerebral 
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spinal fluid (Karlsson et al, 2001).   The presence of maternal antibodies to the 
parasitic protozoa Toxoplasma gondii, which can be transmitted to the mother from 
contact with cat faeces or from eating undercooked meat, has been shown to increase 
the risk of developing schizophrenia by 2.5% (Torrey & Yolken, 2003).  
A study in 2008 by Khashan and colleagues suggests that severe stress to a mother 
during the first trimester of pregnancy may alter the risk of schizophrenia in 
offspring. Results from this study showed that the stress of a first relative dying or a 
relative being diagnosed with cancer, acute myocardial infarction, or stroke 
syndrome up to 6 months before conception or during pregnancy increased the risk 
of child developing schizophrenia (adjusted relative risk, 1.67 [95% confidence 
interval, 1.02-2.73]). The season of birth has also been implicated in schizophrenia; 
patients are more likely to be born during the winter months. The increased risk is 
approximately 10% for those born in winter compared to summer births (Torrey, 
1997). The relationship between the increase in the incidence of schizophrenia and 
winter births may be explained by the timing of the peak flu season during the early 
stages of pregnancy. It is widely recognised that individuals with schizophrenia were 
more likely to have experienced a cluster of obstetric complications involving 
hypoxia than were controls (Clarke et al, 2006). In addition, interesting interactions 
have been described between foetal hypoxia and genetic risk for schizophrenia on 
brain structure. One particular study found that a history of foetal hypoxia is 
associated with greater structural brain abnormalities in groups with schizophrenia 
than among controls (Cannon et al, 2002). Schizophrenia patients have been shown 
to have lower mean birth weights compared to unaffected siblings (McNeil et al, 
1993). Furthermore, in a monozygotic twin study, the patient with schizophrenia was 
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significantly more likely to have a lighter birth weight than their co-twins (Torrey, 
1977).  
1.1.3 Epidemiology of Schizophrenia 
Socioeconomic class has been shown to influence the susceptibility to developing 
schizophrenia. People belonging to the “working class” social group are 
approximately five times more likely to develop schizophrenia than people in the 
other social classes (Mulvany et al, 2001; Muntaner et al, 2004).  
Ethnic status has frequently been related to differential predisposition to 
schizophrenia. Immigrants to the UK from the Caribbean and Africa have ten times 
the prevalence of schizophrenia compared to other members of the population 
(Harrison et al, 1988; Wessley et al, 1991), whereas other non-black immigrants do 
not show such an increased risk (Cooper, 2005). The increased risk of schizophrenia 
in the Caribbean and African immigrants to the UK cannot be solely attributed to 
genetics since the origin of birth countries do not show an increased risk of 
developing schizophrenia. 
Gender has been known to influence risk of developing schizophrenia since as early 
as 1919-1971, when Kraepelin described dementia praecox as a disorder that mostly 
affected young men. The age of onset of schizophrenia in men is earlier compared to 
women, with most studies reporting onset in the early 20s for men and late 20s in 
women (for review see Salem & Kring, 1998). Men are at increased risk of 
developing schizophrenia with male:female incidence of approximately 1.4:1 (Able 
et al, 2010). Men also have worse symptomatology, express more negative 
symptoms and show poorer response to certain medication (Leung and Chue 2000; 
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Moriarty et al, 2001; Canuso & Pandina, 2007). These differences in the onset of 
schizophrenia in men and women could be attributed to the putative anti-
dopaminergic effects of oestrogens (Lindamer et al, 1997; Cutter et al, 2003). 
Cannabis abuse has been shown to significantly reduce the age of onset of 
schizophrenia in male patients (Veen et al, 2004; Large et al, 2011) and also 
increased likelihood of developing schizophrenia in psychosis free people (van Os et 
al, 2010). In addition, it has been suggested that heavy cannabis use in adolescence 
can increase the risk of developing schizophrenia later in life (Zammit et al, 2002). 
Further studies have demonstrated that schizophrenia subjects who previously 
exhibited psychotic symptomatology have poorer prognosis when using cannabis 
(Martinez-Arevalo et al, 1994).  
1.1.4 Neurochemistry and Schizophrenia 
1.1.4.1 Dopamine 
Dopamine is transmitted via four main pathways. The first is the mesolimbic 
pathway, and extends mostly from the ventral tegmental area (VTA; A10) and to a 
lesser extent from the retrorubal field (A8) and substantia nigra (A9) to the nucleus 
accumbens. The positive symptomatology of schizophrenia is likely to be modulated 
by the mesolimbic dopamine pathway. 
The second, mesocortical pathway, transmits dopamine from the VTA to the frontal 
cortex and is linked to negative symptoms and cognition. The third, the nigrostriatal 
pathway, transmits dopamine from the pars compacta of substantia nigra (A9), 
ascends via the medial forebrain bundle and innervates the striatum. This pathway is 
vital for motor coordination, movement and initiation of movement. Blockade of this 
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dopaminergic system, required for reducing psychosis, particularly using the 
classical antipsychotics, induces extrapyramidal side effects. 
The final main pathway is the tuberoinfundibular pathway, which transmits 
dopamine from the hypothalamus to the pituitary gland. Blockade of dopamine in 
this pathway prevents the inhibitory effect of dopamine on prolactin release which 
causes an increase in blood prolactin levels (hyperprolactinemia). Elevated prolactin 
levels can cause abnormal lactation (galactorrheoa) in men and women, disruptions 
to the menstrual cycle in women, headache, visual problems and sexual dysfunction 
(Stahl, 2000; Serri et al, 2003). 
In June 1974, [
3
H] haloperidol was prepared by Dr. P.A.J. Janssen (of Janssen 
Pharmaceutica, Beerse, Belgium) for Dr. Paul Seeman to detect the specific binding 
to striatal brain tissue (Seeman et al, 1975). The results confirmed that the 
“antipsychotic receptor” was in fact a dopamine receptor since dopamine was the 
most effective at inhibiting the binding of [
3
H] haloperidol. Subsequently, five 
dopamine receptors subtypes have been identified, all members of the super family 
of transmembrane domain, G-protein coupled receptors and cluster into D1-like and 
D2-like families of receptors. Two D1-like receptor subtypes (D1 and D5) couple to 
G-protein receptors Gq and Gs and activate adenlyl cyclase, whereas the D2-like 
receptor subtypes (D2, D3 and D4) couple to G-protein receptors Gi and Go and 
inhibit adenlyl cyclase. 
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                                  Dopamine receptors 
 
 
Figure 2 Dopamine receptor subtypes and their second messengers; 
(+), stimulation; (−), inhibition (taken from Hussain & Lokhandwala, 2003) 
 
The classical dopamine hypothesis of schizophrenia is the most widely considered 
neurochemical hypothesis and was first proposed by Snyder (1973). This hypothesis 
postulates that hyperactive dopaminergic neurotransmission resulting from an excess 
of DA in the brain, activating D2 receptors account for the phenomenon of 
schizophrenia (Seeman, 1984). This hypothesis was formulated from three main 
sources: 
 Post mortem studies on schizophrenic brains have shown unusually high levels of 
dopamine and its metabolites (e.g. homovanillic acid) especially in the limbic 
regions (Iverson, 1979; Mackay et al, 1982). Subsequently, there is a large amount of 
consistent data showing increased density of striatal D2 receptors in the post mortem 
brains of schizophrenics (Reynolds et al, 1987; Knable et al, 1997; Sumiyoshi et al, 
1995). However, it has been suggested that the increase in D2 receptor density may 
be the result of adaptation to antipsychotic drug treatment (i.e. up regulation of D2 
receptors) rather than a biochemical abnormality intrinsic to schizophrenia. 
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Furthermore, some PET studies show no significant difference in D2 receptor 
densities between neuroleptic-naive schizophrenics and healthy controls (Farde et al, 
1990). D1-like receptors are predominantly found in the PFC, whereas D2-like 
receptors are found in sub-cortical regions (see Guillin et al, 2007), although D4 
receptors are found in both PFC and hippocampus (Lahti et al, 1998). 
1.1.4.1.1 D2 antagonists 
There is a strong relationship between clinical efficacy of classical antipsychotic 
drugs and potent affinity for D2 receptors. All drugs that antagonise the D2 receptor 
tend to improve the positive symptoms of schizophrenia (Creese et al, 1976; Seeman, 
1986). As the classical antipsychotic drugs are D2 receptor antagonists, an alteration 
of dopamine transmission at this receptor has long been suspected to play a role in 
the pathophysiology of schizophrenia. Specifically, excess D2 transmission has been 
proposed to underlie positive symptomatology since these symptoms improve 
following D2 receptor blockade compared with negative or cognitive symptoms 
(Snyder, 2008).  
1.1.4.1.2 Dopamine agonists 
Additionally, it has been shown that the dopamine agonist amphetamine and the 
dopamine pre-cursor L-DOPA, enhance the activity of dopamine and produce 
psychotic symptoms when administered to healthy adults (for review see Angrist & 
van Kammen, 1984; Lieberman et al, 1987). These dopamine agonist-induced 
psychotic symptoms can be abolished with the administration of dopamine 
antagonists, providing further evidence of dopamine’s involvement in schizophrenia. 
Additionally, these dopamine agonists have been shown to exacerbate the psychotic 
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symptoms in schizophrenia patients. A study demonstrating enhanced amphetamine-
induced dopamine release in schizophrenia patients using PET (photon emission 
tomography), suggested the existence of a dysregulation of dopamine neurones 
leading to an increased dopamine transmission in response to amphetamine (Laruelle 
et al 1996). 
Despite decades of extensive research, the causes and exact sites of the presumed 
dopamine-mediated hyperactivity remain elusive; therefore providing evidence to 
suggest that dopamine alone may be insufficient to explain all aspects of 
schizophrenia. Although the administration of the dopamine antagonist medications 
modify brain dopamine levels within minutes, the concomitant improvement in 
patient symptoms are usually not visible for at least several days, suggesting that 
dopamine may not be directly responsible for the illness (Thompson, 2000). 
Furthermore, dopamine antagonists demonstrate limited ability to treat the negative 
symptoms of schizophrenia, in addition the inability of dopamine agonists to fully 
recapitulate all the symptoms of the disease in humans suggests the involvement of 
other neurotransmitters. 
1.1.4.2 Serotonin hypothesis 
Serotonin (5-hydroxtryptamine; 5-HT) is a monoamine neurotransmitter, synthesised 
from dietary tryptophan. Tryptophan is converted to 5-hydroxytrptophan by the 
enzyme tryptophan hydroxylase and then decarboxylated to 5-HT by the action of 
amino acid decarboxylase (Figure 3).  
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Figure 3 The synthesis of 5-HT (Taken from Goridis & Rohrer, 2002) 
 
The neurones of the raphe nuclei are the main source of 5-HT in the brain, axons 
from these neurones form a neurotransmitter system that reaches almost every part of 
the CNS. Axons of neurons in the rostrally located nuclei terminate in parts of the 
cortex, hippocampus, basal ganglia, limbic system and hypothalamus whereas the 
caudally situated nuclei project to the cerebellum, medulla and spinal cord (figure 4). 
Molecular biological techniques have allowed the identification of at least 15 
different 5-HT receptor subtypes which have been classified and divided into seven 
groups (5-HT1-7) and further subdivided into 5-HT2A-C, 5-HT1B, 5-HT1D, 5-HT1E, and 
5-HT1F.   
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Figure 4 5-HT pathways in the rat brain (taken from Rang et al, 1995) 
 
The role of the 5-HT system in schizophrenia was first suggested in 1954 by Wooley 
and Shaw, they observed that lysergic acid diethylamide (LSD), acting upon the 5-
HT system (5-HT agonist) induced symptomatology of schizophrenia in man, such 
as hallucinations, delusions and other abnormal behavioural changes. Later it was 
identified that LSD exerts its action through the 5-HT2A/2c receptor subtypes 
(McKenna et al, 1989).  
The discovery of the atypical antipsychotic agent clozapine in 1959 with low D2 and 
high 5-HT2A affinity (Deutsch et al, 1991), and lower incidence of extrapyramidal 
side effects (EPSE’s) compared to classical antipsychotics provoked the re-surge in 
interest in the 1980s in the serotonin system as a potential therapeutic target for 
schizophrenia (Busatto & Kerwin, 1997). Many of the atypical antipsychotics have 
significant affinity for the 5-HT2A receptor, which has directed interest in this 
receptor subtype with regard to therapeutic antipsychotic development. The 
relationship of serotonergic and dopaminergic function has been extensively studied 
with the main focus on the mechanism of action by which clozapine in addition to 
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other atypical antipsychotics exert superior therapeutic efficacy. The serotonin-
dopamine hypothesis of schizophrenia was suggested by Meltzer (1989) and 
implicated enhanced dopaminergic and serotonergic transmission in subcortical areas, 
leading to the manifestation of positive symptoms and decreased dopaminergic and 
serotonergic transmission in the prefrontal cortex leading to the negative and 
cognitive symptoms. 
Many of the atypical antipsychotics have affinities not only for 5-HT2A receptors but 
also for other 5-HT receptor subtypes including 5-HT1A, 5-HT2C, 5-HT6 and 5-HT7 
(Schotte et al, 1996; Kuroki et al, 2008). It is likely that these 5-HT receptor 
subtypes may also be involved in the mechanism of action of atypical antipsychotics. 
Although physiological roles of the central 5-HT receptor subtypes have yet to be 
fully understood, the serotonin–dopamine interaction via 5-HT receptor subtypes has 
been thought to play an important role in the production of clinical effects of atypical 
antipsychotics (Kuroki et al, 2008). 
Post-mortem studies in un-medicated patients with schizophrenia have revealed a 
reduced number of 5-HT2A receptors (Arora & Meltzer et al, 1991) and an increase 
in the number of 5-HT1A receptors in the frontal cortex (Hashimoto et al, 1991). 
Other post-mortem studies have reported confounding results with respect to the 
hippocampus. Joyce and colleagues (1993) also reported an increase in hippocampal 
5-HT1A receptors, whereas another study did not (Hashimoto et al, 1991). 
1.1.4.3 Glutamate hypothesis 
The glutamate hypothesis of schizophrenia originated with the observation that the 
dissociative anaesthetic PCP (Sernyl) produced psychotomimetic symptoms in 
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surgical patients (Luby et al, 1959). Glutamate is the major excitatory amino acid 
neurotransmitter in the central nervous system (CNS) and was first implicated in 
schizophrenia when decreased concentrations, up to 50% reductions compared to 
healthy controls, were found in the cerebrospinal fluid of schizophrenic patients 
alongside an increase in the density of NMDA receptors in the striatum (Kim et al, 
1980). However, attempts to replicate these findings have been unsuccessful (Gattaz 
et al, 1982; Perry, 1982). Glutamate acts at two classes of receptors, ligated gated ion 
channels (ionotropic receptors; N-methyl-D-aspartate (NMDA-), AMPA-, kainite- 
and G-protein coupled metabotropic receptors. 
1.1.4.3.1 Ionotropic glutamate receptors 
The ionotropic glutamate receptors initiate rapid depolarization by facilitating 
sodium or calcium entry into neurons through channels made by the receptor itself. 
The NMDA receptor channels are permeable to calcium and are distinctive because 
they are "doubly gated" by voltage and ligands, which means they are activated only 
when glutamate binds at the same time as a depolarizing shift in the membrane 
potential.  
1.1.4.3.2 Metabotropic glutamate receptors 
To date, eight metabotropic glutamate receptors (mGlu1-mGlu8) have been 
identified by molecular cloning studies (Pin & Duvoisin, 1995) and control 
neurotransmission by activating G-protein coupled synaptic transduction 
mechanisms. Some mGlu receptors, in particular the mGlu5 subtype have been 
shown to interact closely with NMDA receptors and may directly modulate the 
function of the NMDA receptor channel (see review by Moghaddam, 2003). 
21 
 
 
Figure 5 The ionotropic receptors and associated ion channels form one complex from co-
assembly of multiple subunits. The metabotropic receptors are coupled to their associated 
ion channels by a second messenger cascade. Each mGluR is composed of one polypeptide, 
which is coupled to a G-protein (taken from Kandel et al, 1991). 
 
1.1.4.3.3 NMDA receptors 
Autoradiography studies in the rat have shown that NMDA receptors are widely 
distributed throughout the brain, the largest density is found in the nucleus 
accumbens, hippocampus and prefrontal cortex (Monaghan & Cotman, 1985; 
Maragos et al, 1988). The NMDA receptor is a tetrameric-transmembrane channel 
consisting of combinations of the necessary NR1 subunit with NR2 and/or NR3 
subunits (see review by Henson et al, 2010). The function of the NMDA receptor is 
controlled by its subunit composition (Monyer et al, 1992), the most common 
NMDA receptors consist of 2 NR1 and 2 NR2 subunits of the identical subtype 
(Dingledine et al, 2000). 
Since the classical antipsychotics are unable to treat the cognitive and negative 
symptoms of schizophrenia another theory other than the dopamine hypothesis came 
to light. One of these theories, the ‘glutamate hypothesis of schizophrenia’, emerged 
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in the early 1980s as an alternative to the popular theory of altered dopamine 
neurotransmission. Olney and Farber (1995) proposed a mechanism, which could 
help to explain the symtoms of schizophrenia based upon NMDA receptor 
hypofunction. The hypofunction of the NMDA receptor could be reproduced by 
pharmacological antagonism of the NMDA receptors. The glutamate hypothesis is 
based on studies showing that non-competitive NMDA receptor antagonists such as 
MK801, ketamine and phencyclidine can induce symptomatic, neurocognitive and 
neurochemical aspects of the disorder.  
Results from genetic studies have reported that the majority of genes that have 
recently been implicated in the increased risk for schizophrenia can influence the 
function of glutamate receptors (Harrison et al, 2003; Moghaddam, 2003). 
Furthermore, post-mortem studies have reported alterations in the marker of viable 
neuronal tissue, the neuropeptide N-acethylaspartate (NAA) and the neurotransmitter 
N-acetylaspartylglutamate (NAAG) (Tsai et al, 2005). In addition, changes in 
glutamate receptor binding, transcription and subunit protein expression in the 
prefrontal cortex, thalamus, and hippocampus have been reported in subjects with 
schizophrenia (Clinton & Meader-Woodruff, 2004).  
The growing evidence supporting the glutamate hypothesis of schizophrenia has led 
to interest in the modulation of glutamatergic neurotransmission as a therapeutic 
target. The glycine modulatory site of the NMDA receptor is currently a favoured 
therapeutic target, with several modulatory agents currently undergoing clinical 
development. For example the full agonists’ glycine and D-serine have both been 
shown to significantly reduce negative and cognitive symptoms when added to 
classical and atypical antipsychotics in clinical studies (Javitt, 2004). However, 
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glycine has limited permeability of the blood-brain barrier and therefore large doses 
need to be administered (Javitt et al, 2000), whereas d-serine has been shown to 
produce necrosis of the kidney tubules in rats (Krug et al, 2007). 
1.1.4.4 GABA 
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter, 
synthesized from glutamate by glutamic acid decarboxylase (GAD), in the vertebrate 
central nervous system. There are two classes of GABA receptors; GABAA and 
GABAB. GABAA receptors are divided into six subunits (GABAA1-6) and are ligand-
gated ion channels (ionotropic receptors), and GABAB receptors are divided into 
three sub-units (GABAB1-3) and are G protein-coupled receptors (metabotropic 
receptors). 
GABA acts post-synaptically (Kmjevic, 1976) by increasing membrane conductance 
to chloride ions. The main effect is to inhibit the production of an action potential in 
the postsynaptic cell. The inhibitory action of GABA led to the belief of a deficiency 
of GABA in schizophrenia with subsequent dysfunction in brain functioning 
(Roberts, 1972). 
The GABAergic neurones are the second most prevalent cell population in the brain 
and most neuronal circuitry involves GABA. GABAergic cells are exclusively 
interneurones that are important for regulating the activity of the glutamatergic 
pyramidal cells (Benes & Berretta, 2001). Subsequently, the activities of the 
GABAergic interneurons are controlled by the glutamatergic afferents from 
projecting neurones (Coyle, 2004). GABAergic interneurons are known to express 
calcium binding proteins which include calbinin, calretinin and parvalbumin and are 
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important for modulation of intracellular calcium by acting as calcium buffers. These 
calcium binding proteins are the major determinants of the kinetics of fluctuations of 
intracellular calcium (Mojumder et al, 2008) and are predominantly expressed by 
chandelier and basket cells in the cortex (Mikkonen et al, 1997). 
Parvalbumin modulates the activity of calcium-dependent K
+
 channels and restores 
intracellular calcium (McPhalen et al, 1994), thereby protecting neurons from 
hyperexcitability (Rewal et al, 2005).  Late expression of parvalbumin has been 
hypothesized as a possible mechanism for schizophrenia, as without parvalbumin, 
neurons are vulnerable to calcium mediated damage (Reynolds et al, 2004). Studies 
have shown that parvalbumin expression in the prefrontal cortex (Beasley & 
Reynolds, 1997; Hashimoto et al, 2003) and hippocampus (Zhang & Zeynolds, 2002) 
is reduced in schizophrenia. Similarly, reduced density of calbindin-containing 
interneurons in the prefrontal cortex (Beasley et al, 2002) and hippocampus without 
any change in calretinin expression (Zhang et al, 2002; Hashimoto et al, 2003) has 
been observed in post-mortem schizophrenia brains. These results suggest that the 
calretinin containing GABAergic neurones are preserved in schizophrenia. 
The rate limiting GABA-synthesizing enzyme: glutamic acid decarboxylase (GAD), 
exists in both 65 kD (GAD65) and 67 kD (GAD67) forms, catalyzes the conversion 
of glutamate into GABA, and is a marker of GABAergic neurons (Olsen et al, 1999). 
Decreased GAD65 mRNA expression in the hippocampus is consistent with findings 
of reduced GAD activity and GABA concentrations in schizophrenia patients that 
had been free from antipsychotic treatment for at least 12 months (Todtenkopf & 
Benes, 1998). 
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Studies have reported alterations of GABAA receptors in schizophrenia patients 
(Benes et al, 1992; Impagnatiello et al, 1998; Lewis et al, 2004; Ichikawa et al, 2004). 
However, there are few studies indicating that the GABAB receptor is downregulated 
in the hippocampus or in the entorinal and temporal cortices in schizophrenia (see 
review by Wassef et al, 2003). Although there is some evidence for a role of GABAB 
receptor in schizophrenia, studies investigating the potential beneficial effects of 
using selective GABAB receptor agonists in schizophrenia have been mostly negative 
(see review by Guidotti et al, 2005). 
The growing evidence GABA dysfunction in schizophrenia strongly suggests a role 
for GABA in the pathophysiology of schizophrenia and supports the development of 
novel antipsychotic agents targeting this system. Recently, development of 
compounds with selective efficacy for different α subunits at the benzodiazepine site 
of the GABAA receptor has renewed interest for the therapeutic potential of 
GABAergic drugs (Gray & Roth, 2007). One of these compounds is known as α5IA 
is a triazolophthalazine that selectively attenuates the effects of GABA at GABAA 
receptors containing an α5 subunit. It has been shown to enhance long-term 
potentiation in an in vitro model of mouse hippocampal synaptic plasticity, gives 
good in vivo receptor occupancy and improves cognitive performance in normal rats 
as measured using the delayed-matching-to-place version of the Morris water maze 
yet, importantly, it is without anxiogenic or proconvulsant liabilities (Atack et al, 
2009). 
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1.1.5 Animal models 
1.1.5.1 Genetic mouse models 
The rapid growth in knowledge of the neurobiology and genetics of schizophrenia 
will allow more models of the disease to be developed in an attempt to understand 
the molecular mechanisms and pathophysiological changes in schizophrenia and 
design more effective therapies. Recent advances in molecular technologies to 
manipulate the mouse genome have made genetic mouse models the first choice for 
most human genetic diseases (Chen et al, 2006). The development of mice with 
specific mutations via gene knockout or transgenesis has allowed scientists to 
identify the functional significance of a targeted gene and encoded protein (Tecott & 
Wehner, 2001). Several schizophrenia susceptibility genes have been identified and 
led to the development of mouse models based on mutations of these genes 
(Harrison & Weinberger, 2005; Carter, 2009). 
1.1.5.1.1 DISC1 
The disrupted in schizophrenia (DISC1) gene which encodes for a synaptic protein, 
was first identified in a Scottish family (Millar et al, 2000). Transgenic mice have 
been developed based on the original findings that the DISC1 gene was truncated by 
a translocation that is associated with psychiatric diseases (Jaaro-Peled et al, 2010). 
The development of mouse models with truncated DISC1 have yielded interesting 
phenotypical information, such as enlarged lateral ventricles, and in some studies, 
decreased parvalbumin immunoreactivity in the mPFC and hippocampus, both 
pathologies observed in schizophrenic brains (Hikida et al, 2007; Shen et al, 2008; 
Brandon et al, 2009). Furthermore, mice with impaired DISC1 function have been 
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shown to have selective deficits in working memory which may relate to the working 
memory deficits observed in patients with schizophrenia (Kvajo et al, 2008). 
However, the behavioural data surrounding DISC1 mutant mice are rather variable 
(Jaaro-Peled et al, 2010). 
1.1.5.1.2 NRG1 
Neuregulin1 (NRG1) has been identified as a susceptibility gene for schizophrenia in 
an Icelandic population (Chen et al, 2006; Li et al, 2004) and plays an important role 
in the developing brain. NRG1 controls neurite outgrowth and neuronal migration, 
proliferation of oligidendrocytes and glia cells (Chen et al, 2006). NRG1 is also 
involved in excitatory and inhibitory neurotransmission in the mature brain via an 
interaction with receptor expression including GABA and glutamate receptors 
(Austin et al, 2005). Hypomorphic and hypermorphic transgenic NRG1 mice have 
been shown to exhibit behaviours that are associated with schizophrenia such as 
hyperactivity in an open field, decreased prepulse inhibition and decreased social 
interaction (Kato et al, 2010). On the contrary, these mice demonstrate an increase in 
paravalbumin immunoreactivity in the prefrontal cortex and decreased, rather than 
increased, dopamine levels in the hippocampus and prefrontal cortex (Kato et al, 
2010). 
1.1.5.1.3 COMT 
The catechol-O-methyltransferase (COMT) gene has a known functional mutation in 
the encoding sequence that is linked with an increased risk of schizophrenia (Chen et 
al, 2006) and is thought to lead to a decrease in prefrontal cortex dopamine levels 
(Stefansson et al, 2004). Mice with COMT-knockout could be viewed as the 
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treatment model for schizophrenia (Chen et al, 2006). Studies have shown that 
transgenic mice (Val-tg) that over express COMT show disrupted attentional set-
shifting abilities, impaired working memory in a T-maze task and disruption of novel 
object recognition memory (Papaleo et al, 2008). The brain pathology of the 
transgenic Val-tg mice has not yet been elucidated. 
Most of the susceptibility genes have been linked with the cognitive dysfunctions 
associated with schizophrenia (Egan et al, 2001). Investigation of the roles of 
susceptibility genes in cognitive function using the susceptibility based genetic 
models could provide valuable information on novel molecular mechanisms 
associated with schizophrenia. However, it is very difficult to model the symptoms 
of schizophrenia in mice. Furthermore, schizophrenia is a polygenic disease, most 
likely related to gene-gene and gene-environment interactions that cannot be 
assessed using mice with single gene mutations (see review by Chen et al, 2006). 
1.1.5.2 Prenatal models 
As already described, research into schizophrenia has reported the risk for 
developing schizophrenia is significantly increased by exposure to prenatal virus (see 
review by Jones & Cannon, 1998), hypoxia (Verdoux et al, 1998), maternal stress, 
and other maternal medical complications (Kinney et al, 2010) and the subsequent 
onset of schizophrenia does not emerge until after puberty or early adulthood. It is 
not yet fully understood how disruption of early brain development may eventually 
lead to brain malfunction.  Evidence has suggested that pre-natal manipulation of the 
foetus could potentially lead to an animal model of schizophrenia. 
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So far, models attempted include the prenatal stress model of schizophrenia.  This 
involves the rodent foetus being exposed to elevated levels of corticosterone (cortisol 
in humans) during the third week of gestation. Like the developing human brain, the 
emergent rat brain is vulnerable to environmental stress. Exposing pregnant female 
rats to stressful manipulations during the third week of pregnancy, the developmental 
equivalent to the second trimester of human pregnancy (Bayer et al, 1993), is 
thought to reprogram the hypothalamic-pituitary-adrenal (HPA) axis (Henry et al, 
1994; Zuckerman et al, 2003; Lee et al, 2007). The effect is perceptible at 56 days 
old, whereby the rats show reduced PPI, reduced cognitive performance in spatial 
tasks and enhanced locomotor activity in response to amphetamine (Walker et al, 
1997). 
Another prenatal procedure in the rat, involves feeding the pregnant dam a low 
protein-diet (prenatal protein deprivation; PPD), which has been shown to decrease 
learning, memory and hippocampus morphology in the offspring. Furthermore, these 
animals also displayed increased dopamine receptor binding in striatum and 
increased NMDA receptor binding in both striatum and hippocampus (Palmer et al, 
2004). 
Experimental data show that prenatal exposure to immune-activating agents such as 
the bacterial endotoxin lipopolysaccharide (LPS) induces long-term cognitive 
disruptions in spatial working memory, reference memory and novel object 
recognition (Meyer et al, 2005; Samuelsson et al, 2006; Ozawa et al, 2006). 
Pre-natal methylazoxymethanol acetate (MAM) treatment has been proposed as a 
suitable model for the neurodevelopmental aspects of schizophrenia since the 
morphological abnormalities it induces in the brain are subtle and consistent with the 
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neuropathology in schizophrenic brains. MAM is a short acting, alkylating agent that 
permeates the placenta and leads to the death of cells that are actively replicating 
DNA (Matsumoto et al, 1972). Treatment with MAM at differential gestational days 
has resulted in behavioural changes such as reduced social behaviour (Talamini et al, 
1999) and deficits in both the acquisition and retention phases of the Morris water  
maze (Fiore et al, 2002). Furthermore, administration of MAM to pregnant rats on 
gestational days 5-17 has been shown to induce a dose-dependent disruption in the 
development of the ventral hippocampal regions and the surrounding perirhinal 
cortex when the brain was examined after the rat reached adulthood (Lodge & Grace, 
2009). 
1.1.5.3 Postnatal neurodevelopmental models 
Neurodevelopmental models of schizophrenia test hypotheses that this disease is 
caused by a defect in cerebral development, which manifests in altered neural 
connectivity and pathology, brain neurochemistry and abnormal behaviour observed 
in adult life (Lehner et al, 2003). It is proposed that the first 2 weeks of postnatal life 
in the rat corresponds to the second trimester of pregnancy in humans, during which 
exposure to toxins (environmental and viral) increases the risk of subsequently 
developing schizophrenia as an adult (Clancy et al, 2001). Glutamate has been 
shown to promote neuronal development and the NMDA receptor has been 
implicated in the structure and plasticity of neuronal circuits (see review by Mouri et 
al, 2007), which has created interest in using NMDA receptor antagonist treatments 
during postnatal development as a potential model for schizophrenia. The postnatal 
administration of PCP to rats on postnatal days (PND) 7, 9 and 11 is proposed as a 
neurodevelopmental model of schizophrenia (Wang et al, 2001).  
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Behavioural studies using adult rats that had previously received PCP on PND 7, 9 
and 11 have shown enhanced locomotor activity (LMA) following an acute low-dose 
PCP and d-amphetamine challenge (Depoortere et al, 2005), disruptions in 
sensorimotor gating in PPI (Takahashi et al, 2006), deficits in ability to shift 
attentional set (Broberg et al, 2008), and reduction in total brain weight (Brookes et 
al, 1997). Postnatal PCP treatment (PND 7, 9 and 11) has been shown to disrupt 
social novelty, whereby the rats fail to discriminate between a familiar and novel rat. 
The disruption in social novelty induced by postnatal PCP treatment has been 
reversed with clozapine, mGluR2/3 agonist and an mGluR2 poteniator (Depoortere 
et al, 2005; Harich et al, 2007). 
1.1.5.4 Psychotomimetic Agents  
1.1.5.4.1 Phencyclidine 
Phencyclidine (1-(1-phenylcyclohexyl) piperidine) is a non- competitive N-methyl-
d-aspartate (NMDA) receptor antagonist, synthesized in 1926 and developed in the 
1950s as an intravenous dissociative anaesthetic. Phencyclidine is more commonly 
referred to as PCP or ‘angel-dust’ and was discontinued from use as an anaesthetic in 
the 1960’s because PCP was found to induce psychosis in healthy humans that was 
indistinguishable to psychiatrists from schizophrenia (Collins et al, 1960).  
Furthermore, when acute PCP is administered to patients with schizophrenia, a 
persistent worsening of the pre-existing psychotic symptoms occurs (Luby et al, 
1959). Unlike the effects of the psychotomimetic agent amphetamine, PCP is 
proficient in mimicking all the core symptoms of schizophrenia that include, the 
positive, negative and importantly the cognitive symptomology (Javitt & Zukin, 
1991; Jentsch & Roth, 1999; for review see Svensson, 2000).  PCP has been shown 
32 
 
to induce cognitive dysfunction such as impairments in executive functioning, verbal 
fluency and recognition memory (Malhotra et al, 1996).  The psychotomimetic 
ability of PCP, its derivative ketamine and the more selective NMDA receptor 
antagonist MK-801, suggests a powerful relationship between human psychosis and 
NMDA receptor blockade. 
PCP has a diverse pharmacology, the main action is to antagonise, non-competitively 
the NMDA class of glutamate receptor (Anis et al, 1983). The PCP binds to the PCP 
site within the channel pore, but can only bind to this PCP site when the channel is 
open and the antagonism is therefore ‘use dependent’, PCP has also been shown to 
inhibit other ion channels and membrane proteins, including sodium and potassium 
channels, nicotinic acetylcholine receptors, sigma receptors and the dopamine and 
nor-adrenaline transporters (Morris et al, 2005). All these effects of PCP are much 
lower than the affinity for the NMDA receptor but the activity of PCP at the variety 
of sites may add to its psychotomimetic potential. 
 
Figure 6 Schematic diagram of the NMDA receptor complex with PCP binding site (taken 
from Javitt, 2010). 
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1.1.5.4.1.1 Acute PCP 
Acute administration of PCP has been shown to induce behavioural and 
neurochemical changes. Microdialysis studies have demonstrated an increase in 
extracellular dopamine, GABA, 5-HIAA in the dorsolateral striatum following acute 
treatment with PCP in conscious rats (Lillrank et al, 1994). Further microdialysis 
studies have demonstrated increased dopamine and glutamate release in the pre-
frontal cortex and nucleus accumbens in rats treated with acute PCP (Hertel et al, 
1995; Adams & Moghaddam, 1998). Optimum brain dopamine levels have long 
been implicated in cognitive processes. The relationships between cognitive 
performance and dopamine levels follow an “Inverted-U–shaped” function; where 
both too little and too much DA impairs performance (see review by Cools & 
D’Esposito, 2011). Additionally, acute PCP treatment has been shown to increase 
cerebral blood flow in the basal ganglia, thalamus, hippocampus and PFC in the rat 
(Gozzi et al, 2008). All these effects of acute PCP treatment most likely contribute to 
the disturbance of cognitive functions (Jentsch & Roth, 1999). There is extensive 
behavioural data following acute PCP exposure in the rat, which includes increased 
locomotor activity, stereotyped behaviours and ataxia (positive symptoms), social 
interaction/withdrawal (negative symptoms) and sensory information processing, 
selective attention and working memory (cognitive symptoms) (Geyer et al, 1984; 
Ogren & Goldstein, 1994; Sams-Dodd, 1995; Adams & Moghaddam, 1998; Jentsch 
& Anzivino, 2004; Klamer et al, 2004; Egerton et al, 2008; Palsson et al, 2005; Javitt, 
2007). Furthermore, studies in our laboratory have demonstrated selective 
impairments in an operant serial reversal learning task following acute treatment 
with PCP (Abdul-Monim et al, 2003; Idris et al, 2005).  
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Limitations 
The use of acute PCP treatment is not without limitations. The ability of acute PCP 
treatment to induce cognitive and negative symptomology associated with 
schizophrenia in animals is most certainly affected by the nonspecific alterations in 
general locomotor activity and arousal. In addition, studies have demonstrated that 
acute PCP treatment to animals, increases forebrain dopaminergic transmission, 
whereas long-term PCP treatment reduces frontal dopamine transmission which is 
associated with hypofrontality and some of the cognitive deficits observed in 
schizophrenia (Jentch & Roth, 1999). Furthermore, schizophrenia is an enduring 
disease with lasting symptomatology especially surrounding the negative and 
cognitive aspects. Long term administration of NMDA receptor antagonists have 
been shown to induce long-term neurochemical and behavioural changes that are 
more relevant to schizophrenia. 
 
 
Figure 7 The biological and psychiatric effects of acute versus repeated exposures to 
PCP/ketamine in humans (taken from review by Jentch & Roth, 1999). 
 
 
 
35 
 
1.1.5.4.1.2 Sub-chronic PCP treatment 
Longer-term treatment with PCP may provide a more valid tool for modelling 
aspects of schizophrenia symptomatology in animals (see figure 7). Chronic PCP 
users are subjected to a huge array of side effects and describe the following 
symptoms: persistent problems with memory, speech and difficulty thinking. Recent 
memory capability appears to be primarily affected. Users complain of stuttering, 
inability to speak and difficulty with articulation. Speech and memory difficulties 
reported to last as long as 6 months to 1 year following prolonged daily use of large 
doses of phencyclidine (Cosgrove & Newell, 1991). They also complained of 
anxiety or nervousness during and following periods of regular PCP use. Depression 
and attempted suicide on repeated occasions after chronic exposure to PCP was also 
described. Users reported personality changes, social withdrawal and social isolation. 
In some cases, violent behaviour was one of the effects, as well as aggressive 
behaviour, paranoia, delusional thinking, and auditory hallucinations (Peterson & 
Stillman, 1978).  These psychological and behavioural effects produced by chronic 
PCP use in humans have been shown to persist for several weeks after the cessation 
of PCP use, which provides support for the withdrawal/subchronic/repeated PCP 
administration regimen as a pharmacological model relevant to schizophrenia 
(Jentsch & Roth, 1999; Enomoto et al, 2007; Mouri et al, 2007; Seillier & Giuffrida, 
2009; Neill et al, 2010). 
Long-term PCP use has been shown to lead to a decrease in frontal blood flow in the 
human brain (Hertzman et al, 1990; Wu et al, 1991) and reduced glucose utilisation 
in the pre-frontal cortex of the rat, similar to that observed in man (Wolkine et al, 
1992; Cochran et al, 2003). This provides support for its use to mimic schizophrenia 
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symptoms and support to clinical findings of hypofrontality in relation to cognitive 
dysfunction observed in schizophrenia (Weinberger & Berman, 1988; Goldman-
Rakic, 1990). 
It has been suggested that antagonism of the NMDA receptor results in an excessive 
release of the excitatory transmitter glutamate and subsequent overstimulation of 
postsynaptic neurones might explain the cognitive and behavioural disturbances 
associated with the NMDA receptor hypofunctionality in schizophrenia (Olney et al, 
1999).   
The behavioural effects of sub-chronic PCP treatment observed in animals are 
accompanied by pathological changes to the brain. Studies have shown reductions in 
the neurochemical marker, parvalbumin mRNA expression in GABAergic 
interneurones in areas of the prefrontal cortex and hippocampus (Abdul-Monim et al, 
2006). Similarly, parvalbumin has also been shown to be altered in post-mortem 
tissue from schizophrenic brains (Ohnuma et al, 1999; Lewis, 2000; Zhang et al, 
2002). 
Cognitive effects of sub-chronic PCP treatment 
Recent studies using the sub-chronic PCP treatment regimen (2 mg/kg, twice daily 
for seven days) and the chronic intermittent PCP treatment regimen (2.58 mg/kg, 
once daily on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) have been shown to 
produce cognitive deficits in an array of animal tests. 
Sub-chronic administration of PCP has shown to consistently induce robust 
cognitive deficits in the established reversal learning paradigm that have been 
reversed by atypical antispychotics, novel agents but not classical antipsychotics 
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(Abdul-Monim et al, 2007; McLean et al, 2008; Idris et al, 2010). Studies in our 
laboratory have shown impairments in the 5CSRTT following sub-chronic PCP 
treatment which (Barnes et al, 2012). Other laboratories have shown impairments in 
5CSRTT following intermittent repeated PCP treatment which was ameliorated 
following administration of the atypical antipsychotic clozapine (Amitai et al, 2007). 
The rodent model of attentional set-shifting which has already been shown to be 
sensitive to the effects of natural aging (Barense et al, 2002), prefrontal cortex 
lesions (Birrell & Brown, 2000) and muscarinic antagonism (Chen et al, 2004), has 
also ability to detect cognitive impairments in the extra-dimensional shift (EDS) 
stage of the task induced by sub-chronic PCP treatment (Rodefer et al, 2008; 
McLean et al, 2008). It has also been shown that the chronic intermittent PCP dosing 
regimen-induced impairments in attentional set-shifting in rats, which was 
subsequently reversed by treatment with modafinil (Dawson et al, 2010). Results 
from experiments using the NOR test in mice have demonstrated disruptions in 
recognition memory, specifically the ability of the mice to differentiate between 
novel and familiar objects in the retention trial following a sub-chronic PCP 
treatment dosing regimen (10 mg/kg, once daily for 10 days). This sub-chronic PCP-
induced cognitive impairment was subsequently restored by sub-chronic (2 weeks) 
administration of clozapine (5 mg/kg), but not haloperidol (0.1 mg/kg) (Hashimoto 
et al, 2005). Sub-chronic PCP treatment has been shown to induce impairments in 
social behaviours in the social interaction test (Sams-Dodd, 1995; Bruins Slot et al, 
2005). Furthermore, studies in our laboratory have shown that sub-chronic treatment 
with PCP induces deficits in social behaviour in the social interaction task, which are 
reversed by acute treatment with ziprasidone (Snigdha & Neill, 2008).  The cognitive 
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deficits and other behavioural indices of positive and negative symptomatology 
induced by sub-chronic PCP treatment provide good predictive validity (see table 2). 
 
Animal models of psychiatric disorders can be classified as 
having construct, face or predictive validity 
Construct 
Validity 
Comparable underlying neurophysiological concept. 
  
Face Validity 
Comparable endpoint measurements in clinical and experimental 
models. 
  
Predictive 
Validity 
Comparable pharmacological profile in clinical and experimental 
studies. 
  
 
Table 2 (adapted from van der Staay et al, 2009). 
 
1.1.5.4.2 D-Amphetamine 
The dopamine hypothesis of schizophrenia and the pharmacological demonstration 
of dopamine agonists producing and exacerbating symptoms gave rise to dopamine 
based models of schizophrenia. The administration of dopamine receptor agonists 
such as amphetamine has been shown to induce positive symptoms of schizophrenia 
such as hallucinations and delusions in normal humans and exacerbate symptoms in 
schizophrenia patients but is unable to induce the negative symptoms of 
schizophrenia (Ellinwood, 1967; Snyder, 1973; Meltzer, 1991).  The dopamine 
hypothesis of schizophrenia suggests that symptoms may be due to 
hyperdopaminergia or increased sensitivity to the neurotransmitter, both of which 
can be simulated by administration of the dopamine agonist d-amphetamine.    
In both humans and animals d-amphetamine has been seen to profoundly affect 
dopamine activity.  It is thought to block the dopamine transporter (DAT) producing 
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elevated levels of extracellular dopamine and disruption of dopamine vesicular stores 
(Jones et al, 1998).  D-amphetamine also exerts similar effects on serotonin (SERT) 
and noradrenaline transporters (NET) which is thought to attribute to its 
psychotropic effects (Kuczenski & Segal, 1997).  In animals, d-amphetamine 
increases locomotor activity (LMA), stereotyped behavior and catalepsy (Gambill & 
Kornetsky, 1976). Furthermore, attention, sensory motor function and learning and 
memory are disrupted (Seiden et al 1993). Acute administration of d-amphetamine to 
model the symptomatology of schizophrenia is not without limitations since the 
effects are not chronic and self sustaining and it fails to mimic the negative 
symptoms (Sams-Dodd, 1998; Krystal et al, 2005).    
1.1.5.5 Isolation rearing 
Many years of research into the effects of post-weaning isolation rearing of rats from 
their normal social group have resulted in the identification of a number of 
abnormalities in behaviour, neurochemistry and physiology, symptoms of a 
condition known as the ‘isolation syndrome’ (Hatch et al, 1963; Sahakian, 1975; 
Gentsch et al, 1981; Heidbreder et al, 2000; Lapiz et al, 2003; Fone & Porkess, 
2008). 
Original early studies by Einon and Morgan (1977) into the effects of isolation 
rearing in the rat demonstrated a crucial timing of the start of isolation. Isolation of 
rats between (PND) 25 and postnatal day (PND) 45 produced irreversible increases 
in levels of object contact in an open field and were slower to emerge from a small 
enclosure into an unfamiliar environment. Isolation at PND 16-25 or after PND 45 
had no long lasting effect upon behaviour. More recent studies have reported that 
isolation of the rats between PND 20-30, produces robust disruption in a variety of 
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behaviours (see review Fone & Porkess, 2008). Studies have demonstrated that to 
obtain persistent and reproducible behavioural effects with isolation rearing, it is 
very important to ensure strict control of the social environment, for example, 
minimal contact with the experimenter and no environmental enrichment in the 
home cages (Marsden et al, 2011).  
The altered behavioural profile exhibited by these isolated rats include an enhanced 
level of spontaneous locomotor activity (Gentsch et al, 1963; Smith et al, 1997; 
Heidbreder et al, 2000), an enhanced reactivity to psychoactive agents such as d-
amphetamine and cocaine (Jones et al, 1990; Jones, 1992), a heightened response to 
conditioned and unconditioned reinforcers (Schenk et al, 1987; Jones et al, 1990; 
Smith et al, 1997), a reduction in pain threshold (i.e. hyperalgesia) (Puglisi-Allegra 
& Oliverio, 1983) and an increase in food consumption and weight gain (Fiala et al, 
1977). Furthermore, isolated rats have sensorimotor gating deficits, measured by 
reduced pre-pulse inhibition (PPI) of the startle response (Geyer et al, 1993; Cilia et 
al, 2001), recognition memory deficits, measured by NOR (Bianchi et al, 2006) and 
enhanced sensitivity to sub-chronic PCP induced hyperactivity (Lapiz et al, 2003). 
Many of these behavioural effects implicate alterations in dopamine function, 
particularly within the mesolimbic system. Further evidence suggesting that isolation 
rearing alters mesolimbic dopamine function has been gathered using in-vivo 
microdialysis techniques and suggests that isolation rearing produces an increase in 
extracellular levels of dopamine in the nucleus accumbens (NAc) and striatum, along 
with a reduction in 5-HT levels in the NAc (Jones, 1991; Fulford & Marsden, 1998). 
Isolation rearing has been shown to alter brain neurochemistry, however the results 
are often contradictory. Radioligand binding studies have identified that the 
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functional high affinity state D2 receptor numbers in the striatum are increased by 
isolation rearing (King et al, 2009). However, other groups have observed no 
changes in density or affinity of D1 or D2 receptors in the nigrostriatal system (Bardo 
& Hammer, 1991). There are also studies showing that isolation rearing induces 
changes in pre-synaptic dopamine receptor function in addition to post synaptic 
dopamine changes including decreased D2 receptors in the nucleus accumbens (Hall 
et al, 1998). 
The link between the mesolimbic dopamine system and the serotonergic system led 
to investigations into the effects of isolation rearing on serotonergic function. Results 
to date suggest that isolated rats showed reduced 5-HT activity in the nucleus 
accumbens but not in the caudate putamen or prefrontal cortex (Jones et al, 1992). 
In-vivo microdialysis has been used to investigate 5-HT release in isolated rats 
compared to social controls. Bickerdike and colleagues (1993) demonstrated a KCl-
stimulated and novelty-induced increase in 5-HT levels in the frontal cortex of 
socially reared rats compared to isolates, suggesting that isolation reared rats have 
reduced pre-synaptic neuronal function. The changes in pre-synaptic dopamine and 
5-HT function in NAC are also associated with decreased pre-synaptic 5-HT 
function in the frontal cortex and hippocampus (Lapiz et al, 2003). Findings by 
Heidbreder et al, (2000) have shown decreases in the basal dopamine turnover in the 
infralimbic area of the medial prefrontal cortex, a region important for cognition 
(Jentsch et al, 1997). 
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1.1.6 Animal tests of cognition  
The MATRICS initiative has highlighted pre-clinical tests of cognition that are 
relevant translational models to study the seven cognitive domains impaired in 
schizophrenia (see table 3). 
 
 
Table 3 Pre-clinical tests of cognition highlighted by the MATRICS initiative. 
 
1.1.6.1 Executive functioning 
Executive function is a high-order cognitive capacity that utilises the domains of 
attention, planning, multi-tasking and the ability to switch between several tasks and 
sources of information (Chan et al, 2008). People suffering with schizophrenia 
exhibit executive functioning deficits, these impairments are noticeable against a 
background of generalized cognitive deficits, and affect 40% to 95% of individuals 
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with this disorder. Damage to the prefrontal cortex in humans results in a variety of 
functional impairments but especially impairments of executive function. The 
Wisconsin Card Sorting Task (WCST) is a neuropsychological test developed by 
Berg (Grant & Berg, 1948), thought to measure aspects of executive function such as 
abstract reasoning, cognitive flexibility and the ability to maintain and shift cognitive 
set according to changing schedules of reinforcement (Nagahama et al, 1996; Moore 
et al, 2009). It has been shown that lesions to the dorsolateral prefrontal cortex in the 
Rhesus monkey induced impairments in executive functioning measured by a 
primate analogue of the WCST (Moore et al, 2009). 
The attentional set-shifting task was developed by Birrel and Brown (2000) as a 
rodent analogue test of the WCST and the CANTAB ID/ED task (Downes et al, 
1989). It requires the subject to simultaneously discriminate in two dimensions to 
obtain food reinforcement. For example, the food may be buried in sand versus 
gravel, and contained in a round bowl versus a square box. When the rats attend to a 
category (e.g., bowl shape) of a stimulus, learning to discriminate novel complex 
stimuli is more rapid when the discrimination rule is based on the same perceptual 
dimension (an intra-dimensional shift; IDS). However, if the new discrimination 
requires that attention is directed to a different category of dimension (e.g., texture of 
substrate within the bowl) and the previously attended stimulus (bowl shape) must 
be disregarded (an extra-dimensional shift; EDS), the new discrimination is acquired 
less rapidly. It has been reported that selective ibotenic acid lesions of the medial 
prefrontal cortex in the rat induce impairments of the EDS phase of the attentional 
set-shifting task (Birrell & Brown, 2000). 
44 
 
The five-choice serial reaction time task (5-CSRTT) has been widely used to assess 
attention and executive function in the rat. This task supplies information on 
attentional capacity, as measured by the accuracy of reporting of stimuli, in addition 
to inhibitory response control or executive functioning. The 5-CSRTT is conducted 
in an automated operant chamber with five exposed apertures located opposite the 
food magazine dispenser. The rat is required to sustain and divide its attention across 
five spatial locations in order to detect a visual light cue that flashes randomly in one 
of five nose poke locations. Numerous measures are recorded such as; target 
accuracy (response accuracy), premature ‘impulsive’ responses, perseverative 
‘compulsive’ responses and latency. A variety of lesions to distinct areas of the 
prefrontal cortex have been shown to selectively impair differential aspects of the 5-
CSRTT (Dalley et al, 2004). 
1.1.6.2 Working memory 
Working memory is the most severely affected domain in schizophrenia patients; it 
is a core feature of the illness and persists throughout the course of the illness 
(Manoach, 2003). Interestingly, working memory deficits have been shown to be 
present in healthy relatives of schizophrenia patients, which could mean that working 
memory deficits are a behavioural marker of genetic liability to schizophrenia (Parks 
et al, 1995). Spatial working memory tests have provided consistent results whereas 
verbal working memory tests are rather less predictable in schizophrenia patients.  In 
rats and mice, the radial arm maze is one test that can be used to measure spatial 
working memory. It was first developed by Olton and Samuelson in 1976 and 
consists of 8 arms, radiating out from a central platform, that have shallow cups for 
placement of food rewards.  Rats are trained to locate food rewards in the selected 
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arms over a varying number of days, visits to un-baited arms or re-visits to 
previously visited baited arms are scored as errors. Working memory is then required 
to prevent re-visiting the baited arms while reference memory is required to avoid 
visiting arms that have never been baited (Kay et al, 2010).  
Another pre-clinical working memory task that has been selected and highlighted by 
the MATRICS initiative is the delayed nonmatch to sample task (DNMTS). The 
DNMST task requires the subject to compare a presented sample object with a 
previously presented comparison object and encourages the selection of a novel 
object with an object’s second presentation. The DNMST is an operant task that has 
three behavioural components; the sample phase, retention phase (delay) and the 
choice phase. During the sample phase the rat is presented with a brief light flash 
above one of two levers (e.g. left light), to gain a food reward the rat must press the 
lever directly under light that flashed. During the retention phase (delay), which is 
usually 1-15s, the rats must turn around and move to the back of the box and 
remember the sample phase information. During the choice phase, both lights flash 
(left and right), and the rat must press a non-matching lever (e.g. non matching to the 
sample; right lever). A correct non-match to sample results in a small food or water 
reward. Lesions of the prefrontal cortex and hippocampus have been shown to 
impair the ability of experimental animals to perform DNMST (Hampson et al, 1999; 
Porter et al, 2000). Hippocampal lesions are delay dependent (i.e. rats perform at a 
lower level when the delay increases compared to controls), whereas prefrontal 
lesions are independent of delay (Porter et al, 2000). 
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1.1.6.3 Novel object recognition 
The novel object recognition task (NOR) was first described in 1950 by Berlyn and 
was later utilised by Ennaceur and Delacour in 1987 for their studies on the 
nootropic effects of piracetam. The NOR test has been identified by the MATRICS 
initiative and Treatment Units for Research on Neurocognition and Schizophrenia 
(TURNS) as measuring visual learning and memory, a pre-clinical tool for 
identification of potential pro-cognitive co-treatments for cognitive deficits in 
schizophrenia. The NOR test measures recognition memory and is ethologically 
relevant, relies on exploratory behaviour and utilises the innate instinct of rodents to 
explore novel compared with familiar objects and importantly requires no training or 
administration of food rewards. The NOR test is relevant to the cognitive 
dysfunction associated with schizophrenia since recognition memory impairments 
have been extensively described in schizophrenia patients (Huron et al, 2003). 
Furthermore, face recognition memory and visual object memory performance 
impairments have been observed in schizophrenia patients compared to healthy 
controls (Calkins et al, 2005). The NOR test is relatively fast and easy for the 
experimenter and consists of 3 phases; acquisition trial, inter-trial interval (ITI) and 
retention trial.  The experiment is carried out in an open field test box and during the 
acquisition trial two identical objects are presented to the rodent for a time period, 
usually 3-5 min and exploration of the objects is timed. The ITI can be varied 
(typically, 1 min-48 h), depending upon the aspect of memory and brain region of 
interest, during this time the rodents are placed back in to their home cage or a 
separate holding box. The third phase is the retention trial; rats are again presented 
with two objects, one familiar (a triplicate object from the acquisition trial) and one 
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novel object, exploration of the two objects is carefully timed.  Lesion studies in the 
mouse have demonstrated that, when the hippocampus is inactivated, impaired object 
recognition is observed at relatively long ITIs (24 h) but not at short ITIs (5 min) 
whereas the perirhinal cortex/PFC are believed to be responsible for recognition 
memory following it is less than 5 min (Hammond et al, 2004; reviewed by Dere et 
al, 2007). Evidence to support the role of the PFC in the NOR test has been shown in 
neuroimaging studies of object recognition in normal subjects. PET scanning has 
shown activation of brain regions implicated in the pathogenesis of schizophrenia: 
the bilateral medial temporal lobes and prefrontal areas during the recognition of 
previously seen objects and the thalamus, prefrontal, and medial temporal lobe areas 
during the recognition of new objects (Schacter et al 1995), (Schacter et al 1997; 
Schacter et al 1999; Uecker et al 1997). In comparison with control subjects, patients 
with schizophrenia demonstrated abnormal thalamic and prefrontal cortical function 
during object recognition testing (Heckers et al, 2000). 
1.1.6.4 16-Holeboard maze 
The 16-holeboard maze was first described by Oades and Isaacson in 1978 and later 
by van der Staay et al, 1990, also known as the ‘cognitive’ holeboard and is 
described by the TURNS pre-clinical subcommittee as a test of visual learning and 
memory and working memory (visit http://www.turns.ucla.edu). The 16-holeboard 
maze requires the rats to be food deprived which encourages exploration and 
foraging behaviour on the maze. During the habituation procedure, rats are 
habituated to the box for 1h for 5 days with all 16 holes baited with a food reward. 
The training procedure, based on a description by Oades and Isaacson (1978) is 
divided into two sessions per day (morning and afternoon) consisting of 10 trials for 
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a total of 10 sessions whereby rats are trained to forage around the 16-holeboard 
maze to find and eat the 4 food rewards in the fixed set of 4 holes. A visit to a hole 
can be scored when the nose of a rat turned to the edge of a hole, moved over it or 
was placed in it (Oades & Isaacson, 1978) whereas others define a hole visit as head-
dip into the hole (Wrubel et al, 2007). Rats use win-shift learning strategy to visit the 
food rewarded holes and avoid revisiting holes from which they already collected the 
food reward within a trial (Olton, 1987).  Measures of cognition on the 16-holeboard 
range from working memory errors (number of re-visits to food rewarded holes), 
working memory ratio or working memory score (food rewarded hole-visits/total 
hole visits), reference memory ratio (total food hole rewarded visits/total non food 
rewarded visits). For comprehensive and detailed information regarding the 16-
holeboard maze measures see review by van der Staay et al (2012). It has been 
reported that lesions of the hippocampus and ventral tegmental area (VTA) produce 
impairments of both reference memory and working memory in the 16-holeboard 
maze. 
1.1.7 Antipsychotics 
1.1.7.1 Typical antipsychotics 
The first antipsychotic medication to be developed was in the 1950s with a drug 
belonging to the phenothiazine class, called chlorpromazine. This drug was 
synthesised by the chemist Paul Charpentier and went forward into clinical trials in 
1952. Pierre Deniker performed a study in Paris and results from his study using 38 
psychotic patients receiving daily injections of chlorpromazine showed dramatic 
improvements in thinking and emotional behaviour (Lopez-Munoz et al, 2005).  By 
1994, chlorpromazine was being used throughout the USA to treat schizophrenia, 
49 
 
mania, psychomotor excitement, and other psychotic disorders. The discovery of 
chlorpromazine was the beginning of the pharmacological era in psychiatry. 
Chlorpromazine was soon followed by other different classical antipsychotic drugs, 
such as haloperidol, fluphenazine, droperidol, pimozide, sulpiride, perphenazine, 
flupenthixol, zuclopenthixol and trifluoperazine. Their main benefit is in treating the 
positive symptoms of schizophrenia. However, these drugs are less effective against 
the negative symptoms or the cognitive symptoms associated with schizophrenia. 
This may be due to the sedative and anticholinergic properties or extrapyramidal 
symptoms (EPS) (Csernansky, 2002). The effect that is common to all classical 
antipsychotics is a high affinity for dopamine D2 receptors, and there is a strong 
correlation between the therapeutic doses of these drugs and their binding affinity for 
the D2 receptor (Creese et al, 1976). 
As with all drugs, classical antipsychotic treatments can produce side effects which 
include; dry mouth, tremors, weight gain, muscle tremors, and stiffness. In addition, 
classical antipsychotics produce EPS caused by the blockade of D2 receptors in the 
nigrostriatal dopamine pathway. These side effects include; motor disturbances, 
Parkinsonian effects, akathesia (a feeling of "inner restlessness", a constant urge to 
be moving), dystonia (sustained muscle contractions causing twisting and repetitive 
movements or abnormal postures), akinesia (impaired body movement; without any 
or  much movement), tardive dyskinesia (involuntary movements of the tongue, lips, 
face, trunk, and extremities), and neuroleptic malignant syndrome (combination of 
hyperthermia, rigidity, and autonomic dysregulation). Patients exhibiting these side 
effects have described them to be worse than the actual symptoms of schizophrenia 
itself and therefore, EPS are a major cause of noncompliance to drug therapy.  
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1.1.7.2 Atypical antipsychotics 
The original aim was to develop new drugs that would have antipsychotic efficacy 
without the extensive side effects of the classical agents.  The aim was to selectively 
antagonise the D2 receptors in the meso-limbic and meso-cortical pathways whilst 
sparing the nigro-striatal (EPS) and tuberoinfundibular (hyperprolactinaemia) D2 
receptors. The first atypical antipsychotic to be developed was clozapine in the 
1960s, with the term “atypical” originally used to describe drugs that, in animal 
models predict antipsychotic efficacy, but do not produce catalepsy. Clozapine is 
claimed to have superior efficacy and to cause fewer motor adverse effects than 
typical drugs for people with treatment-resistant illnesses. Other atypical 
antipsychotic medications were introduced to the market in the 1990s, including 
olanzapine, risperidone, quetiapine and between 2001-2004 ziprasidone and 
aripiprazole. In 2009, asenapine, the latest atypical antipsychotic was released on to 
the market and is claimed to have a lesser propensity to cause metabolic disorders 
and weight gain (Balaraman & Gandhi, 2010). 
Atypical antipsychotics have enhanced tolerability compared to typical 
antipsychotics and are efficacious in improving the positive symptoms of 
schizophrenia as well as providing some improvement in the negative and cognitive 
symptoms (Meltzer et al, 1999; Reynolds, 2000). They cause fewer EPS effects than 
classical antipsychotics and also have a different pharmacological profile (Essali et 
al, 2009). All the atypical antipsychotics have differential receptor binding profiles 
and demonstrate greater affinity for 5-HT compared with the dopamine receptors 
(see table 4).  
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Receptor Aripiprazole Olanzapine Paliperidone Risperidone Quetiapine Ziprasidone Clozapine Haloperidol Molindone Perphenazine 
Pharmacodynamic receptor binding profile: receptor binding affinity expressed as equilibrium constant (Ki)
a
 
D2 0.66
b,c 20 2.8 3.77 770 2.6 210 2.6 120 1.4c 
5-HT1A 5.5
b,c 610 480 190 300 1.9b,c 160 1,800 3,7997c 421 
5-HT2A 8.7
c 1.5 1.2 0.15 31 0.12 2.59 61 5,000 5c 
5-HT2C 22
c 4.1 48 32 3,500 0.9 4.8 4,700 >10,000c 132c 
α1 26
c 44 10 2.7 8.1 2.6 6.8 17 2,500 10 
Η1 30
c 0.08 3.4 5.2 19 4.6 3.1 260 123,456 8 
Μ1 6,780
c 2.5c >10,000c >10,000c 120c 300c 1.4c >10,000c 384,000 1,500 
Μ2 3,510
c 622c >10,000c >10,000c 630c >3,000c 204c >10,000c N/A N/A 
Μ3 4,680
c 126c >10,000c >10,000c 1,320c >1,300c 109c >10,000c >10,000c 1,848c 
Μ4 1,520
c 350c >10,000c >10,000c 660c >1,600c 27c >10,000c N/A N/A 
Pharmacokinetic profile: half-life 
t1/2, h 72 30 20 3 7 7 16 20 1.5-3 8-12 
Note: based exclusively on data from human brain receptors (49-56). 
a Data represented as the equilibrium constant (Ki) (nM), i.e., nanomolar amount of the antipsychotic needed to block 50% of the receptors in vitro. Therefore, a lower number denotes stronger 
receptor affinity and binding. 
b 
Partial agonism. 
c Data form cloned human brain receptors. 
 
Table 4 Receptor binding affinity for antipsychotic medications (adapted from 
Correll, 2008) 
 
1.1.7.3 Typical antipsychotics and cognition 
Despite being effective in treating the positive symptoms, there is evidence to 
suggest that classical antipsychotics, rather than improving cognitive deficits, 
actually add to the cognitive dysfunction associated with schizophrenia (Marsden, 
1976; Meltzer & McGuirk, 1999; Kasper & Resinger, 2003).  
Furthermore, the most frequent treatment of EPS is the co-administration of drugs 
with powerful anticholinergic properties, which are known to impair cognition in 
schizophrenia patients (Tune et al, 1982; Meltzer & McGurk, 1999). Interestingly, 
these anticholinergic agents have frequently been used in animal studies to model the 
memory impairments observed in Alzheimer’s disease. 
Importantly, the National Institute of Mental Health sponsored a study; Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE). This randomized, 
double blind study compared the cognitive effects of the typical antipsychotic 
perphenazine with three atypical antipsychotic agents; olanzapine, risperidone and 
ziprasidone in chronic schizophrenia patients. Results from this study showed there 
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was no difference between typical and atypical antipsychotics on cognitive 
performance (Keefe et al, 2007). 
1.1.7.4 Pharmacology of atypicals 
The effectiveness of the atypical antipsychotics has been linked to their 5-HT2-D2 
antagonistic properties. The 5-HT2 receptor antagonism and atypical antipsychotic 
profiles correlate but the exact mechanisms by which 5-HT2 antagonism improves 
negative symptoms with fewer EPS remain unclear. The positive symptoms are 
associated with a hyperdopaminergic state in the limbic lobe, which is rich in 
dopaminergic innervation. Serotonin regulates DA release and the presence of 5-HT 
in the nigrostriatal pathway prevents the release of DA but has little effect in the 
mesolimbic DA pathway. When the 5-HT2A receptors are blocked, dopamine is 
released in the nigrostriatal dopamine pathway which is thought to reverse some of 
the D2 induced-EPS symptoms by a process called disinhibition. The 5-HT2A 
antagonism results in elevated DA, which dis-inhibits the D2 receptors and prevents 
the antagonism by the antipsychotic resulting in less EPS. Disinhibition of the D2 
receptors in the mesolimbic DA pathway does not affect the efficacy of the 
antipsychotic because of the low number of 5-HT2A receptors located in this region 
(Stahl, 2000). 
1.1.7.5 Atypicals antipsychotics and cognition 
The atypical antipsychotics may help to improve cognition in patients with 
schizophrenia by reducing the EPS. Furthermore, schizophrenia patients are less 
likely to be prescribed the cognition impairing anticholinergic agents which are more 
likely required to reduce the EPS observed following treatment with the classical 
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antipsychotic agents. In addition, most of the atypical antipsychotic medications 
display a high affinity for 5-HT2 receptors and it has been suggested that an 
interaction with the 5-HT2A receptors are important for cognition (Williams et al, 
2002; Kasper & Resinger, 2003; Nichols, 2009). The 5-HT2A receptors have been 
shown to have a high density in the frontal cortex, an area of great importance to 
cognition and lower densities throughout the rest of the brain (Nichols & Nichols, 
2008). Atypical antipsychotics have been shown to enhance cognition in a variety of 
tests in patients with schizophrenia (Meltzer & McGurk, 1999). A meta-analysis 
revealed that atypical antipsychotics are superior to classical agents in improving 
overall cognitive function (Woodward et al, 2005). However, the reported 
improvements in cognition following the treatment with atypical antipsychotic 
agents are not always replicated. A comparative study by Lieberman (2006) 
demonstrated no significant difference in the efficacy of atypical antipsychotics to 
improve the cognitive impairments when compared with the classical antipsychotic 
agents. 
Despite the expansion of available antipsychotic medication over the last 50 years, 
the functional outcome of schizophrenia patients has not improved significantly 
(Floresco et al, 2005). The current antipsychotics are effective in treating the positive 
symptoms but are much less efficacious at ameliorating the negative symptoms and 
restoring the cognitive impairments. Since all currently marketed antipsychotic 
agents possess some degree of dopamine antagonist effects, the role of other 
neurotransmitters in the primary antipsychotic activity remains largely unclear. It is 
possible that different symptomatology of schizophrenia may benefit from different 
specific classes of medications. Animal models are essential in the initial stage of 
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discovery of novel compounds with potential to treat the cognitive impairments 
associated with schizophrenia. However, improved and refined animal models are 
needed that can predict efficacy in patients. Recently, the importance of predictive, 
in-vivo animal models has been recognized as an essential component of modern 
drug discovery if late stage failure for lack of clinical efficacy is to be avoided 
(Markou et al, 2009). 
1.1.8 Cognitive enhancers 
Since the cognitive dysfunctions associated with schizophrenia are now recognised 
as a core feature of the disease there is a cognitive ‘revolution’ in drug discovery. At 
present the available antipsychotics for the treatment of schizophrenia, are 
insufficient at alleviating the cognitive deficits. 
The MATRICS initiative has highlighted potential targets and classes of drugs that 
may be useful in treating the cognitive impairments observed in schizophrenia. 
These include; dopaminergic agents, including D1 receptor agonists; glutamatergic 
agents and modulators acting on both ionotropic and metabotropic receptors, 
including ampakines; glycine uptake inhibitors, including GlyT-1 inhibitors; 
cholinergic agents, including alpha7 nicotinic acetylcholine (ACh) receptor (nAChR) 
agonists; M1 muscarinic ACh receptor (mAChR) agonists and alpha-2 adrenergic 
receptor agonists and agents acting on the GABA system and on various serotonin 
receptors (see review by Barak & Weiner, 2011). 
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1.1.9 Aims and objectives 
The aim of this thesis is to study, validate and investigate the NOR test using 
behavioural manipulations and psychotomimetic dosing regimens in both male and 
female rats. 
Specific objectives: 
1. Carefully validate the NOR test by determining the object preference and 
inter-trial-interval; effect of time and location, using sub-chronic PCP treated 
and vehicle control rats. 
2. Determine the effect of gender differences on the sensitivity to the cognitive 
impairments induced by acute d-amphetamine, acute PCP and sub-chronic 
PCP in the NOR test. 
3. Evaluate the ability of classical and atypical antipsychotic agents, other 
pharmacological agents and potential novel cognitive enhancers to reverse 
the PCP-induced cognitive deficits in the NOR test.  
4. To investigate the effects of isolation rearing on inter-trial-interval induced 
forgetting and sensitivity to the cognitive impairments induced by acute PCP 
and acute d-amphetamine in the NOR test. 
5. Investigate the effects of acute treatment with d-amphetamine, scopolamine, 
PCP and sub-chronic PCP treatment on a measure of working memory in the 
16-holeboard maze. 
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CHAPTER 2 - General Methods 
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2.1 Materials and methods 
2.1.1 Experimental Animals 
All studies used adult female (180-280g) or male (350-400g) hooded-Lister rats 
(Charles River or Harlan, UK). Rats were housed (4-5 per cage) in solid floored 
plastic cages (38 x 59 x 24 cm) containing sawdust, paper sizzle nest (Datesand, Ltd., 
Manchester, England) and fun tunnels (plastic environmental enrichment tubes., 
Datesand, Ltd., Manchester, England). Food (Special Diet Services Ltd., Essex, 
England) and drinking water was available ad-libitum in the home cage. The rats 
were disturbed only for cleaning, which consisted of changing the cage twice per 
week.  Rats were housed in a single sex colony which was maintained under a 
constant temperature of approximately 21 ± 1 °C and humidity (40-50 %) under a 
12h light:dark cycle (lights on at 0700 h). All experiments were conducted during the 
light phase and were carried out between 0900 h and 1630 h. All studies were 
compliant with the Animal Scientific Procedures act (1986) and approved by the 
University of Bradford Ethical Review Process. 
Cohort of rats used and total n= Chapter (and experiment) 
1 (n=50) 
1 (n=50) 
3 (object preference and 
differential ITI; sub-chronic PCP) 
2-6 (n=180) 
4 (sex; acute PCP, acute d-amph and sub-
chronic PCP in males and female rats) 
7-13 (n=364) 5 (pharmacology; sub-chronic PCP) 
14 & 15 (n=66) 6 (isolation rearing; acute PCP and d-amph) 
16 & 17 (n=28) 
7 (16-holeboard maze; acute PCP, d-amph, 
scopolamine and sub-chronic PCP) 
 
Table 2.1 Cohorts of rats used throughout these studies 
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2.1.2 Drugs 
 
Drug Source 
Dose 
(mg/kg) 
Volume 
(ml/kg) 
Route 
Vehicle and pre-
treatment time 
Receptors 
d-amphetamine 
Sigma-
Aldrich, 
UK 
0.25, 
0.5, 
0.75, 
1.0, 2.5 
1 i.p. 
0.9% saline (30 
min) 
DAT 
Chlordiazepoxide 
hydrochloride 
Sigma-
Aldrich, 
UK 
1.25, 
2.5, 5.0 
1 i.p. 
0.9% saline (30 
min) 
GABAA 
Clozapine 
Tocris, 
UK 
1.0, 5.0 1 i.p. 
Distilled H2O + 
10μl acetic acid  
and pH balanced 
with NaOH (1M) 
(30 min) 
5-HT2A, α1 and 
α2-
adrenergic,H1, 
M1, D1, D2, D4. 
Fluoxetine 
hydrochloride 
Sigma-
Aldrich, 
UK 
5.0 1  
0.9% saline (30 
min) 
5-HT 
Transporter 
Fluphenazine 
dihydrochloride 
Sigma-
Aldrich, 
UK 
0.2 1 i.p. 
0.9% saline (30 
min) 
5-HT1A, 5-HT2A, 
5-HT2C, 5-HT3, 
5-HT6, 5-HT7, α1 
and α2-
adrenergic, H1, 
M1, D1, D2, D3, 
D4. 
Haloperidol 
Baker, 
UK 
0.05, 
0.075 
1 i.p. 
Distilled H2O (30 
min) 
D2, α2-
adrenergic 
Modafinil 
Tocris, 
UK 
50 2 p.o. 
1% methylcellulose 
(30 min) 
DAT. NET 
(-)-Nicotine 
hydrogen tartrate 
Sigma-
Aldrich, 
UK 
0.2 1 i.p. 
0.9% saline (30 
min) 
nAChRs agonist 
Phencyclidine 
hydrochloride 
Sigma-
Aldrich, 
UK 
2.0 1 i.p. 
Distilled H2O 
(Acute: 30 min) 
NMDA 
antagonist 
PNU-282987 
hydtrate 
Tocris, 
UK 
5.0, 10, 
20 
2 s.c. 
Isotonic H2O (60 
min) 
Nicotinic Alpha 
7 agonist 
PNU-120596 
Tocris, 
UK 
5.0, 10, 
20 
2 p.o. 
100% PEG400 (60 
min) 
Nicotinic alpha 
7 PAM 
Risperidone 
GSK, 
UK 
0.2 1 i.p. 
Distilled water + 
10μl acetic acid  
and pH balanced 
with NaOH (1M) 
(30 min) 
5-HT2A, 5-HT7, 
α1 and α2-
adrenergic, D2 
Scopolamine 
Tocris, 
UK 
0.75 1 i.p. 
0.9% saline (30 
min) 
M1 antagonist 
 
Table 2.2 Routes and volume of administration (intra-peritoneal (i.p.), sub-cutaneous (s.c), 
per os, (i.e. oral, p.o), vehicles and receptor affinity of the drugs used. DAT (dopamine 
transporter), NET (norepinephrine transporter), PAM (positive allosteric modulator). 
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2.1.3 Sub-chronic PCP dosing regimen 
The sub-chronic PCP dosing regimen was adapted from earlier studies by Jentsch 
and Roth (1999) and has been shown to produce enduring behavioural, 
neurochemical and pathological changes associated with schizophrenia (Fletcher et 
al, 2005). Sub-chronic PCP was administered via the intraperitoneal route (i.p.) in a 
volume of 1 ml/kg, calculated as the base equivalent weight, twice per day for 7-days. 
Treatment with PCP or vehicle was followed by a 1-week washout period prior to 
NOR testing. The 1-week washout period following sub-chronic PCP treatment is 
necessary to prevent the behaviour of the rats being influenced either by direct drug 
effects or by drug withdrawal effects (Jentsch et al, 1998). 
2.1.4 NOR apparatus  
The apparatus consisted of an open box made of Plexiglas (52 cm L; 52 cm W; 31 
cm H) and was positioned 27 cm above the floor on a moveable trolley. The walls of 
the box were black and the objects to be discriminated (in triplicate) were made of 
Plexiglas, metal, glass or wood. The height of the objects was approximately equal 
(10 cm ± 2 cm) and they were heavy enough not to be displaced by the animals, to 
achieve this, some objects were filled with NaCl e.g. bottles. Objects were positioned 
6 cm away from the walls of the box, in opposite corners. After each trial, ethanol 
(10 % v/v) was used to clean the objects in an attempt to remove any lingering 
olfactory trails on the objects and in the box.  
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Figure 2.1(a)                                                      Figure 2.1(b) 
 
Figure 2.1 A Selection of some of the objects used throughout the NOR experiments (a) and 
the moveable trolley with NOR arena with the position of the camera (b). 
 
 
 
Figure 2.2(a)     Figure 2.2(b) 
 
Figure 2.2 The NOR arena showing a rat exploring during the habituation trial (a) and 
exploring the two identical objects during the acquisition trial (b). 
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Figure 2.2 (c) 
 
Figure 2.2(c) A rat exploring the novel object during the retention trial in the NOR test box. 
 
2.1.5 NOR testing 
2.1.5.1 Habituation 
Rats were handled and habituated to the empty NOR apparatus and test room 
environment for 3 consecutive days for 20 min, always allowing one of the 
habituation days to precede the test day. 
2.1.5.2 Behavioural testing 
A further 3 min habituation session to the NOR box preceded the experimental trials 
on the day of testing. 
2.1.5.2.1 Acquisition trial 
In the acquisition trial the rats were exposed to two identical objects A1 and A2 for a 
period of 3 min. 
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2.1.5.2.2 Inter-trial-interval (ITI) 
The rats were returned to their home cage for a 1 min ITI (or otherwise stated in 
section 3.2.4.3), during this period, both objects were removed, the entire box and 
objects were cleaned with an ethanol solution (10 % v/v) and dried with paper towels 
to remove any lingering olfactory trails. A novel object and a triplicate copy of the 
familiar object was replaced into the NOR test apparatus. 
2.1.5.2.3 Retention trial 
Following the 1 min ITI, rats were returned to the NOR apparatus to explore the 
familiar and novel objects for a period of 3 min. The location of the novel object in 
the retention trial was randomly assigned for each rat using a pseudorandom 
schedule. The pseudorandom sequences followed the criteria suggested by 
Gellerman, 1933, and thus reduced the effects of object and place preference. 
 
 
 
Figure 2.3 Schematic diagram showing the positioning (A or B) of the novel objects in the 
retention trial. 
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2.1.5.3 Behavioural assessment 
Object exploration was defined as the rats sniffing, licking or touching the objects 
with forepaws whilst sniffing but not by leaning against, turning around, standing or 
sitting on the objects (Grayson et al, 2007). The exploration time (s) of each object in 
each trial was recorded manually using two stopwatches by an experimenter blind to 
treatment and the following factors were calculated. The exclusion criterion for the 
NOR test was defined; If an animal failed to explore one or both of the objects (for 
less than 1 (s) in the acquisition or retention trial it was excluded from the final data 
analysis. 
E1 = the total exploration time of both objects in the acquisition trial (EA1 + EA2), E2 
= the total exploration time of both objects in the retention trial (EA + EB). DI = 
discrimination index (EB-EA)/(EB+EA), the DI represents the difference in 
exploration time expressed as a proportion of the total time spent exploring the two 
objects in the retention trial. 
Line crossings were recorded by counting the total number of sectors (i.e. lines) 
crossed by the rats during the acquisition and retention trials, one line crossing was 
counted when the base of the rat’s tail crossed over a line, there were 9 square 
sectors in the box measuring 17.3 cm x 17.3 cm. 
2.1.5.4 Statistical analysis 
All data are expressed as the mean ± S.E.M and were analysed by IBM SPSS version 
18. Exploration data (including differential ITI) were analysed by a repeated 
measures two-way ANOVA. This detected the main effect of drug treatment, main 
effect of the task (exploration of both objects) and the interaction between drug 
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treatment and the two trials (acquisition and retention). Further analysis by Student’s 
t-test was carried out to compare the time spent exploring the novel and familiar 
objects. 
DI and line crossing data were analysed by a one-way ANOVA, followed by a post-
hoc Dunnett’s t-test or LSD test (chapter 5; DI). 
2.1.6 Isolation rearing 
The rats were randomly assigned to one of two housing conditions for a period of 12 
weeks prior to experimentation. Isolation reared rats were housed in individual cages 
(38 x 24 x 18 cm; figure 2.4 (a)) such that they could hear, see and smell other rats, 
but were prevented from any physical contact. Group housed rats were housed in 4 
per cage (38 x 59 x 24 cm; figure 2.4(b)). Food and drinking water were available 
ad-libitum. The rats were disturbed only for cleaning, which consisted of changing 
the cage once per week for isolates and twice per week for group housed rats. Both 
isolates and group housed animals were housed in a single sex colony in the same 
holding room which was maintained under a constant temperature of approximately 
21 ± 1°C and humidity of 40 – 50 %, under a 12 h light: dark cycle (lights on at 0700 
h). All experiments were conducted during the light phase and were carried out 
between 0900 h and 1600 h. No handling of the rats occurred during the period 
before experimentation except for cage cleaning. 
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      Figure 2.4 (a) Isolation rearing cages 
 
 
 
  
     Figure 2.4 (b) Social housing cages. 
 
2.1.7 Locomotor Activity (LMA) 
Locomotor activity experiments were conducted in a behavioural laboratory 
maintained at 21 ± 1°C. The room contained no windows and was illuminated with 
white ceiling strip lights and included a radio to supply background noise. Following 
transportation to the laboratory, rats were allowed a 1h environmental 
acclimatisation period before LMA testing began. LMA was measured in individual 
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translucent Plexiglas boxes which were covered with a translucent Plexiglas lid, 
using AM1052 Activity Monitor, positioned on a four-tier shelf against a wall in a 
total bank of 16 boxes (figure 2.5 (b)). Each LMA box (figure 2.5 (a)) measured 16 x 
26 x 19 cm, contained a small amount of wood shavings and was fitted with 11 
infrared photocell units incorporating emitters and detectors. Movement of the rat 
within the LMA box produced multiple breaks in the light beams resulting in LMA 
counts. Counts were recorded using AmLogger software (Linton Instruments, UK), 
every 5 minutes over a total test period of 60 minutes. 
 
 
Figure 2.5 (a) An individual automated                  Figure 2.5 (b) A bank of 16 photocell                 
photocell cage.              cages    
             
 
 
2.1.7.1 Statistical analysis 
Locomotor activity data was analysed by a one-way ANOVA, followed by a post-
hoc Dunnett’s t-test. 
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2.1.8 16-Holeboard maze 
2.1.8.1 Apparatus 
The apparatus (figure 2.6(a)) consisted of an open box made of Plexiglas (70 cm L; 
70 cm W; 50 cm H) and was positioned 30 cm above the floor on a small table inside 
a designated behavioural test room, environmental conditions were identical to the 
animal holding room (19-23°C and 45-65% relative humidity). The walls of the box 
were clear and the floor was grey. There were 16 individual equally spaced bait 
holes on the floor of the box which were 4 cm in depth. A camera was positioned 
above the 16-holeboard maze and connected to a portable TV positioned outside the 
behavioural test room to allow observation and scoring of animal behaviour without 
any disturbance from the experimenter. Background radio music was constantly 
played within the behavioural test room. 
 
Figure 2.6 (a) Photograph of a rat exploring the 16-holeboard maze. 
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Figure 2.6 (b) Schematic diagram of the 16-holeboard maze with dimensions (baited holes 
are shown with an X). 
 
2.1.8.2 Food restriction 
Rats were food restricted to 90% of their free feeding body weight by daily 
administration of 12-15 g of standard rat chow (Special Diet Services Ltd., Essex, 
England). Rats were weighed daily and food quantity altered to ensure a healthy and 
stable bodyweight.  
2.1.8.3 16-Holeboard maze protocol 
2.1.8.3.1 Handling 
Since the 16-holeboard maze paradigm requires a great deal of handling of the rats 
by the experimenter during the training phase (Oades, personal communication), it 
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was necessary to handle the rats daily for 1 week prior to training on the 16-
holeboard maze; handling includes scruffing and firmly holding the rats until they 
appeared relaxed. This habituation process ensured that the rats were not stressed 
during the training protocol, allowing them to rapidly learn the task without fear of 
the experimenter (Oades, personal communication). Pre-handling may have 
prevented any of the rats from being excluded from the study. 
2.1.8.3.2 Habituation 
The 16-holeboard maze was thoroughly cleaned with ethanol (10% v/v) into which 2 
g per 100 ml of TestDiet AIN-76A Rodent Tablet was dissolved, this was to remove 
lingering olfactory trails prior to habituation and also to prevent the rats working out 
the food reward distribution by olfactory stimuli. Approximately 20 food pellets 
(TestDiet AIN-76A Rodent Tablet) were placed in all 16-holes. Rats were habituated 
in cage groups (n=3 or 5 rats) and placed in the 16-holeboard maze apparatus twice 
per day (morning 09:00h and afternoon 14:00h) for a period of 30 min for 5 days. 
2.1.8.3.3 Training  
Training sessions were performed in the morning (09:00h) and again in the afternoon 
(02:00) for 4 days. On the 5
th
 day, a training session in the morning (09:00h) 
preceded a drug testing session in the afternoon (14:00h).  
During training, individual rats underwent sessions of 10-trials with an ITI of 20 s, 
whereby the rats were gently held by the experimenter whilst the 16-holeboard maze 
was thoroughly cleaned with ethanol (10% v/v)/TestDiet AIN-76A Rodent Tablet 
solution. 
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Each trial required 4 food pellets to be placed in the same 4 holes (A1, B3, C2 and 
D4; see figure 2.6(b) throughout the entire training procedure. The trial ended when 
all of the 4 food pellets had been found and eaten or after a period of 2 min whereby 
the rats had not been successful in finding the 4 food pellets.  
2.1.8.3.4 Testing  
The testing phase was identical to the training procedure and was adapted from 
methodology by Oades and Isaacson, 1978. On the afternoon (14:00h) of day 5, an 
acute injection of PCP (2.0 mg/kg, i.p., chapter 7), d-amphetamine (0.75 mg/kg, i.p., 
chapter 7), scopolamine (0.25 mg/kg, i.p.,) or vehicle (0.9% saline, i.p.) was 
administered 30 min prior to testing (see table 7.1). Rats used in the acute studies 
were given a 1-week washout period in-between experiments (see section 7.2.1). The 
rats used in the sub-chronic PCP study were also tested following a 1-week washout 
period. 
2.1.8.4 Behavioural assessment 
The number of visits to each hole and the time (latency) taken to find and eat all the 
food pellets (i.e. complete the task) were recorded manually by an experimenter 
blind to drug treatment. Rats that failed to complete the task in less than 2 min were 
removed from the 16-holeboard maze before being replaced back into the arena for 
the next trial.  
2.1.8.4.1 Food hole and non-food hole visits 
A visit to a hole was recorded when a rat placed its nose into a hole.  
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2.1.8.4.2 Working memory score (WMS)  
This was adapted from Oades et al (1981) and calculated by the number of visits to 
the food holes that contain food (i.e. 4) / total number of hole visits (food holes + 
non food hole visits) with the maximum achievable score being 1 (i.e. 4/4 =1).  In 
this study, for example, on day 9 of training (figure 7.1) the rats visited all the 4 food 
holes (ate the food pellets) and either re-visited the food holes or visited the non-food 
holes approximately a further 4 times to gain a total number of hole visits of 8. 
Therefore total number of hole visits = 8. 4/8 = WMS would be 0.5.  
With further training sessions on the 16-holeboard maze a higher WMS may be 
obtained but it was observed that even when rats had learnt the pattern of food holes 
(i.e. A1, B3, C2 and D4; figure 2.6(b) they were likely to explore a hole as they 
passed by to complete the task. 
2.1.8.4.3 Latency 
Time (s) taken to complete the task. 
2.1.8.5 Statistical Analysis 
All data are expressed as the mean ± S.E.M. The training data (WMS and latency) 
was analysed by a one-way ANOVA followed by post-hoc Dunnett’s t-test. 
Following drug treatments, the WMS and latency was analysed by a repeated 
measures two-way ANOVA. This detected the main effect of drug treatment, main 
effect of the trial and the interaction between drug treatment and the trial (1-10). 
Planned further analysis by unpaired Student’s t-test was carried out to compare 
differences in WMS or latency between drug groups and vehicle control over the 10 
trials. 
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CHAPTER 3 - Initial validation of the NOR test: 
Investigation of object preference and varying inter-
trial intervals 
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3.1 Introduction 
Cognitive deficits from many domains are observed in schizophrenia patients, and 
appear to be the main determinants of the patients’ functional outcome (Bowie & 
Harvey, 2006).  Furthermore, there are a number of studies demonstrating deficits in 
recognition memory in schizophrenia patients (Pelletier et al, 2005; Calkins et al, 
2005; Gruzelier, 1999). Additionally, schizophrenia patients are more susceptible to 
distraction during visual memory tests when compared to control subjects (Anticevic 
et al, 2011).  
The MATRICS initiative has highlighted seven key cognitive domains that are 
disrupted in schizophrenia, and recommended a battery of neuropsychological tests 
(Green et al, 2004). Given that rodents are primarily selected as subjects for pre-
clinical tests, paradigms are required to assess the learning and memory deficits 
associated with schizophrenia in these animals.  
The need to design and develop paradigms to assess the various cognitive domains 
that are disrupted in schizophrenia is vitally important since as yet, no medication 
has been licensed to treat these symptoms. The NOR test was selected and mapped 
on to the MATRICS test battery and described as measuring visual learning and 
memory. The NOR test is ethologically relevant and uses rodents’ natural affinity for 
novelty, i.e. rats explore a novel object compared with a familiar one (see chapter 1). 
This spontaneous preference for novelty ensures no training is needed which 
manifests in the speed of the test to generate results. The NOR test is non-aversive 
and does not require the animals to be food restricted; therefore no confounding 
effects of food deprivation induced-stress on the data are produced. The ITI period, 
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between the acquisition and retention trial, can be manipulated to modify the 
cognitive load and determine the specific brain region of interest (see review by Dere 
et al, 2007).  
Previous research in our laboratory (Abdul-Monim et al, 2006) and others 
(Hashimoto et al, 2005; Rodefer et al, 2008; Egerton et al, 2008) have shown that the 
sub-chronic PCP dosing regimen induces impairments in cognitive function in 
rodents. 
The main focus of the studies in this thesis have been to validate and characterize the 
NOR test and object recognition deficits induced by PCP following a 1 min ITI. 
Preliminary methododological validation studies are important when creating and 
developing animal tests to ensure results are meaningful and reproducible. 
The aim of these studies was to establish a set of objects with equal preference in 
control and sub-chronic PCP treated rats that could be used hereafter to study NOR 
deficits in the NOR test. Furthermore the ITI was investigated in an attempt to 
determine the effects of manipulations (such as time and location of the rats) during 
the ITI period on the cognitive impairments following sub-chronic PCP treatment in 
the NOR test. 
3.2 Materials and Methods 
3.2.1 Experimental Animals and Design 
The initial object preference study used a total of 50 adult female hooded-Lister rats 
(Charles River, UK) weighing 190-240 g at the start of the experiment (cohort 1; see 
table 2.1). 
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The differential ITI experiments used all the same rats as described above (cohort 1) 
and weighed 200-250 g at the start of this experiment.  For housing conditions see 
section 2.1.1. 
3.2.2 Sub-chronic PCP dosing regimen 
Half of the rats (n=25) were treated with PCP hydrochloride and half (n=25) treated 
with vehicle (distilled water). For details of the sub-chronic PCP dosing regimen see 
section 2.1.3. Since the aim of these studies was to validate the sub-chronic PCP 
treatment regimen in NOR, both control and sub-chronic PCP treatment groups were 
used to determine object preference. For details of the drugs used in this study, see 
table 2.2 
3.2.3 Apparatus 
For information regarding the NOR apparatus see section 2.1.4. 
3.2.4 Object preference and differential ITI testing 
3.2.4.1 Habituation 
For information regarding habituation procedure see section 2.1.5.1. 
3.2.4.2 Object preference testing 
A further 3-min habituation session in the NOR box preceded the experimental trials 
on the day of testing.  
Ten different combinations of the objects were tested in the acquisition and retention 
trials of the NOR test (see table 3.1). Rats were habituated to the NOR test box and 
tested as described earlier.  
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Figure 3.1 Objects (available in 
triplicate) that were used in 
experimental procedure 1. From 
left to right: Frijj© bottle, Coke© 
can, wood cone, plastic cone and 
water bottle. 
 
 
 
Each object was compared to each other, with 10 possible combinations of objects. 
The individual object preference experiments were separated by 3 days (i.e. tested on 
Monday and Friday), rats were tested twice (i.e. the rats tested on Monday were re-
tested on Friday using different object combinations; n=5 per combination) and the 
study took 1 week to complete. Rats were placed into the NOR apparatus to explore 
the objects for a period of 3 min. The location of the objects within the NOR 
apparatus was randomly assigned for each rat using a pseudorandom schedule. The 
pseudorandom sequences followed the criteria suggested by Gellerman, 1933, and 
thus reduced any effects of object location (left or right) within the NOR box upon 
object preference.  Following the 3 min test period, objects were removed; the entire 
box and objects was cleaned with an ethanol solution (10% v/v) and dried with paper 
towels to remove any lingering olfactory trails. All experiments were video recorded 
for subsequent behavioural analysis by an experimenter, blind to treatment.  
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Experiment order Objects 
1 Coke can cf. Wood cone 
2 Coke can cf. Frijj bottle 
3 Coke can cf. Plastic cone 
4 Coke can cf. Water bottle 
5 Wood cone cf. Frijj bottle 
6 Wood cone cf. Plastic cone 
7 Wood come cf. Water bottle 
8 Frijj bottle cf. Plastic cone 
9 Frijj bottle cf. Water bottle 
10 Plastic cone cf. Water bottle 
 
Table 3.1 Experimental order and object combinations used in the object preference study 
 
3.2.4.3 Differential ITI testing 
The differential ITI experiments were separated by 3 days (i.e tested on Monday and 
Friday), rats were tested twice and the study took 1 week to complete. 
A further 3-min habituation session to the NOR box preceded the experimental trials 
on the day of testing. Testing consisted of a 3-min acquisition trial whereby rats 
explored two identical objects followed by a differential ITI period and location 
(NOR box or home cage). All combinations of objects (see table 3.1), except the 
wooden cone, were randomly selected as pairs for these experiments and all 
subsequent NOR experiments. The five ITI experiments were selected in an attempt 
to determine the effects of manipulations (such as time and location of the rats) 
during the ITI period as shown below (table 3.2), on the cognitive impairments 
following sub-chronic PCP treatment in the NOR test. In experiment 4 (0 min ITI in 
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the NOR box), following the acquisition trial, the identical objects were removed 
when the rat was facing the wall of the NOR box and the novel and familiar objects 
were replaced immediately for the retention trial. For experiment 5, the distracter 
object was placed in the centre of the NOR box during the 1 min ITI and was quietly 
removed prior to the retention trial. The distracter object was carefully selected on 
the basis that rats found it highly interesting, based on previous studies showing that 
time spent exploring the wooden cone was significantly greater compared to some of 
the other objects (see summary table 3.4). Following the differential ITIs, the objects 
were cleaned with an ethanol solution (10% v/v) and dried with paper towels to 
remove any lingering olfactory trails. For details of the retention trial see section 
2.1.5.2.3 and for details of animal batches used see table 2.1. 
 
Experiment 
order  
Initial 
number 
of rats 
Number 
of rats 
excluded 
ITI and location 
1 5 0 
1 min ITI in the home cage (normal 
conditions) 
2 5 0 10 s ITI in the home cage 
3 5 0 1 min ITI in the NOR test box 
4 5 0 0 min ITI in the NOR test box 
5 5 0 
1 min ITI in the NOR test box with a 
distracter 
 
Table 3.2 Experimental order and the selected ITIs used for to assess the role of distraction 
in vehicle and sub-chronic PCP treated rats. 
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3.2.5 Statistical analysis 
Object preference data are expressed as the mean ± S.E.M. (Veh; n=5 and PCP; n=5). 
Student’s paired t-test was used to compare the time spent exploring the different 
objects. For statistical analysis of the differential ITI see 2.1.5.4. 
3.3 Results 
3.3.1 Determination of object preference for the NOR test 
Student’s paired t-test revealed a significant (t(5)=2.9; P<0.05; figure 3.2) increase in 
object preference when comparing the time spent exploring the wood cone compared 
to the coke can in the sub-chronic PCP-treated rats and the time spent exploring the 
wood cone compared with the water bottle in the vehicle treated rats, (t(5)=-3.06; 
P<0.05; figure 3.8). There were no significant object preferences in the other pairs of 
objects tested in vehicle or sub-chronic PCP treated rats. 
A one way ANOVA on the overall total object exploration times totalled throughout 
the series of object preference experiments in the vehicle treated rats revealed a 
significant effect (F4, 99=3.1, P<0.05, table 3.3). However, post-hoc analysis revealed 
no significant individual effects. 
A one-way ANOVA on the overall total object exploration times totalled throughout 
the series of object preference experiments in sub-chronic PCP treated rats revealed a 
significant effect (F4, 99=3.7, P<0.01). Post-hoc analysis revealed a significant 
(P<0.01) increase in the total exploration of the wood cone when compared to the 
water bottle (table 3.3). 
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Independent Student’s t-test comparisons revealed no significant differences in 
overall total exploration times throughout the series of object preference experiments 
when comparing the vehicle and sub-chronic PCP treated rats (table 3.3). 
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Figure 3.2 Object preference comparing the time (s) spent exploring two novel objects 
(coke can and wood cone) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline (veh, 
i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group). 
*P<0.05; significant increase in object exploration time. 
0
10
20
30
40
50
60 Vehicle PCP
   coke can    frijj bottle    coke can    frijj bottle
E
x
p
lo
r
a
ti
o
n
 t
im
e
 (
s)
 
Figure 3.3 Object preference comparing the time (s) spent exploring two novel objects 
(coke can and Frijj bottle) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline (veh, 
i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Figure 3.4 Object preference comparing the time (s) spent exploring two novel objects 
(coke can and plastic cone) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Figure 3.5 Object preference comparing the time (s) spent exploring two novel objects 
(coke can and water bottle) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Figure 3.6 Object preference comparing the time (s) spent exploring two novel objects 
(wood cone and Frijj bottle) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group). 
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Figure 3.7 Object preference comparing the time (s) spent exploring two novel objects 
(wood cone and plastic cone) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Figure 3.8 Object preference comparing the time (s) spent exploring two novel objects 
(wood cone and water bottle) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group). 
*P<0.05; significant increase in object exploration. 
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Figure 3.9 Object preference comparing the time (s) spent exploring two novel objects (frijj 
bottle and plastic cone) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline (veh, 
i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Figure 3.10 Object preference comparing the time (s) spent exploring two novel objects 
(frijj bottle and water bottle) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Figure 3.11 Object preference comparing the time (s) spent exploring two novel objects 
(plastic cone and water bottle) in female rats treated with PCP (2mg/kg, i.p.) or 0.9% saline 
(veh, i.p.) twice daily for 7 days. Data are expressed as the mean ± S.E.M. (n=5 per group).  
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Comparisons between 
objects 
Vehicle       
Exploration time (s) 
Sub-chronic PCP 
Exploration time (s) 
Coke can 28.4 ± 1.9 24.6 ± 2.0 
Wood cone 37.0 ± 2.8 33.6 ± 3.2** 
Frijj bottle 28.4 ± 2.1 27.0 ± 2.6 
Plastic cone 29 ± 1.6 25.8 ± 1.6 
Water bottle 28.7 ± 2.0 25.4 ± 2.4 
 
Table 3.3 The effect of treatment with PCP (2 mg/kg, i.p., twice daily for 7 days) or 0.9% 
saline (veh, i.p.) on the total (mean of 4 object preference experiments) object exploration 
time throughout the series of object preference experiments (n=20). Data were expressed as 
the mean ± S.E.M. and analysed by one-way ANOVA followed by Dunnett’s t-test. 
**P<0.01; significant increase in total exploration time compared to the water bottle.  
 
Object Comparisons 
Object preference: 
Vehicle 
Object preference: 
Sub-chronic PCP 
Coke can cf. Wood cone No   Yes * 
Coke can cf. Frijj bottle No No 
Coke can cf. Water bottle No No 
Wood cone cf. Frijj bottle No No 
Wood cone cf. Plastic cone No No 
Wood cone cf. Water bottle   Yes * No 
Frijj bottle cf. Plastic cone No No 
Frijj bottle cf. Water bottle No No 
 
Table 3.4 Summary table showing the effect of treatment with 0.9% saline (veh, i.p.) or sub-
chronic PCP (2 mg/kg, i.p., twice daily for 7 days) on the object preference throughout the 
series of experiments. Significant increase (*P<0.05) in object preference for the wood cone 
compared to the comparator object.  
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3.3.2 Effect of sub-chronic PCP treatment in the acquisition trial in 
female rats in the 1 min ITI in the home cage 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce 
any significant effect on object exploration in the acquisition trial of the NOR test 
(F1, 18=2.6, NS; figure 3.12). Rats from both treatment groups spent similar times 
exploring both objects. An unpaired Student’s t-test on the total exploration time in 
the acquisition trial revealed no significant effect of drug treatment (table 3.5). 
3.3.3 Effect of sub-chronic PCP treatment in the retention trial in female 
rats following a 1 min ITI in the home cage 
The two way ANOVA revealed that treatment with sub-chronic PCP did not produce 
a significant effect on object exploration time in the retention trial of the NOR test 
(F1, 18=2.2, NS; figure 3.13). Further, planned post-hoc comparisons revealed that 
vehicle control rats spent significantly (P<0.001) more time exploring the novel 
object during the retention trial following the 1 min ITI within the home cage. This 
significant preference in the vehicle treated rats for the novel object was not 
observed in the rats treated with sub-chronic PCP, i.e. these rats spent a similar 
amount of time exploring both objects. Analysis of the total exploration times in the 
retention trial by an unpaired Student’s t-test revealed no significant effect of drug 
treatment (table 3.5). 
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3.3.4 Effect of sub-chronic PCP treatment on the DI in female rats 
following a 1 min ITI in the home cage 
An unpaired Student’s t-test on the DI data showed a significant (P<0.05) effect of 
sub-chronic PCP treatment compared to vehicle control on the rats’ ability to 
discriminate between the familiar and the novel objects following a 1- min ITI 
within the home cage (figure 3.14). 
3.3.5 Effect of sub-chronic PCP treatment on the number of line crossings 
in female rats in the 1 min ITI in the home cage 
Figure 3.15 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings of the rats during the acquisition and retention trials in the NOR test. 
An unpaired Student’s t-test revealed no significant effect. 
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Figure 3.12 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration times (s) of two identical objects in the 3 min acquisition 
trial of the NOR test in female rats. Data are shown as the mean ± S.E.M. (n=10 per group). 
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Figure 3.13 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration time (s) of a familiar object and a novel object in the 3 min 
retention trial of the NOR test in female rats following a 1 min ITI in the home cage. Data 
are shown as the mean ± S.E.M. (n=10 per group). ***P<0.01; significant increase in the 
time spent exploring the novel compared with the familiar object. 
 
Veh PCP
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
*
1 min ITI in the home cage: DI
Treatment
D
is
c
r
im
in
a
ti
o
n
 I
n
d
e
x
 
Figure 3.14 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the DI following a 1 min ITI in the home cage of the NOR test in female 
rats. Data are shown as the mean ± S.E.M. (n=10 per group) *P<0.05; significant reduction 
in DI when compared to vehicle. 
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Figure 3.15 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the total number of line crossings in the acquisition and retention trials 
of the NOR test in female rats following a 1 min ITI in the home cage. Data are shown as the 
mean ± S.E.M. (n=10 per group). 
 
Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Vehicle 26.0 ± 3.3 17.5 ± 2.0 
PCP 29.7 ± 3.2 28.5 ± 5.2 
 
Table 3.5 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% saline 
(veh, i.p.) on the total exploration time (s) in the acquisition and retention trials of the NOR 
test in female rats following a 1 min ITI in the home cage. Data are shown as the mean ± 
S.E.M.  (n=10 per group).  
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3.3.6 Effect of sub-chronic PCP treatment in the acquisition trial in 
female rats in the 10 s ITI in home cage 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce 
any significant effect on object exploration in the acquisition trial of the NOR test 
(F1, 18=1.7, NS; figure 3.16). Rats from both treatment groups spent similar times 
exploring both the objects. An unpaired Student’s t-test on the total exploration times 
in the acquisition trial revealed no significant effect of drug treatment (table 3.6). 
3.3.7 Effect of sub-chronic PCP treatment in the retention trial in female 
rats following a 10 s ITI in the home cage 
An overall two-way ANOVA revealed that treatment with sub-chronic PCP did not 
produce a significant effect on object exploration in the retention phase of the NOR 
test (F1, 18=1.3, NS; figure 3.17). Planned post-hoc comparisons revealed that vehicle 
control rats spent significantly (P<0.05) more time exploring the novel objects 
during the retention trial following a 10 s ITI within the home cage. This significant 
preference in the vehicle treated rats for the novel object was not observed in the rats 
treated with sub-chronic PCP, i.e. these rats spent a similar amount of time exploring 
both objects. Analysis of the total exploration times in the retention trial by an 
unpaired Student’s t-test revealed no significant effect of drug treatment (table 3.6). 
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3.3.8 Effect of sub-chronic PCP treatment on the DI in female rats 
following a 10 s ITI in the home cage 
An unpaired Student’s t-test on the DI data showed that although there was a 
decrease in the DI following sub-chronic PCP treatment, it did not reach statistical 
significance following a 10 s inter-trial interval in the home cage (figure 3.18). 
3.3.9 Effect of sub-chronic PCP treatment on the number of line crossings 
in female rats (10 s ITI in the home cage) 
Figure 3.19 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings of the rats during the acquisition and retention trials in the NOR test. 
An unpaired Student’s t-test revealed no significant effect. 
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Figure 3.16 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration times (s) of two identical objects in the 3 min acquisition 
trial of the NOR test in female rats. Data are shown as the mean ± S.E.M. (n=10 per group). 
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Figure 3.17 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration time (s) of a familiar object and a novel object in the 3 min 
retention trial in the NOR test in female rats following a 10 s ITI in the home cage. Data are 
shown as the mean ± S.E.M. (n=10 per group). *P<0.05; significant increase in the time 
spent exploring the novel compared with the familiar object. 
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Figure 3.18 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the DI in the NOR test in female rats following a 10 s ITI in the home 
cage. Data are shown as the mean ± S.E.M. (n=10 per group). 
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Figure 3.19 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the total number of line crossings in the acquisition and retention trials 
of the NOR test in female rats following a 10 s ITI in the home cage. Data are shown as the 
mean ± S.E.M. (n=10 per group). 
 
Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Vehicle 29.7 ± 2.8 31.9 ± 5.1 
PCP 33.2 ± 4.6 33.1 ± 2.7 
 
Table 3.6 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% saline 
(veh, i.p.) on the total exploration time (s) in the acquisition and retention trials of the NOR 
test in female rats following a 10 s ITI in the home cage. Data are shown as the mean ± 
S.E.M. (n=10 per group).  
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3.3.10 Effect of sub-chronic PCP treatment in the acquisition trial in 
female rats in the 1 min ITI in the NOR test box 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce 
any significant effect on object exploration in the acquisition trial of the NOR test 
(F1, 18=0.3, NS; figure 3.20). Rats from both treatment groups spent similar times 
exploring both the objects. An unpaired Student’s t-test on the total exploration times 
in the acquisition trial revealed no significant effect of drug treatment (table 3.7). 
3.3.11 Effect of sub-chronic PCP treatment in the retention trial in female 
rats following a 1 min ITI in the NOR test box 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce a 
significant effect on object exploration in the retention trial of the NOR test (F1, 
18=0.9, NS; figure 3.21). However, planned post-hoc comparisons revealed that both 
treatment groups of rats spent significantly (P<0.05 - P<0.01) more time exploring 
the novel objects during the retention trial following a 1 min ITI within the NOR test 
box. Analysis of the total exploration times in the retention trial by an unpaired 
Student’s t-test revealed no significant effect of drug treatment (table 3.7). 
3.3.12 Effect of sub-chronic PCP treatment on the DI in female rats 
following a 1 min ITI in the NOR test box 
An unpaired Student’s t-test on the DI data showed no significant effect of sub-
chronic PCP treatment on the rats’ ability to discriminate between the familiar and 
novel objects following a 1 min ITI within the NOR test box (figure 3.22). 
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3.3.13 Effect of sub-chronic PCP treatment on the number of line 
crossings in female rats following a 1 min ITI in the NOR test box 
Figure 3.23 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings of the rats during the acquisition and retention trials in the NOR test. 
An unpaired Student’s t-test revealed no significant effect. 
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Figure 3.20 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration times (s) of two identical objects in the 3 min acquisition 
trial of the NOR test in female rats. Data are shown as the mean ± S.E.M. (n=10 per group). 
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Figure 3.21 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.)  on exploration time (s) of a familiar object and a novel object in the 3 min 
retention trial in the NOR test in female rats following 1 min ITI in the NOR test box. Data 
are shown as the mean ± S.E.M. (n=10 per group). *P<0.05-**P<0.01; significant increase 
in the time spent exploring the novel compared with the familiar object. 
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Figure 3.22 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the DI in the NOR test in female rats following a 1 min ITI in the test 
box. Data are shown as the mean ± S.E.M. (n=10 per group). 
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Figure 3.23 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the total number of line crossings in the acquisition and retention trials 
of the NOR test in female rats following a 1 min ITI in the test box. Data are shown as the 
mean ± S.E.M. (n=10 per group). 
 
 
Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Vehicle 32.1 ± 2.4 35.4 ± 4.5 
PCP 29.7± 3.0 32.1± 4.3 
 
Table 3.7 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% saline 
(veh, i.p.)  on the total exploration time (s) in the acquisition and retention trials of the NOR 
test in female rats following a 1 min ITI in the test box. Data are shown as the mean ± S.E.M. 
(n=10 per group).  
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3.3.14 Effect of sub-chronic PCP treatment in the acquisition trial in 
female rats in the 0 min ITI in the NOR test box study 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce a 
significant effect on object exploration in the acquisition trial of the NOR test (F1, 
14=1.6, NS). Rats from both treatment groups spent similar times exploring both the 
objects (figure 3.24). An unpaired Student’s t-test on the total exploration times in 
the acquisition trial revealed no significant effect of drug treatment (table 3.8). 
3.3.15 Effect of sub-chronic PCP treatment in the retention trial in female 
rats following a 0 min ITI in the NOR test box 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce a 
significant effect on object exploration in the retention trial of the NOR test (F1, 
14=3.9, P=0.07, NS; figure 3.25). However, planned post-hoc comparisons revealed 
that both treatment groups of rats spent significantly (P<0.001) more time exploring 
the novel objects during the retention trial following a 0 min ITI within the NOR test 
box. Analysis of the total exploration times in the retention trial by an unpaired 
Student’s t-test revealed no significant effect of drug treatment (table 3.8). 
3.3.16 Effect of sub-chronic PCP treatment on the DI in female rats 
following a 0 min ITI in the test box 
An unpaired Student’s t-test on the DI data showed no significant effect of sub-
chronic PCP treatment on the rats’ ability to discriminate between the familiar and 
novel objects following a 0 min ITI within the NOR test box (figure 3.26). 
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3.3.17 Effect of sub-chronic PCP treatment on the number of line 
crossings in female rats in the 0 min ITI in the NOR test box study 
Figure 3.27 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings of the rats during the acquisition and retention trials of the NOR test. 
An unpaired Student’s t-test revealed no significant effect. 
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Figure 3.24 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration times (s) of two identical objects in the 3 min acquisition 
trial of the NOR test in female rats. Data are shown as the mean ± S.E.M. (n=8 per group). 
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Figure 3.25 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on exploration of a familiar object and a novel object in the 3 min retention 
trial of the NOR test in female rats following a 0 min ITI in the NOR test box. Data are 
shown as the mean ± S.E.M. (n=8 per group). ***P<0.001; significant increase in the time 
spent exploring the novel compared with the familiar object. 
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Figure 3.26 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the DI in the NOR test in female rats following a 0 min ITI in the NOR 
test box. Data are shown as the mean ± S.E.M. (n=8 per group). 
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Figure 3.27 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% 
saline (veh, i.p.) on the total number of line crossings in the acquisition and retention trials 
of the NOR test in female rats following a 0 min ITI in the NOR test box. Data are shown as 
the mean ± S.E.M. (n=8 per group). 
 
 
Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Vehicle 19.1 ± 1.6 24.0  ± 2.2 
PCP 20.0 ± 3.7 19.6 ± 3.2 
 
Table 3.8 The effect of sub-chronic (PCP treatment (2 mg/kg, i.p. for 7 days) or 0.9% saline 
(veh, i.p.) on the total exploration time (s) in the acquisition and retention trials of the NOR 
test in female rats following a 0 min ITI in the home cage. Data are shown as the mean ± 
S.E.M.  (n=8 per group).  
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3.3.18 Effect of sub-chronic PCP treatment in the acquisition trial in 
female rats in the 1 min ITI in the NOR test box with a distracter object 
study 
A two-way ANOVA revealed that treatment with sub-chronic PCP did not produce 
any significant effect on object exploration in the acquisition trial of the NOR test 
(F1, 18=2.2, NS; figure 3.28). Rats from both treatment groups spent similar times 
exploring both the objects. An unpaired Student’s t-test on the total exploration times 
in the acquisition trial revealed no significant effect of drug treatment (table 3.9). 
3.3.19 Effect of sub-chronic PCP treatment in the retention trial in female 
rats following a 1 min ITI in the NOR test box with a distracter object 
An overall two-way ANOVA revealed that treatment with sub-chronic PCP did not 
produce a significant effect on object exploration in the retention trial of the NOR 
test (F1, 18=2.6, NS; figure 3.29).  Planned post-hoc comparisons revealed that 
vehicle control rats spent significantly (P<0.001) more time exploring the novel 
objects during the retention trial following a 1 min ITI within the NOR test box with 
a distracter object. This significant preference in the vehicle treated rats for the novel 
object was not observed in the rats treated with sub-chronic PCP, i.e. these rats spent 
a similar amount of time exploring both objects. Analysis of the total exploration 
times in the retention trial by an unpaired Student’s t-test revealed no significant 
effect of drug treatment (table 3.9). 
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3.3.20 Effect of sub-chronic PCP treatment on the DI in female rats 
following a 1 min ITI in the NOR test box with a distracter object 
An unpaired Student’s t-test on the DI data showed a significant (P<0.05) effect of 
sub-chronic PCP treatment compared to vehicle control on the rats’ ability to 
discriminate between the familiar and novel objects following a 1 min ITI within the 
NOR test box with a distracter object (figure 3.30). 
3.3.21 Effect of sub-chronic PCP treatment on the number of line 
crossings in female rats in the 1 min ITI in the NOR test box with a 
distracter object 
Figure 3.31 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings of the rats during the acquisition and retention trial in the NOR test. 
An unpaired Student’s t-test revealed no significant effect. 
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Figure 3.28 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days followed by 7 
day washout period) or 0.9% saline (veh, i.p.) on exploration times (s) of identical objects in 
the 3 min acquisition trial in the NOR test in female rats. Data are shown as the mean ± 
S.E.M. (n=10 per group). 
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Figure 3.29 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days followed by 7 
day washout period) or 0.9% saline (veh, i.p.) on exploration time (s) of a familiar object 
and a novel object in the 3 min retention trial in the NOR test in female rats following 1 min 
ITI in the test box with a distracter object. Data are shown as the mean ± S.E.M. (n=10 per 
group). ***P<0.001; significant difference between the time spent exploring the familiar 
compared with the novel object, Student’s t-test. 
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Figure 3.30 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days followed by 7 
day washout period) or 0.9% saline (veh, i.p.) on the discrimination index in the NOR test in 
female rats following a 1 min ITI in the NOR test box with a distracter object. Data are 
shown as the mean ± S.E.M. (n=10 per group). *P<0.05; significant reduction in DI when 
compared to vehicle. 
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Figure 3.31 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days followed by 7 
day washout period) or 0.9% saline (veh, i.p.) on the total number of line crossings in the 
acquisition and retention trial in the NOR test in female rats following a 1 min ITI in the 
NOR test box with a distracter object.  Data are shown as the mean ± S.E.M. (n=10 per 
group). 
 
Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Vehicle 22.8 ± 3.8 16.4 ± 2.1 
PCP 25.0 ± 3.5 20.3 ± 4.1 
 
Table 3.9 The effect of sub-chronic PCP treatment (2 mg/kg, i.p. for 7 days followed by 7 
day washout period) or 0.9% saline (veh, i.p.) on the total exploration time (s) in the 
acquisition and retention trial of the NOR test in female rats following a 1 min ITI in the 
NOR test box with a distracter object. Data are expressed as the mean ± S.E.M. (n=10 per 
group).  
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Treatments 
ITI  and 
location 
 
Deficit in 
the 
retention 
trial 
Deficit        
in the DI 
 
Effect on 
line 
crossings 
Effect on 
total 
explorati
on time 
Sub-chronic 
PCP 
1 min home 
cage  
Yes Yes  No No 
Sub-chronic 
PCP 
10 s home 
cage  
Yes Yes (NS) No No 
Sub-chronic 
PCP 
1 min NOR 
box 
No No No No 
Sub-chronic 
PCP 
0 min ITI 
NOR box 
No No No No 
Sub-chronic 
PCP 
1 min ITI 
(with 
distracter) 
Yes Yes  No No 
 
Table 3.10 Summary table showing the effect of location (home cage or NOR test box) 
during differential ITIs in rats treated with sub-chronic PCP (2 mg/kg, i.p. twice daily for 7 
days). 
3.4 Discussion 
3.4.1 Object Preference 
During the initial object preference experiment, rats treated sub-chronically with 
PCP or vehicle, exhibited an increased exploration time of one of the potential NOR 
test objects compared with all the other selected objects. The object that induced 
increased exploration time was a wooden cone and subsequently discarded from 
further NOR experiments. The wooden cone object was explored more, possibly 
because it absorbed olfactory trails and was attractive because of its susceptibility to 
induce chewing. In contrast, the other objects were made from non-porous, less 
chewable materials which were more easily cleaned. This demonstrates the 
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importance of essential pilot studies before embarking on any behavioural 
experiments. A careful object selection process is required prior commencing NOR 
testing to avoid object bias confounding the subsequent data analysis. 
3.4.2 Differential ITI 
Results presented in this thesis show that rats treated sub-chronically with the 
NMDA receptor antagonist PCP, under certain conditions exhibit NOR deficits in 
visual recognition memory as assessed by the NOR test. It has been consistently 
shown that schizophrenia patients are impaired in recognition memory for familiar 
faces, these patients also show impairments in recognition memory tests for words 
and patterns (Conklin et al, 2002). Memory deficits observed in schizophrenia 
severely influence outcome (Ragland et al, 2009). When trying to remember 
information about prior experiences, internal selection processes are engaged to 
focus cognitive resources on the retrieval effort. Consequently, environmental 
stimulation that inundates our senses with information irrelevant to our memory 
goals can induce distraction during recall (Wais and Gazzaley, 2011).  
The current studies have demonstrated the sub-chronic PCP treated rats’ 
susceptibility to distraction during a short ITI period in the NOR test which is 
consistent with clinical findings in patients with schizophrenia (Cellard et al, 2007). 
Control rats were able to differentiate between the novel and familiar objects 
throughout all the differential ITI periods and their recognition of the previously 
encountered object was unaffected by the distraction of handling, ITI location and 
distracter object.   However, the sub-chronic PCP treated rats were highly susceptible 
to the effect of distraction during the ITI of the NOR test. The ‘normal’ testing 
conditions following sub-chronic PCP treatment in the NOR test in our laboratory 
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utilises a short 1 min ITI, whereby the test rats are removed from the test box and 
placed back into the home cage with their cage mates. Following this 1 min ITI 
period, sub-chronic PCP treated rats are unable to discriminate between the novel 
and familiar object whereas vehicle treated rats can. A series of differential ITI 
experiments were conducted in this chapter to help provide an explanation for the 
sub-chronic PCP treated rats’ inability to recognise the familiar object following 
such a short ITI. The results indicate that it is not only the ITI period that induces the 
deficits in object recognition observed in this test, since sub-chronic PCP treated rats 
were capable of discriminating between novel and familiar objects during a 1 min 
ITI period when they remained un-touched by the experimenter in the NOR test box. 
Furthermore, the sub-chronic PCP treated rats were still unable to differentiate 
between the novel and familiar objects when the ITI period was substantially 
reduced to 10 s in the home cage. The use of the highly ‘interesting’ wooden cone 
object as the distracter in the NOR test box during the 1 min ITI was important in 
providing further evidence for the role of distraction during the 1 min ITI. In 
summary, results suggest that distraction produced either by the experimenter 
handling the rats/home cage social interaction or interaction with the distracter object, 
produces distraction-induced object recognition deficits in sub-chronic PCP treated 
rats but not in control rats. This finding is in support of the clinical data showing that 
patients with schizophrenia are more susceptible to impairments in short term 
memory tests when subjects are presented with distracters during a computerised 
visual spatial task (Spring et al, 1991; Cellard et al, 2007). The distracter regimen 
selected for all subsequent studies in this thesis was a 1-min ITI in the home cage. 
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CHAPTER 4 - Effects of sex on deficits in recognition 
memory induced by acute d-amphetamine, PCP and 
sub-chronic PCP in the NOR test 
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4.1 Introduction  
Gender differences in schizophrenia have provided much interest for researchers for 
many years. Schizophrenia affects both men and women, systematic independent 
reviews have concluded that the incidence of schizophrenia is significantly higher in 
men compared to women (Aleman et al, 2003; McGrath et al, 2004). A meta-
analysis revealed that the average age of onset of schizophrenia peaks earlier in men, 
usually between 10-25 years, compared to women where the peak is observed at 25-
35 years (Buchanan & Carpenter, 2005). Another peak occurs, particularly in women 
in mid life; with 23% of people with schizophrenia experiencing their first episode 
after the age of 40 (Salokangas et al, 2003). This second peak of incidence of 
schizophrenia coincides with the decrease in oestrogen observed during the 
menopause in women and supports the theory that oestrogen may provide some 
protection against schizophrenia in women (Seeman, 2012). 
The literature regarding gender differences with respect to cognition in schizophrenia 
remains equivocal. Some researchers suggest that male schizophrenia patients are 
more impaired than female subjects (Goldstein et al, 1998; Seidman et al, 1997), and 
others report women to be more impaired than men (Goldberg et al, 1995; Lewine et 
al, 1996), whereas some report no significant sex differences on cognitive function 
(Bozikas et al, 2010; Hoff et al, 1998). 
Sex differences have also been observed following administration of 
psychotomimetics to humans. Work presented in the literature suggests that female 
anaesthesia patients are more sensitive to the psychotomimetic effects of the NMDA 
receptor antagonist ketamine compared to male patients (Bovill et al, 1971). 
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Conversely, men showed a greater vulnerability to the amnesic effects of ketamine 
than women (Morgan et al, 2006). 
As discussed earlier in chapter 1, it is well known that treatment with PCP or d-
amphetamine can induce a model psychosis that mimics the positive symptoms of 
schizophrenia, but only PCP also mimics the negative symptoms (Sams-Dodd, 1998). 
There has been a surge of interest into the cognitive effects of these psychotomimetic 
agents. Research in our laboratory has demonstrated that acute and sub-chronic 
treatment with both PCP and acute d-amphetamine induces selective cognitive 
deficits in the reversal learning paradigm in female rats (Neill et al, 2010). In another 
study, acute treatment with d-amphetamine disrupted both reference and working 
memory in male rats on a baited 6-arm radial maze (Beatty et al, 1984). Furthermore, 
Jentsch & Taylor (2001) showed impairments when acquiring the reversal of a 
previously-learned stimulus-reward in male rats treated with acute PCP. 
It is important when developing and validating a paradigm in the rat to model a 
human disease which affects both sexes, such as the cognitive impairments 
associated with schizophrenia, that the model can detect cognitive deficits in both 
male and female rats. 
The principle aim of this work is to compare the performance of both male and 
female rats in the NOR test following treatment with acute d-amphetamine and both 
acute and sub-chronic treatment with PCP. 
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4.2 Materials and methods 
4.2.1 Experimental Animals and Design 
A total of 100 female and 82 male, adult, rats were used in these studies. See section 
2.1.1 for housing conditions. 
Treatment 
Doses 
(mg/kg) 
Cohort Male n= 
and weight (g) 
Female n= 
and weight (g) 
Acute PCP 
0.5, 1.0, 
1.5, 2.0, 
2.5, 5.0 
2 (females) 
3 (males) 
30 (290-320) 40 (180-210) 
Acute 
d-amph 
0.1, 0.5, 
1.0, 2.5 
2 (females) 
4 (males) 
32 (260-290) 40 (180-215) 
Sub-chronic 
PCP 
2.0 
5 (females) 
6 (males) 
20 (270-310) 20 (220-240) 
Total n=   82 100 
 
Table 4.1 showing the treatments, rat weights and cohorts used in this study. 
 
4.2.2 Drugs 
For drugs used in this study see tables 4.1 and 2.2 and for the number of rats used in 
each treatment group, see tables 4.2 - 4.5. Due to lack of efficacy of the lower dose 
range of PCP to produce a NOR deficit in male rats, a second experiment was carried 
in the male rats using a higher dose range (2.5-5.0 mg/kg) of PCP (see table 4.3). 
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Dose of PCP 
(mg/kg) 
Male Female 
Initial 
number 
of rats 
Number of rats 
excluded 
Initial 
number 
of rats 
Number of rats 
excluded 
Veh 7 0 10 2 
0.5   10 4 
1.0 7 1 10 2 
1.5 8 2 10 2 
2.0 8 2 10 1 
Table 4.2 The number of male and female rats excluded from the study following acute 
administration of PCP (0.5-2.0 mg/kg, i.p.) or vehicle (0.9% saline, i.p.). 
 
Dose of PCP 
(mg/kg) 
Male 
Initial number of rats Number of rats excluded 
Veh 7 1 
1.0 7 1 
2.5 8 2 
5.0 8 1 
Table 4.3 The number of male rats excluded from the NOR study following acute 
administration of a higher dose range PCP (1.0-5.0 mg/kg, i.p.) or vehicle (0.9% saline, i.p.). 
 
Dose of d-amph 
(mg/kg) 
Male Female 
Initial 
number of 
rats 
Number of 
rats excluded 
Initial 
number of 
rats 
Number of 
rats excluded 
Veh 8 0 10 0 
0.1 8 0 10 0 
0.5 8 0 10 0 
1.0 8 0 10 0 
2.5 8 0   
Table 4.4 The number of male and female rats excluded from the NOR study following 
acute administration of d-amphetamine (0.1-2.5 mg/kg, i.p.) or vehicle (0.9% saline, i.p.). 
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Dose of PCP 
(mg/kg) 
Male Female 
Initial 
number of 
rats 
Number of 
rats excluded 
Initial 
number of 
rats 
Number of 
rats excluded 
Veh 10 0 10 1 
2.0 10 0 10 0 
Table 4.5 The number of male and female rats excluded from the study following acute 
administration of PCP (2.0 mg/kg, i.p.) or vehicle (0.9% saline, i.p.). 
 
4.2.3 NOR Apparatus 
For details regarding the NOR apparatus see section 2.1.3. 
4.2.4 NOR testing 
4.2.4.1 Habituation 
Rats were habituated to the NOR apparatus (see section 2.1.5.1). 
4.2.4.2 Behavioural testing 
For details regarding acquisition, ITI and retention trials see section 2.1.5.2. 
4.2.4.3 Behavioural assessment 
For details regarding behavioural assessment see section 2.1.5.3. 
4.2.5 Statistical analysis 
4.2.5.1 Acute PCP and d-amph 
For details regarding statistical analysis see section 2.1.5.4. 
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4.2.5.2 Sub-chronic PCP 
Male and female comparisons in total exploration time and DI were analysed by a 
repeated measures two-way ANOVA. This detected the main effect of drug 
treatment, main effect of sex (male and female) and the interaction between drug 
treatment and sex. Further planned analysis by unpaired Student’s t-test was carried 
out to compare males with females on the total exploration time during the 
acquisition or retention trials. Paired Student’s t-test was carried out to compare 
males with females on the DI. 
4.3 Results 
4.3.1 Effect of acute PCP treatment in the acquisition trial in female rats 
A two-way ANOVA revealed that acute treatment with PCP did not produce any 
significant effect on object exploration in the acquisition trial of the NOR test (F4, 
35=0.78, NS). Rats from all treatment groups spent similar times exploring both the 
objects (figure 4.1). A small reduction in total exploration of the identical objects 
was observed at the two highest doses of PCP (1.5 and 2.0 mg/kg), however a one-
way ANOVA on the total exploration times revealed no significant effect (F4, 
39=0.67, NS; table 4.6). 
4.3.2 Effect of acute PCP treatment in the retention trial in female rats 
An overall two-way ANOVA revealed that treatment with acute PCP produced a 
significant effect on object exploration in the retention trial of the NOR test (F4, 
35=4.29, P<0.01; figure 4.2). Post-hoc analysis revealed that vehicle control rats had 
a significant preference for the novel compared with the familiar object (P<0.05). 
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This preference in the vehicle treated rats for the novel object was not observed in 
the acute PCP treated rats at any of the doses tested (0.5 – 2.0 mg/kg), i.e. these rats 
spent similar amount of time exploring both objects i.e. rats lost the ability to 
discriminate the familiar object from the novel object. Analysis of the total 
exploration time of the objects in the retention trial by a one-way ANOVA revealed 
no significant effect of drug treatment (F4, 39=0.53, NS; table 4.6). 
4.3.3 Effect of acute PCP treatment on Discrimination Index (DI) in 
female rats 
One-way ANOVA on the DI data showed a significant effect of PCP treatment on 
the rats’ ability to discriminate between the familiar and novel objects (F4, 39=3.48, 
P<0.05). Further post-hoc analysis revealed that rats treated with 1.5 mg and 2.0 
mg/kg of acute PCP showed a significant (P<0.05) reduction in DI when compared 
with the vehicle control group (Figure 4.3). 
4.3.4 Effect of acute PCP treatment on the number of line crossings in the 
NOR test in female rats 
Figure 4.4 shows the effect of acute PCP treatment on the total number of line 
crossings during the acquisition and retention trials of the NOR test. One-way 
ANOVA revealed no significant effect of acute PCP on line crossings (F4, 39=0.59, 
NS). 
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Figure 4.1 The effect of acute PCP (0.5-2.0 mg/kg, i.p.) on exploration times (s) of two 
identical objects in the 3 min acquisition trial in a NOR test in female rats. Data are shown 
as mean ± S.E.M. (n=6-10 per group). 
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Figure 4.2 The effect of acute PCP (0.5-2.0 mg/kg, i.p.) on exploration times (s) of a 
familiar and a novel object in the 3 min retention trial in the NOR test in female rats. Data 
are shown as mean ± S.E.M. (n=6-10 per group) *P<0.05, significant increase in time spent 
exploring the novel compared with the familiar object. 
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Figure 4.3 The effect of acute PCP (0.5-2.0 mg/kg, i.p.) on the DI in the NOR test in female 
rats. Data are expressed as mean ± S.E.M. (n=6-10 per group). *P<0.05 significant reduction 
compared to vehicle. 
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Figure 4.4 The effect of acute PCP (0.5-2.0 mg/kg, i.p.) on the total number of line 
crossings in the acquisition and retention trials of the NOR test in female rats. Data are 
expressed as mean ± S.E.M. (n=6-10 per group).  
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PCP (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
veh 23.1 ± 3.9 18.1 ± 4.3 
0.5 24.8 ± 2.9 14.8  ± 1.7 
1.0 22.9 ± 3.6 15.6  ± 2.9 
1.5  16.3 ± 1.2 16.9  ± 3.6 
2.0 14.2 ± 2.3 11.6  ± 2.3 
 
Table 4.6 The effect of acute PCP (0.5-2.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on 
the total exploration time in the acquisition and retention trials of the NOR test in 
female rats. Data are expressed as the mean ± S.E.M. (n=6-10 per group). 
 
4.3.5 Effect of acute PCP treatment (1.0-2.0 mg/kg) in the acquisition trial 
in male rats 
A two-way ANOVA revealed that treatment with PCP (0.5-2.0 mg/kg) did not 
produce any significant effect on object exploration in the acquisition trial of the 
NOR test (F3, 21=0.35, NS). Rats from all treatment groups spent similar times 
exploring both the objects (figure 4.5). Analysis of the total exploration of the 
objects in the acquisition trial by a one-way ANOVA revealed no significant effect 
of drug treatment (F3, 24=0.75, NS; table 4.7). 
4.3.6 Effect of acute PCP treatment (1.0-2.0 mg/kg) in the retention trial 
in male rats 
An overall two-way ANOVA revealed that treatment with PCP (0.5-2.0 mg/kg) did 
not produce a significant effect on object exploration in the retention trial of the 
NOR test (F3, 21=2.07, NS; figure 4.6). However, planned post-hoc analysis revealed 
120 
 
a significant preference for the novel object when compared with the familiar object 
following treatment with vehicle (P<0.001), 1.0 mg/kg of PCP (P<0.001) and 2.0 
mg/kg PCP (P<0.01). Rats treated with the middle dose of PCP (1.5 mg/kg) failed to 
demonstrate a preference for the novel compared to familiar object. Acute treatment 
with PCP (1.0-2.0 mg/kg) did not produce any clear cognitive deficit in male rats; 
hence a higher dose range was selected (see section 4.3.10). Analysis of the total 
exploration time of the objects in the retention trial by a one-way ANOVA revealed 
no significant effect of drug treatment (F3, 24=1.57, NS; table 4.7). 
4.3.7 Effect of acute PCP treatment (1.0-2.0 mg/kg) on the Discrimination 
Index (DI) in male rats 
One-way ANOVA on the DI data showed no significant effect of acute PCP 
treatment on the male rats’ ability to discriminate between the familiar and novel 
objects (F3, 24=1.56, NS; Figure 4.7). 
4.3.8 Effect of acute PCP treatment (1.0-2.0 mg/kg) on the number of line 
crossings in the NOR test in male rats 
Figure 4.8 shows the effect of acute PCP treatment on the total number of line 
crossings during the acquisition and retention trial of the NOR test. One-way 
ANOVA revealed no significant effect of PCP on line crossings (F3, 24=0.35, NS). 
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Figure 4.5 The effect of acute PCP (1.0-2.0 mg/kg, i.p.) on exploration times (s) of two 
identical objects in the 3 min acquisition trial in the NOR test in male rats. Data are shown 
as mean ± S.E.M. (n=6-7 per group). 
 
veh 1.0 1.5 2.0
0
5
10
15
20
25
30
35
Familiar
Novel
*** ***
**
Male acute PCP: Retention trial
Dose (mg/kg)
E
x
p
lo
r
a
ti
o
n
 t
im
e
 (
s)
 
Figure 4.6 The effect of acute PCP (1.0-2.0 mg/kg, i.p.) on exploration times (s) of a 
familiar and a novel object in the 3 min retention trial of the NOR test in male rats. Data are 
shown as mean ± S.E.M. (n=6-7 per group) **P<0.01-***P<0.001, significant increase in 
time spent exploring the novel compared with the familiar objects. 
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Figure 4.7 The effect of acute PCP (1.0-2.0 mg/kg, i.p.) on the DI in the NOR test in male 
rats. Data are expressed as mean ± S.E.M. (n=6-7 per group). 
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Figure 4.8 The effect of acute PCP (1.0-2.0 mg/kg, i.p.) on the total number of line 
crossings in the acquisition and retention trials of the NOR test in male rats. Data are 
expressed as mean ± S.E.M. (n=6-7 per group).  
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PCP (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 36.0 ± 3.3 35.6 ± 3.2 
1.0 34.8 ± 6.0 36.8  ± 4.6 
1.5 33.6 ± 4.4 30.7  ± 5.1 
2.0 33.5  ± 3.3 43.0 ± 2.9 
 
Table 4.7 The effect of acute PCP (1.0-2.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the total 
exploration time in the acquisition and retention trials of the NOR test in male rats. Data are 
expressed as the mean ± S.E.M. (n=6-7 per group). 
 
4.3.9 Effect of acute PCP treatment (1.0-5.0 mg/kg) on the acquisition 
trial in male rats 
A two-way ANOVA revealed that treatment with PCP (1.0-5.0 mg/kg) did not 
produce any significant effect on object exploration in the acquisition trial of the 
NOR test (F3, 21=0.66, NS). Rats from all treatment groups spent similar times 
exploring both the objects (figure 4.9). Analysis of the total exploration of the 
objects in the acquisition trial by a one-way ANOVA showed a significant effect of 
drug treatment (F3, 24=5.5, P<0.01). Further post-hoc analysis revealed that the 
highest dose of PCP (5.0 mg/kg) produced a significant (P<0.01) reduction in total 
object exploration time in the acquisition trial when compared with vehicle treated 
rats (table 4.8). 
4.3.10 Effect of acute PCP treatment in the retention trial in male rats 
(higher dose range) 
An overall two-way ANOVA revealed that treatment with PCP (1.0-5.0 mg/kg) did 
not produce any significant effect on object exploration in the retention trial of the 
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NOR test (F3, 21=0.83, NS; figure 4.10). Planned post-hoc analysis revealed 
significant preferences for the novel object when compared with the familiar object 
following treatment with vehicle (P<0.05) and 5.0 mg/kg of PCP (P<0.05). Rats 
treated with the low dose of PCP (1.0 mg/kg) and middle dose of PCP (2.5 mg/kg) 
demonstrated a trend towards a preference for the novel compared to familiar object 
(P=0.08 and P=0.09 respectively). Analysis of the total exploration time of the 
objects in the retention trial by a one-way ANOVA revealed no significant effect of 
drug treatment (F3, 24=1.44, NS; table 4.8). 
4.3.11 Effect of acute PCP treatment on the DI in the NOR test in male 
rats (higher dose range) 
One-way ANOVA on the DI data showed no significant effect of PCP treatment on 
the rats’ ability to discriminate between the familiar and novel objects (F3, 24=0.49, 
NS; figure 4.11). 
4.3.12 Effect of acute PCP treatment on the total number of line crossings 
in the NOR test male rats (high dose range) 
One-way ANOVA on the line crossings data showed a significant effect of PCP 
treatment (F3, 24=5.22, P<0.01; figure 4.12). However, post-hoc analysis failed to 
demonstrate any individual treatment effects. 
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Figure 4.9 The effect of PCP (1.0-5.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on exploration 
times (s) of two identical objects in the 3 min acquisition trial of the NOR test in male rats. 
Data are shown as mean ± S.E.M. (n=6-7 per group). 
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Figure 4.10 The effect of PCP (1.0-5.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.)  on exploration 
times (s) of  a novel and familiar objects in the 3 min retention trial of the NOR test in male 
rats. Data are shown as mean ± S.E.M. (n=6-7 per group) *P<0.05, significant increase in 
time spent exploring the novel compared with the familiar object, Student’s t-test. 
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Figure 4.11 The effect of PCP (1.0-5.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the DI of 
the NOR test in male rats. Data are expressed as mean ± S.E.M. (n=6-7 per group). 
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Figure 4.12 The effect of acute PCP (1.0-5.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the 
total number of line crossings in the acquisition and retention trials of the NOR test in male 
rats. Data are expressed as mean ± S.E.M. (n=6-7 per group).  
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PCP (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 27.0 ± 4.2 23.3 ±4.8 
1.0 22.7 ± 2.8 20.7 ± 4.2 
2.5 18.2 ± 3.1 15.2 ± 3.8 
5.0 9.3 ± 2.9 ** 12.6 ± 4.1 (P=0.17) 
 
Table 4.8  The effect of acute PCP (1.0-5.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the total 
exploration times in the acquisition and retention trial of the NOR test in male rats. Data are 
expressed as the mean ± S.E.M. (n=6-7 per group). **P<0.01; significant reduction in total 
exploration time when compared to vehicle control. 
 
4.3.13 Effect of acute d-amph treatment in the acquisition trial in female 
rats 
A two-way ANOVA revealed that treatment with d-amph did not produce any 
significant effect on object exploration in the acquisition trial of the NOR (F3, 
36=1.06, NS). Rats from all treatment groups spent similar times exploring both the 
objects (figure 4.13). A one-way ANOVA on the total exploration times in the 
acquisition trial revealed a significant effect (F3, 39=2.97, P<0.05). Post-hoc analysis 
showed that the highest dose of d-amph (1.0 mg/kg) significantly (P<0.05) reduced 
the total exploration times of the identical objects when compare to vehicle control 
(table 4.9). 
4.3.14 Effect of acute d-amph treatment in the retention trial in female 
rats 
An overall two-way ANOVA revealed that treatment with d-amph did not produce a 
significant effect on object exploration in the retention trial of the NOR test (F3, 
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36=1.79, NS; figure 4.14). However, planned post-hoc comparisons revealed that rats 
spent significantly (P<0.05) more time exploring the novel objects during the 
retention trial in the vehicle control group and at the lowest dose of d-amph (0.1 
mg/kg). This significant preference in the vehicle and lowest dose of d-amph (0.1 
mg/kg) treated rats for the novel object was not observed in the rats treated with the 
higher doses of d-amph (0.5 – 1.0 mg/kg), i.e. these rats could not discriminate 
between the objects. Analysis of the total exploration time of the objects in the 
retention trial by a one-way ANOVA revealed no significant (F3, 39=2.68, NS) effect 
of drug treatment. However, planned post-hoc analysis revealed that the highest dose 
of d-amph (1.0 mg/kg) significantly (P<0.05) reduced the total exploration time of 
the objects when compared to vehicle control (table 4.9). 
4.3.15 Effect of acute d-amph treatment Discrimination Index (DI) in 
female rats 
One-way ANOVA on the DI data showed no significant effect of d-amph treatment 
on the rats’ ability to discriminate between the familiar and novel objects (F3, 36=2.42, 
NS). Rats treated with the highest doses of d-amph (0.5-1.0 mg/kg) displayed a 
reduction in DI; however this failed to reach statistical significance (figure. 4.15).  
4.3.16 Effect of acute d-amph treatment on line crossings in female rats 
Figure 4.16 shows the effect of acute d-amph treatment on total line crossings of the 
rats during the acquisition and retention trials in the NOR test. One-way ANOVA 
revealed a significant effect of d-amph on line crossings (F3, 39=8.46, P<0.001). 
Further post-hoc analysis of the total line crossings revealed that the two highest 
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doses of d-amph (0.5 and 1.0 mg/kg) induced a significant (P<0.01 and P<0.05 
respectively) increase in line crossings. 
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Figure 4.13 The effect of acute d-amph (0.1-1.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on 
exploration times (s) of two identical objects in the 3 min acquisition trial in the NOR test in 
female rats. Data are shown as mean ± S.E.M. (n=10 per group). 
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Figure 4.14 The effect of acute d-amph (0.1-1.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on 
exploration times (s) of a novel and familiar object in the 3 min retention trial in the NOR 
test in female rats. Data are shown as mean ± S.E.M. (n=10 per group). *P<0.05; significant 
increase in time spent exploring the novel compared with the familiar object. 
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Figure 4.15 The effect of acute d-amph (0.1-1.0mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the 
DI in female rats. Data are expressed as mean ± S.E.M. (n=10 per group).  
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Figure 4.16 The effect of acute d-amph (0.1-1.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the 
total number of line crossings in the acquisition + retention trial in the NOR task in female 
rats. Data are expressed as mean ± S.E.M. (n=10 per group).  *P<0.05-**P<0.01; significant 
increase in line crossings compared to vehicle. 
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d-amph 
(mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Vehicle 33.5 ± 3.3 27.9  ± 2.2 
0.1 28.1 ± 4.2 26.6 ± 4.4 
0.5 22.8 ± 2.0 (P=0.058) 24.5 ± 4.1 
1.0  21.5 ± 3.3* 14.9 ± 3.6* 
 
Table 4.9 The effect of acute treatment with d-amph (0.5-1.0 mg/kg, i.p.) and 0.9% saline 
(veh, i.p.) on the total exploration time in the acquisition and retention trial of the NOR test 
in female rats. Data are expressed as the mean ± S.E.M. (n=10 per group). *P<0.05, 
significant reduction in total exploration time when compared to vehicle control. 
 
 
4.3.17 Effect of acute d-amph treatment in the acquisition trial in male 
rats 
A two-way ANOVA revealed that treatment with d-amph did not produce any 
significant effect on object exploration in the acquisition trial of the NOR (F3, 
28=0.59, NS). Rats from all treatment groups spent similar times exploring both the 
objects (figure 4.17). A one-way ANOVA on the total exploration times in the 
acquisition trial revealed a significant effect (F3, 31=3.3, P<0.05). Post-hoc analysis 
showed that the highest dose of d-amph (2.5 mg/kg) significantly (P<0.05) reduced 
the total exploration times of the identical objects when compare to vehicle control 
(table 4.10). 
4.3.18 Effect of acute d-amph treatment in the retention trial in male rats 
An overall two-way ANOVA revealed that treatment with d-amph produced a 
significant effect on object exploration in the retention trial of the NOR test (F3, 
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28=2.9, P<0.05; figure 4.18). Planned post-hoc comparisons revealed that rats spent 
significantly (P<0.05) more time exploring the novel objects during the retention 
trial in the vehicle control group and following treatment with the lowest dose of d-
amph (0.5 mg/kg). This significant preference in the vehicle and lowest dose of d-
amph (0.5 mg/kg) treated rats for the novel object was not observed in the rats 
treated with the higher doses of d-amph (1.0 – 2.5 mg/kg), i.e. these rats could not 
discriminate between the objects. Analysis of the total exploration time of the objects 
in the retention trial by a one-way ANOVA revealed no significant (F3, 31=1.08, NS) 
effect of drug treatment (table 4.10). 
4.3.19 Effect of acute d-amph treatment Discrimination Index (DI) in 
male rats 
One-way ANOVA on the DI data showed a significant effect of d-amph treatment on 
the rats’ ability to discriminate between the familiar and novel objects (F3, 31=3.0, 
P<0.05). Rats treated with the highest dose of d-amph (2.5 mg/kg) displayed a 
significant reduction in DI (figure. 4.19).  
4.3.20 Effect of acute d-amph treatment on the line crossings in male rats 
Figure 4.20 shows the effect of acute d-amph treatment on total line crossings of the 
rats during the acquisition and retention trials in the NOR test. One-way ANOVA 
revealed a significant effect of d-amph on line crossings (F3, 31=18.2, P<0.001). 
Further post-hoc analysis of the total line crossings revealed that the two highest 
doses of d-amph (1.0 and 2.5 mg/kg) induced a significant (P<0.01 and P<0.001 
respectively) increase in line crossings. 
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Figure 4.17 The effect of acute d-amph (0.5-1.0 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on 
exploration times (s) of two identical objects in the 3 min acquisition trial in the NOR test in 
male rats. Data are shown as mean ± S.E.M. (n=8 per group). 
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Figure 4.18 The effect of acute d-amph (0.5-2.5 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on 
exploration times (s) of a novel and familiar objects in the 3 min retention trial in the NOR 
test in male rats. Data are shown as mean ± S.E.M. (n=8 per group). *P<0.05-**P<0.01; 
significant increase in time spent exploring the novel compared with the familiar object. 
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Figure 4.19 The effect of acute d-amph (0.5-2.5 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the 
DI in male rats. Data are expressed as mean ± S.E.M. (n=8 per group). P<0.05; significant 
reduction in DI compared to vehicle. 
 
 
 
vehicle 0.5 1.0 2.5
0
20
40
60
80
100
120
Dose (mg/kg)
Male acute d-amphetamine: Line crossings
***
**
L
in
e
 C
r
o
ss
in
g
s
 
 
Figure 4.20 The effect of acute d-amph (0.5-2.5 mg/kg, i.p.) or 0.9% saline (veh, i.p.) on the 
total number of line crossings in the acquisition + retention trial in the NOR test in male rats. 
Data are expressed as mean ± S.E.M. (n=8 per group).  **P<0.01-**P<0.001; significant 
increase in line crossings compared to vehicle. 
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d-amph 
(mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
veh 30.0 ± 2.8 21.4 ± 4.0 
0.5 28.9 ± 3.2 25.4 ± 2.7 
1.0 22.6 ± 3.5 23.1 ± 3.9 
2.5  18.8 ± 1.8 * 16.9 ± 3.1 
 
Table 4.10 The effect of acute treatment with d-amph (0.5-2.5 mg/kg, i.p.) and 0.9% saline 
(veh, i.p.) on the total number of line crossings in the acquisition and retention trial of the 
NOR test in female rats. Data are expressed as the mean ± S.E.M. (n=8 per group). *P<0.05; 
significant reduction in total exploration time when compared to vehicle control. 
 
4.3.21 Effect of sub-chronic PCP treatment in the acquisition trial in 
female rats 
A two-way ANOVA revealed that sub-chronic treatment with PCP did not produce 
any significant effect on object exploration in the acquisition trial of the NOR test 
(F1, 17=0.89, NS). Rats from both treatment groups spent similar times exploring both 
the objects (figure 4.21). Post-hoc analysis of the total exploration of the objects in 
the acquisition trial by unpaired Student’s t-test revealed no significant effect of drug 
treatment (table 4.11) 
4.3.22 Effect of sub-chronic PCP treatment in the retention trial in female 
rats 
An overall two-way ANOVA revealed that treatment with sub-chronic PCP 
produced a significant effect on object exploration in the retention trial of the NOR 
test (F1, 17=17.94, P<0.001) (figure 4.22). Post-hoc analysis revealed that vehicle 
control rats had a significant preference for the novel compared with the familiar 
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object, P<0.05. This preference in the vehicle treated rats for the novel object was 
not observed in the sub-chronic PCP treated rats, i.e. these rats spent similar amount 
of time exploring both objects. Analysis of the total exploration of the objects in the 
retention trial by unpaired Student’s t-test revealed a significant (P<0.05) increase in 
sub-chronic PCP treated rats compared with the vehicle control group (table 4.11).  
4.3.23 Effect of sub-chronic PCP treatment on Discrimination Index (DI) 
in female rats 
Following treatment with sub-chronic PCP, an unpaired Student’s t-test revealed a 
significant (P<0.001) reduction in DI compared with the vehicle group. (figure 4.23). 
4.3.24 Effect of sub-chronic PCP treatment on total number of line 
crossings in the NOR test in female rats 
Figure 4.24 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings during the acquisition and retention trials of the NOR test. Unpaired 
Student’s t-test revealed no significant effect of sub-chronic PCP treatment on line 
crossings. 
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Figure 4.21 The effect sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on exploration of two identical objects in the 3 min acquisition trial of 
the NOR test in female rats. Data are shown as mean ± S.E.M. (n=9-10 per group). 
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Figure 4.22 The effect sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on exploration of a novel and a familiar object in the 3 min retention 
trial in a NOR test in female rats. Data are shown as mean ± S.E.M. (n=9-10 per group). 
*P<0.05; significant difference between the time spent exploring the familiar compared with 
the novel object. 
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Figure 4.23 The effect of sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on the DI in female rats. Data are expressed as the mean ± S.E.M. 
(n=9-10 per group). *** P<0.001; significant reduction in DI when compared with vehicle. 
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Figure 4.24 The effect sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on the total number of line crossings in the acquisition and retention 
phase in the NOR test in female rats. Data are expressed as the mean ± S.E.M. (n=9-10 per 
group). 
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Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 32.7 ± 4.5 17.8 ± 3.4 
PCP 30.4 ± 6.7 30.3 ± 6.8* 
 
Table 4.11 The effect of sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) on 
the total exploration time in the acquisition and retention trial of the NOR test in female rats. 
Data are expressed as the mean ± S.E.M. (n=9-10 per group). *P<0.05; significant increase 
in total exploration time compared to vehicle.  
 
 
4.3.25 Effect of sub-chronic PCP treatment in the acquisition trial in male 
rats 
A two-way ANOVA revealed that sub-chronic treatment with PCP did not produce 
any significant effect on object exploration in the acquisition trial of the NOR test 
(F1, 18=2.42, NS). Rats from both treatment groups spent similar times exploring both 
the objects (figure 4.25). Post-hoc analysis of the total exploration of the objects in 
the acquisition trial by unpaired Student’s t-test revealed no significant effect of drug 
treatment (table 4.12). 
4.3.26 Effect of sub-chronic PCP treatment in the retention trial in male 
rats 
An overall two-way ANOVA revealed that treatment with sub-chronic PCP 
produced no significant effect on object exploration in the retention trial of the NOR 
test (F1, 18=1.00, NS) (figure 4.26). However, planned post-hoc analysis revealed that 
vehicle control rats had a significant preference for the novel compared with the 
familiar object, P<0.05. This significant preference in the vehicle treated rats for the 
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novel object was not observed in the sub-chronic PCP treated rats, i.e. these rats 
spent equivalent amount of time exploring both objects. Post-hoc analysis of the total 
exploration of the objects in the retention trial by unpaired Student’s t-test revealed 
no significant effect of drug treatment (table 4.12). 
4.3.27 Effect of sub-chronic PCP treatment on Discrimination Index (DI) 
in male rats 
Following treatment with sub-chronic PCP, an unpaired Student’s t-test revealed no 
significant difference in DI compared with the vehicle group (Figure 4.27). 
4.3.28 Effect of sub-chronic PCP treatment on total number of line 
crossings in the NOR test in male rats 
Figure 4.28 shows the effect of sub-chronic PCP treatment on the total number of 
line crossings during the acquisition and retention trials of the NOR test. Unpaired 
Student’s t-test revealed no significant effect of sub-chronic PCP treatment on line 
crossings. 
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Figure 4.25 The effect sub-chronic PCP treatment (2mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on exploration of two identical objects in the 3 min acquisition trial in 
the NOR test in male rats. Data are shown as mean ± S.E.M. (n=10 per group). 
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Figure 4.26 The effect sub-chronic PCP treatment (2mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on exploration of a novel and a familiar object in the 3 min retention 
trial in the NOR test in male rats. Data are shown as mean ± S.E.M. (n=10 per group). 
*P<0.05; significant increase in time spent exploring the novel compared with the familiar 
object. 
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Figure 4.27 The effect sub-chronic PCP treatment (2mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on the DI in male rats. Data are expressed as the mean ± S.E.M. 
(n=10 per group). 
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Figure 4.28 The effect sub-chronic PCP treatment (2mg/kg i.p. twice daily for 7-days) or 
0.9% saline (veh, i.p.) on the total number of line crossings in the acquisition and retention 
trials in the NOR test in male rats. Data are expressed as the mean ± S.E.M. (n=10 per 
group). 
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Treatment 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 13.4 ± 2.4 18.6 ± 2.8 
PCP 18.3 ± 2.1 16.6 ± 3.3 
 
Table 4.12 The effect of sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) on 
the total exploration time in the acquisition and retention trial of the NOR test in male rats. 
Data are expressed as the mean ± S.E.M.  (n=10 per group). 
 
 
 
4.3.29 Male versus female comparisons 
4.3.29.1 Acquisition trial (males v females; total exploration) 
A two-way ANOVA revealed that sub-chronic treatment with PCP did not produce 
any significant effect when comparing males to females on total object exploration in 
the acquisition trial of the NOR test (F1, 18=0.89, NS, table 4.12). However, planned 
post-hoc analysis using unpaired Student’s t-test revealed a significant (P<0.01) 
decrease in total exploration time in the vehicle group of male rats when compared to 
female rats in the acquisition trial. 
4.3.29.2 Retention trial (males v females; total exploration) 
A two-way ANOVA revealed that sub-chronic treatment with PCP did not produce 
any significant effect when comparing males to females on total object exploration in 
the retention trial of the NOR test (F1, 18=0.89, NS; table 4.12).  
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4.3.29.3 DI (males v females) 
A two-way ANOVA revealed that sub-chronic treatment with PCP produced a 
significant effect when comparing males to females on DI in the NOR test (F1, 
18=25.0, P<0.001). Planned post-hoc analysis using unpaired Student’s t-test on the 
vehicle treated rats revealed a significant reduction in DI in the male compared to 
female rats, suggesting reduced object discrimination (table 4.13). 
Sub-
chronic 
treatment 
Female 
Total exploration time (s) 
Male 
Total exploration time (s) 
Acquisition 
trial 
Retention trial Acquisition trial Retention trial 
Veh 32.7 ± 4.5 17.8 ± 3.4 13.4 ± 2.4 ## 18.6 ± 2.8 
PCP 30.4 ± 6.7 30.3 ± 6.8 18.3 ± 2.1 
16.6 ± 3.3 (P= 
0.08 male v 
female) 
 
Table 4.13 The effect of sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) on 
the total exploration time in the acquisition and retention trial of the NOR test in male and 
female rats. Data are expressed as the mean ± S.E.M.  (n=10 per group). ##P<0.01; 
significant decrease in total exploration time in males when compared to female in the 
acquisition trial. 
 
 
Sub-
chronic 
treatment 
Female 
DI 
Male 
DI 
Veh 0.67 ± 0.12 0.26 ± 0.08 
PCP -0.28 ±  0.12 0.13 ± 0.07 
 
Table 4.14 The effect of sub-chronic PCP treatment (2 mg/kg i.p. twice daily for 7-days) on 
the DI of the NOR test in male and female rats. Data are expressed as the mean ± S.E.M.  
(n=10 per group).  
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Treatment 
 
Doses 
tested 
(mg/kg) 
Deficit in 
the 
retention 
trial. 
Dose 
(mg/kg 
Deficit 
in the  
DI. 
Dose 
(mg/kg) 
Effect on 
line 
crossings. 
Dose (mg/kg) 
Effect on total 
exploration. 
Dose    
(mg/kg) 
Females 
Acute 
PCP 
0.5, 1.0, 
1.5, 2.0 
Yes 
0.5, 1.0, 1.5, 
2.0 
Yes 
1.5, 2.0 
No No 
Males 
Acute 
PCP 
0.5, 1.0, 
1.5, 2.0 
Yes 
1.5 
No No No 
Males 
Acute 
(higher 
doses) 
1.0, 2.5, 
5.0 
1.0 P=0.08, 
2.5 P=0.09 
No No 
#(acquisition;5
.0, retention; 
5.0, P=0.17) 
Females 
Acute d-
amph 
0.1, 0.5, 
1.0 
Yes 
0.5, 1.0 
No *0.5, 1.0 
#(acquisition;1
.0, retention; 
1.0) 
Males 
Acute d-
amph 
0.5, 1.0, 
2.5 
Yes 
1.0, 2.5 
Yes 
2.5 
*1.0, 2.5 
#(acquisition;1
.0) 
 
Table 4.15 Summary table showing the effect of acute treatment with PCP (0.5-2.0 mg/kg; 
female and 0.5-5.0 mg/kg; male rats) and d-amph (0.1-1.0 mg/kg, i.p.; female and 0.5-2.5 
mg/kg, i.p.; male rats) on performance in the NOR test. Significant increase* or decrease# 
(P<0.05-P<0.01) compared to the vehicle treated group. 
 
 
 
 
 
146 
 
Treatment 
 
Doses 
tested 
(mg/kg) 
Deficit in 
the 
retention 
trial 
Deficit in 
the  DI 
 
 
Effect on 
line 
crossings 
 
Effect on total 
exploration 
 
Sub-
chronic 
PCP: 
Females  
2.0 Yes Yes No No 
Sub-
chronic 
PCP: 
Males 
2.0 Yes No No No 
 
Table 4.16 Summary table showing the effect of sub-chronic PCP treatment (2 mg/kg, i.p. 
twice daily for 7 days) on the on performance of males and female rats in the NOR test.  
 
 
4.4 Discussion 
4.4.1 Acute PCP (males v females) 
Following acute treatment with PCP a cognitive impairment was observed in female 
rats at all of the doses tested in the NOR test, however the efficacy of acute PCP to 
impair recognition memory in male rats was reduced, such that a higher dose range 
of PCP was selected albeit with inconsistent results. The male rats appeared to be 
somewhat insensitive to the selective cognitive impairment observed in the female 
rats following acute PCP treatment. The acute treatment with PCP in female rats 
produced selective impairments in recognition memory as measured in the retention 
trial, without any non-specific effects in the acquisition trial or an effect on the 
number of line crossings or total exploration times. However, the male rats’ lack of 
sensitivity to PCP was evident, even at 10x the effective dose of PCP needed to 
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produce a cognitive deficit in female rats; the male rats could still effectively 
discriminate between the novel and familiar objects in the retention trial. The 
increased sensitivity to PCP observed in female is in agreement with studies 
demonstrating that female rats are more sensitive to the neurotoxic and to the 
locomotor stimulation effect of acute PCP treatment (Johnson et al, 1998). These 
results may be explained in part by PCP metabolism studies comparing male and 
female rats. Shelnut and colleagues (1999) demonstrated that female rats from three 
different strains showed a significantly reduced ability to metabolise PCP compared 
to males. Furthermore, pharmacokinetic studies in Sprague-Dawley rats showed 
females to be significantly more sensitive to PCP (Nabeshima et al, 1984). Gartlon et 
al (2006) found higher levels of PCP in the plasma and brain tissue of female rats, 
following the same dose of PCP as male rats, which may explain the differential 
effects of acute PCP treatment in the NOR test. Because of the serious potential to 
produce adverse reactions to PCP in humans, clinical studies administering PCP at 
active pharmacological doses have not been conducted in 50 years (Domino, 1992). 
However, gender differences have been studied following the administration of 
ketamine (Lahti et al, 2001), which is an NMDA receptor antagonist like PCP with 
similar chemical structure and mechanism of action. The effects of ketamine are 
similar to PCP, but ketamine is less potent with effects of much shorter duration 
(Hevers et al, 2008). In agreement with the acute PCP studies, female rats have been 
shown to be more vulnerable to the neurotoxic effects of ketamine when compared 
to male rats (Jevtovic-Todorovic et al, 2001) and more susceptible to certain 
behavioural effects (Winters et al, 1986). The animal data is supported by an early 
clinical study in the 1970s which suggested that female surgical patients were more 
sensitive to the psychotomimetic effects of acute ketamine administration than males 
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(Bovill et al, 1971). However, clinical studies examining the effect of gender on the 
cognitive effects of ketamine have shown contradictory results to those of animal 
studies. A meta-analysis has shown that men are more sensitive to the memory 
impairing effects of ketamine than women (Morgan et al, 2006), particularly in a 
verbal recall test. 
4.4.2 Acute d-amphetamine (males v females) 
The effect of d-amphetamine in male and female rats in the NOR test has 
demonstrated an enhanced sensitivity to induce recognition deficits in females. A 
higher dose of amphetamine was required in male rats to induce the recognition 
memory impairment that was observed in the female rats. Furthermore, there was a 
lack of effect of d-amphetamine in male rats to induce a disruption in the DI which 
suggests a lack of effect of d-amphetamine in males. In both males and females, the 
lack of effect of d-amphetamine in the acquisition trial of the NOR test suggests 
selectivity for the retention trial, however the impairment in recognition memory 
induced by d-amphetamine was not observed without a significant increase in the 
total number of line crossings, which is a measure of general activity and therefore 
suggests a lack of specificity of d-amphetamine to disrupt recognition memory in 
this test. In another study, aimed at determining the effect of gender on locomotor 
activity response to amphetamine, it was shown that female rats were more sensitive 
to amphetamine-induced hyperactivity and stereotypic behaviours (Hallé-Milesi et al, 
2007). Furthermore, ovariectomised rats treated with oestrogen demonstrate an 
enhanced amphetamine-induced release of dopamine from striatal tissue in-vitro 
(Becker et al, 2003) and in-vivo using microdialysis techniques (Castner et al, 1993).  
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In our laboratory, we have previously shown that administration of the same dose 
range of d-amphetamine to female rats induces selective impairments in reversal 
learning task, which can be successfully restored by haloperidol (Idris et al, 2005). 
The cognitive dysfunction induced by d-amphetamine is thought to be a result of an 
excessive release of dopamine in the prefrontal cortex (Mason et al, 1992; Ridley et 
al, 1998) and studies in our laboratory have previously shown d-amphetamine 
induced impairments in a version of the Wisconsin test modified for the marmoset 
(Smith et al, 1999). 
4.4.3 Sub-chronic PCP (males v females) 
These data demonstrate that sub-chronic treatment with PCP impairs recognition 
memory when comparing the time spent exploring the novel compared with familiar 
object in the NOR test in all rats (i.e. both male and female rats). However, the 
impairment appeared to be more effective in the female rats as demonstrated by the 
highly significant impairment in the female rats’ ability to discriminate novel and 
familiar objects. There was a lack of effect of sub-chronic PCP treatment to induce a 
recognition deficit as measured by the discrimination index (DI). Interestingly, the 
discrimination index (DI) data in this study indicate that female control rats were 
superior at discriminating between the novel and familiar objects compared to the 
male control rats. These data provide support for the results by Sutcliffe et al (2007), 
whereby female rats compared to male rats, performed significantly better in the 
NOR test following increasing ITIs. The impairment in object recognition memory 
observed in both genders following treatment with sub-chronic PCP was selective 
for the retention trial only, and was observed without any non-specific effects in the 
acquisition trial, number of line crossings or the total exploration times. These 
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findings of improved performance in females and increased effect of sub-chronic 
PCP are in agreement with results of Snigdha and colleagues (2011), who reported 
that male rats were less sensitive to sub-chronic PCP-induced deficits in the extra-
dimensional shift stage of the attentional set-shifting task compared to female rats.  
The sub-chronic PCP induced recognition deficits were of similar magnitude to those 
cognitive deficits observed following acute PCP treatment in the female rats. 
Acute PCP treatment has been shown to enhance dopamine in the PFC 
(hyperdopaminergia), whereas, sub-chronic PCP treatment, similar to the dosing 
regimen used in these studies, has been shown to lead to decreased DOPAC levels in 
the medial pre-frontal cortex, which may suggest a decreased dopamine utilisation in 
this area, cortical dopaminergic hypoactivity and impairments in cognition (Jentsch 
et al, 1998). Furthermore, recent work from our laboratory has shown that the PCP-
induced object recognition deficit is accompanied by impaired dopamine 
neurotransmission in the PFC during the retention trial of the task (Snigdha et al, 
2008). This result was also recently confirmed in another study in our laboratory 
(McLean, unpublished observations), suggesting a critical role for prefrontal 
dopamine in object recognition memory and lack of ability of sub-chronic PCP 
treated rats to recognise the familiar object in the retention trail. 
Female gonadal steroid hormone levels such as oestrogen and progesterone and 
vaginal cytology of the female rats were not measured in this study, consequently it 
is not clear which stage of the oestrous cycle the rats were in during the NOR testing. 
However, it has recently been shown in our laboratory that the oestrous cycle has no 
effect on performance in the NOR test (Sutcliffe et al, 2007) or reversal learning 
(McLean et al, 2009). 
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CHAPTER 5 - Further validation of the NOR test: 
Pharmacological validation and effects of novel 
cognitive enhancers to reverse PCP-induced 
deficits.    
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5.1 Introduction 
Neurochemical animal models of schizophrenia based on the dopamine hypothesis 
have been important in explaining some of the symptoms of schizophrenia, 
principally the positive symptoms and developing treatment considerations (Javitt, 
2010). There are limitations surrounding the dopamine hypothesis and a major flaw 
is that only the positive symptoms of schizophrenia are treated with classical 
antipsychotics, the negative and cognitive symptoms appear to be untreated. 
Furthermore, there is no evidence to suggest that any intrinsic deficits have been 
observed within the dopamine system to account for the hyperdopaminergic state 
associated with schizophrenia (Javitt, 2007). 
Sub-chronic treatment with PCP has been shown to produce cognitive impairments 
that mimic those observed in schizophrenia patients (Javitt & Zukin, 1991; Jentsch et 
al, 1997). People who repeatedly self-administer PCP or ketamine, demonstrate 
robust and long lasting cognitive deficits (Cosgrove & Newell, 1991; Curran & 
Morgan, 2000).  Additionally,  sub-chronic PCP administration has been shown to 
induce cognitive impairments in the extra-dimensional shift stage of the attentional 
set-shifting task in rats (McLean et al, 2008; Rodefer et al, 2008) and also selective 
impairments in the reversal phase of a reversal learning task (Abdul-Monim et al, 
2006). Moreover, the cognitive impairments induced by sub-chronic PCP in the 
reversal learning and attentional set-shifting tasks can be reversed by atypical 
antipsychotics but not classical agents (Idris et al, 2010; McLean et al, 2010). The 
sub-chronic PCP model in the rat has also been shown to produce neurobiological 
changes of relevance to schizophrenia such as the decrease in parvalbumin 
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containing neurones found in the hippocampus (Abdul-Monim et al, 2007) and pre-
frontal cortex (McKibben et al, 2010). 
There is evidence from post mortem studies suggesting a decrease in the α-7 
nicotinic receptors in the hippocampus of schizophrenia patients and further 
evidence substantiates the involvement by genetic linkage to the region containing 
the α-7 nicotinic receptor (Freedman et al, 1995; Freedman et al 1997; Breese et al, 
2000). One therapeutic target identified by the MATRICS initiative is the α-7 
nicotinic acetylcholine receptor (kucinski et al, 2011). Studies have demonstrated 
pro-cognitive findings of agonists of the α-7 nicotinic receptors, especially in the 
domain of working memory (see review by Leiser et al, 2009). The α-7 nicotinic 
receptor is less sensitive to nicotine than other nicotinic receptors, and therefore the 
heavy smoking displayed by schizophrenia patients may provide evidence that they 
are trying to activate this receptor, to perhaps compensate for its lower than normal 
expression in schizophrenia patients (Olincy et al, 1997). Research in our laboratory 
has demonstrated improvements in cognition following the administration of the α-7 
nicotinic receptor full agonist PNU-282987 and the PAM (positive allosteric 
modulator) of the α-7 nicotinic receptor PNU-120596 in sub-chronic PCP-induced 
deficits in reversal learning (McLean et al, 2011). Additionally, clinical trials are 
taking place to determine the effect of compounds that activate or modulate the α-7 
nicotinic receptor in schizophrenia patients (www.biospace.com). One of these 
compounds, EVP-6124 an α-7 nicotinic receptor agonist, has demonstrated positive 
effects on cognition and negative symptoms in schizophrenia patients in phase II 
clinical trials,  and will be advancing into phase III in 2012. 
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During the development of potential animal models, pharmacological specificity 
must be determined so that only compounds that are clinically active in affecting 
memory should be active in the behavioural test, whereas compounds of other 
pharmacological classes such as antidepressants and anxiolytics should be inactive. 
The main aim of the work presented in this chapter is to further validate the NOR 
test in rats treated with sub-chronic PCP, comparing the classical antipsychotics with 
the atypical agents, other pharmacological agents such as an anxiolytic, 
antidepressant, analeptic and potential novel pro-cognitive compounds. 
5.2 Materials and methods 
5.2.1 Experimental Animals and Design 
All experiments (using cohorts 7-13) were conducted using adult (180-255g) female 
hooded-Lister rats (Harlan, UK), details are shown in the table 5.1. Experiment 6 
was carried out over two separate experiments, and subsequently the data were 
pooled. For housing conditions see section 2.1.1. For further information regarding 
the drugs used in this study, see table 2.2. 
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Experiment 
number 
Cohort 
number 
Total number of rats 
used 
Weight 
range (g) 
Compound 
tested 
1 7 42 (n=10 veh; n=32 PCP) 190-235 Haloperidol 
2 7 42 (n=10 veh; n=32 PCP) 190-235 Clozapine 
3 8 50 (n=10 veh; n=40 PCP) 210-255 Risperidone 
4 9 50 (n=10 veh; n=40 PCP) 180-220 CDP 
5 10 60 (n=10 veh; n=50 PCP) 190-240 
Fluphenazine 
Fluoxetine 
Risperidone 
Modafinil 
6 
11 & 
12 
70 (n=20 veh; n=50 PCP) 190-220 
PNU-282987 
Nicotine 
7 13 50 (n=10 veh; n=40 PCP) 180-240 PNU-120596 
 
Table 5.1 Details of the rats used in these studies. 
 
Six cohorts of rats, totalling 322 were randomly assigned to receive either vehicle 
(n=70; 0.9% 0.9% saline twice a day, i.p.) or PCP (n=252; 2mg/kg twice a day, i.p.) 
in a volume of 1 ml/kg for 7 days. Subsequently, animals were given a 7-day drug 
free prior to NOR testing. For the sub-chronic PCP dosing regimen, see section 2.1.3. 
In experiment 1, a total of 42 rats were used (n=10 veh; n=32 PCP, cohort 7). Ten 
sub-chronically vehicle treated rats received vehicle acutely and 32 sub-chronic PCP 
treated rats were randomly assigned to receive an acute injection of haloperidol (0.05 
or 0.075 mg/kg, i.p.) or vehicle (distilled water) 30 min prior to NOR testing (see 
table 5.2). Haloperidol (Serenace liquid; 2 mg/ml, Baker Norton) was diluted in 
distilled water. The doses of haloperidol were selected on the basis of previous 
studies showing that haloperidol (0.05 mg/kg) significantly attenuated the d-amph-
induced reversal learning impairment in female hooded-Lister rats (Idris et al, 2005). 
Furthermore, this dose of haloperidol has been shown to occupy 50% of dopamine 
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D2 receptors (Kapur & Seeman, 2001, Kapur et al, 2003). For animal numbers in the 
treatment groups see table 5.2. 
Dose of haloperidol         
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 10 0 
PCP + Veh 10 3 
PCP + 0.05 12 0 
PCP + 0.075 10 1 
 
 
Table 5.2 The number of rats excluded from the NOR study following acute administration 
of haloperidol (0.05-0.075 mg/kg, i.p.) or vehicle (dH2o, i.p.) to sub-chronically PCP treated 
rats (2mg/kg, i.p., twice daily for seven days). 
 
In experiment 2, following a 1-week washout period from experiment 1, a total of 42 
rats were used (n=10 veh; n=32 PCP, cohort 7), Ten sub-chronically vehicle treated 
rats received vehicle acutely (distilled water, i.p.), 30 min prior to testing. The 32 
sub-chronically PCP treated rats were randomly assigned to receive an acute 
injection of clozapine (1 & 5 mg/kg, i.p.) or vehicle (distilled water, i.p.) 30 min 
prior to NOR testing. The doses of clozapine selected in this study were based upon 
previous work in the laboratory showing that 5 mg/kg of clozapine significantly 
attenuated a sub-chronic PCP-induced reversal learning impairment in female 
hooded-Lister rats (Abdul-Monim et al, 2006). For animal numbers in the treatment 
groups see table 5.3 
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Dose of clozapine           
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 10 0 
PCP + Veh 8 0 
PCP + 1.0 12 0 
PCP + 5.0 12 0 
 
Table 5.3 The number of rats excluded from the NOR study following acute administration 
of clozapine (1.0-5.0 mg/kg, i.p.) or vehicle (dH2o, i.p.) to sub-chronically PCP treated rats 
(2mg/kg, i.p., twice daily for seven days). 
 
In experiment 3, a total of 50 rats were used (n=10 veh; n=40 PCP, cohort 8). Ten 
sub-chronically vehicle treated rats received vehicle acutely (saline 0.9%, i.p.), 30 
min prior to testing. The sub-chronically PCP treated rats were randomly assigned to 
receive an acute treatment with risperidone (0.05-0.2 mg/kg, i.p.) or vehicle (saline 
0.9%, i.p.), 30 min prior to testing. The dose range of risperidone (0.05-0.2 mg/kg) is 
slightly lower than the doses required for clinically comparable D2 receptor 
occupancy (0.5-1.0 mg/kg; Kapur & Remington, 2001, Kapur et al, 2003). However, 
it has been demonstrated in operant studies that risperidone (0.2 mg/kg) is 
efficacious against sub-chronic PCP and acute PCP-induced cognitive deficit 
(McLean et al, 2010). For animal numbers in the treatment groups see table 5.4. 
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Dose of risperidone        
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 9 1 
PCP + Veh 11 0 
PCP + 0.05 10 1 
PCP + 0.1 10 0 
PCP + 0.2 10 0 
 
Table 5.4 The number of rats excluded from the NOR study following acute administration 
of risperidone (0.05-0.2 mg/kg, i.p.) or vehicle (dH2o, i.p.) to sub-chronically PCP treated 
rats (2mg/kg, i.p., twice daily for seven days). 
 
In experiment 4, a total of 50 rats were used (n=10 veh; n=40 PCP, cohort 9). Ten 
sub-chronically vehicle treated rats received vehicle acutely (saline 0.9%, i.p.), 30 
min prior to testing. The sub-chronically PCP treated rats were randomly assigned to 
receive an acute treatment with CDP (1.25-5.0 mg/kg, i.p.) or vehicle (saline 0.9%, 
i.p.), 30 min prior to testing. The doses of CDP were selected from data showing 
anxiolytic-like behavioural effects in the open field test in rats at doses of 2.5-10 
mg/kg (Angrini et al, 1998). For animal numbers in the treatment groups see table 
5.5. 
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Dose of CDP                   
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 10 0 
PCP + Veh 10 1 
PCP + 1.25 10 0 
PCP + 2.5 10 0 
PCP + 5.0 10 1 
 
 
Table 5.5 The number of rats excluded from the NOR study following acute administration 
of CDP (1.25-5.0 mg/kg, i.p.) or vehicle (saline 0.9%, i.p.) to sub-chronically PCP treated 
rats (2mg/kg, i.p., twice daily for seven days). 
 
In experiment 5, a total of 60 rats were used (n=10 veh; n=50 PCP, cohort 10). Ten 
sub-chronically vehicle treated rats received vehicle acutely (saline 0.9%, i.p.), 30 
min prior to testing. The sub-chronically PCP treated rats were randomly assigned to 
receive an acute treatment with fluphenazine (0.2 mg/kg, i.p.), fluoxetine (5.0 mg/kg, 
i.p.), risperidone (0.2 mg/kg, i.p.), modafinil (50 mg/kg, p.o.) or vehicle (saline 0.9%, 
i.p.), 30 min prior to testing. The dose of fluphenazine was chosen based on a study 
showing that 0.01-2.5 mg/kg fluphenazine inhibited the hyperactivity response to 
bilateral infusions of dopamine (25μg/24h for 13 days) into the nucleus accumbens 
of marmosets (Costall et al, 1987). The dose of fluoxetine is based upon a 
microdialysis study (Malagié et al, 2000) which demonstrated an increase in 
extracellular levels of serotonin (5-hydroxytryptamine, 5-HT) in the frontal cortex, 
ventral hippocampus and raphe nuclei in anaesthetised rats following treatment with 
fluoxetine (1-20 mg/kg). Furthermore, acute administration of fluoxetine (5 mg/kg), 
significantly reduced immobility in the tail-suspension test in wild-type mice 
(Svenningsson et al, 2002). For animal numbers in the treatment groups, see table 
5.6. Risperidone (0.2 mg/kg) was included in this experiment as a positive control 
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comparator since we had previously demonstrated efficacy of risperidone to reverse 
the sub-chronic PCP-induced cognitive deficit in NOR. The dose of modafinil was 
selected based on data showing the ability of modafinil (64 mg/kg) to ameliorate the 
sub-chronic PCP-induced deficit in extra-dimensional shift in the attentional set-
shifting task in the rat (Goetghebeur and Dias, 2009). Furthermore, acute modafinil 
treatment 64 mg/kg dramatically improved performance on a serial reversal 
discrimination task performed in a T-maze in mice (Béracochéa et al, 2003). 
Treatment                       
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 10 0 
PCP + Veh 10 2 
PCP + Fluphenazine 0.2 10 2 
PCP + Fluoxetine 5.0 10 2 
PCP + Risperidone 0.2 10 0 
PCP + Modafinil 50 10 2 
 
 
Table 5.6 The number of rats excluded from the NOR study following acute administration 
of fluphenazine (0.25 mg/kg, i.p.), fluoxetine (5.0 mg/kg, i.p.), risperidone (0.2 mg/kg, i.p.), 
modafinil (50 mg/kg, p.o.) or vehicle (saline 0.9%, i.p.) to sub-chronically PCP treated rats 
(2mg/kg, i.p., twice daily for seven days). 
 
In experiment 6, a total of 60 rats were used (n=10 veh; n=50 PCP, cohort 11 & 12). 
Twenty sub-chronically vehicle treated rats received vehicle acutely (isotonic H2O 
s.c.), 60 min prior to testing. The sub-chronically PCP treated rats were randomly 
assigned to receive an acute treatment with PNU-282987 (10 and 20 mg/kg, s.c.), 
nicotine (0.2 mg/kg, s.c.) or vehicle (isotonic H2O s.c.), 60 & 30 min respectively, 
prior to testing. The doses of PNU-282987 were selected based on operant reversal 
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learning data showing efficacy to reverse a sub-chronic PCP-induced cognitive 
deficit in female hooded-Lister rats (McLean et al, 2011). The dose of nicotine was 
selected from studies that demonstrated enhancement of acquisition, consolidation 
and restoration of the information in the NOR test, using a 24 h ITI, in male Wistar 
rats following treatment with nicotine at 0.2 mg/kg (Puma et al, 2009). For animal 
numbers in the treatment groups, see table 5.7. 
Treatment                       
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 20 2 
PCP + Veh 20 2 
PCP + PNU-282987 10 10 0 
PCP + PNU-282987 20 10 0 
PCP + Nicotine 0.2 10 2 
 
 
Table 5.7 The number of rats excluded from the NOR study following acute administration 
of PNU-282987 (10-20 mg/kg, s.c.), nicotine (0.2 mg/kg, i.p.) or vehicle (isotonic H2o, s.c.) 
to sub-chronically PCP treated rats (2mg/kg, i.p., twice daily for seven days). 
 
In experiment 7, a total of 50 rats were used (n=10 veh; n=40 PCP, cohort 13). Ten 
sub-chronically vehicle treated rats received vehicle acutely (100% PEG400), 60 min 
prior to testing. The sub-chronically PCP treated rats were randomly assigned to 
receive an acute treatment with PNU-120596 (5 - 10 mg/kg, p.o.) or vehicle (100% 
PEG400), 60 min, prior to testing. The doses for PNU-120596 were selected on the 
basis of previous work whereby administration of PNU-120596 at a dose of 3 mg/kg 
improved auditory gating deficits induced by d-amph in anaesthetised rats (Hurst et 
al, 2005). For animal numbers in the treatment groups, see table 5.8. 
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Dose of PNU-120596      
(mg/kg) 
Initial number of rats Number of rats excluded 
Veh + Veh 10 0 
PCP + Veh 10 0 
PCP + 5 10 0 
PCP + 10 10 1 
PCP + 20 10 1 
 
 
Table 5.8 The number of rats excluded from the NOR study following acute administration 
of PNU-120596 (5-20 mg/kg, p.o.) or vehicle (100% PEG400, p.o.) to sub-chronically PCP 
treated rats (2mg/kg, i.p., twice daily for seven days). 
 
5.2.2 NOR Apparatus 
For the description of the NOR apparatus see section 2.1.4. 
5.2.3 NOR testing 
Rats were tested in the NOR task as described earlier see section 2.1.5. 
5.2.4 Statistical analysis 
Data were analysed as described earlier see section 2.1.5.4. 
5.3 Results 
5.3.1 Effect of acute haloperidol on sub-chronic PCP treatment in the 
acquisition trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of haloperidol (0.05 – 0.075 mg/kg) 
to rats treated with sub-chronic PCP did not produce any significant effect on object 
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exploration in the acquisition trial of the NOR test (F3, 34=1.4, NS). Rats from both 
treatment groups spent similar times exploring both the objects (figure 5.1). A one 
way ANOVA on the total exploration times in the acquisition trial revealed no 
significant effect of drug treatment (F3, 37=0.8, NS; table 5.9). 
5.3.2 Effect of acute haloperidol on sub-chronic PCP treatment in the 
retention trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of haloperidol (0.05 – 0.075 mg/kg) 
to rats treated with sub-chronic PCP produced a significant effect on object 
exploration in the retention trial of the NOR test (F3, 34=5.1, P<0.01; figure 5.2). 
Planned post-hoc comparisons showed that rats treated sub-chronically with vehicle 
spent significantly (P<0.05) more time exploring the novel object during the 
retention trial. However this significant preference for the novel compared to the 
familiar object was not observed in the sub-chronic PCP treated rats and the sub-
chronic PCP treated rats which were administered acute haloperidol i.e. these rats 
spent equivalent amounts of time exploring both objects. A one way ANOVA on the 
total exploration times in the retention trial revealed no significant effect of drug 
treatment (F3, 37=0.4, NS; table 5.9). 
5.3.3 Effect of acute haloperidol on sub-chronic PCP treatment on the DI 
in the NOR test in female rats 
One-way ANOVA on the DI data showed a significant effect of drug treatment on 
the rats ability to discriminate between the familiar and novel objects (F3, 37=4.5, 
P<0.05; figure 5.3). Post-hoc analysis showed a significant reduction in the DI of the 
sub-chronic PCP treated group (P<0.05) compared to vehicle control. Sub-chronic 
164 
 
PCP rats treated with both doses of haloperidol also showed a significant (P<0.01) 
reduction in DI compared to vehicle. 
5.3.4 Effect of acute haloperidol on sub-chronic PCP treatment on the 
number of line crossings in the NOR test in female rats 
Figure 5.4 shows the effect of haloperidol treatment in sub-chronically PCP treated 
rats on the total number of line crossings during the acquisition and retention trial of 
the NOR test. One-way ANOVA revealed no significant effect of any treatment on 
the number of line crossings (F3, 37=1.80, NS). 
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Figure 5.1 The effect of acute haloperidol (h; 0.05 & 0.075 mg/kg, i.p.) and sub-chronic 
PCP (2.0 mg/kg, i.p., twice daily for seven days) on exploration time (s) of two identical 
objects in the 3 min acquisition trial of the NOR test. Data are expressed as the mean ± 
S.E.M. (n=7-12 per group). 
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Figure 5.2 The effect of acute haloperidol (h; 0.05 & 0.075 mg/kg, i.p.) and sub-chronic 
PCP (2.0 mg/kg, i.p., twice daily for seven days) on exploration time (s) of a familiar object 
and a novel object in the 3 min retention trial. Data are expressed as the mean ± S.E.M. 
(n=7-12 per group). *P<0.05; significant increase in time spent exploring the novel 
compared with the familiar object, Student’s t-test. 
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Figure 5.3 The effect of haloperidol (h; 0.05-0.075 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on the DI. Data are expressed as the mean ± S.E.M. 
(n=7-12 per group). **P<0.01; significant reduction in DI compared to vehicle. 
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Figure 5.4 The effect of acute haloperidol (h; 0.05 & 0.075 mg/kg, i.p) and sub-chronic PCP 
(2.0 mg/kg, i.p., twice daily for seven days) on line crossings in the acquisition and retention 
trial. Data are expressed as mean ± S.E.M. (n=7-12 per group). 
 
Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 16.9 ± 1.0 17.4 ± 2.2 
PCP 19.3 ± 1.4 19.1 ± 2.4 
PCP + h 0.05 21.2 ± 1.1 15.3 ± 2.7 
PCP + h 0.075 17.9 ± 3.7 16.6 ± 2.5 
 
Table 5.9 The effect of acute haloperidol (h; 0.05 & 0.075 mg/kg, i.p.) and sub-chronic PCP 
(2.0 mg/kg, i.p. twice daily for seven days) on the total exploration time in the acquisition 
and retention trial of the NOR test in female hooded-Lister rats. Data are expressed as the 
mean ± S.E.M. (n=7-12 per group). 
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5.3.5 Effect of acute clozapine on sub-chronic PCP treatment in the 
acquisition trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of clozapine (1.0 – 5.0 mg/kg) to 
rats treated with sub-chronic PCP did not produce any significant effect on object 
exploration in the acquisition trial of the NOR test (F3, 38=0.9, NS). Rats from both 
treatment groups spent comparable times exploring both the objects (figure 5.5). A 
one-way ANOVA on the total exploration times in the acquisition trial of the NOR 
test revealed no significant effect of drug treatment ((F3, 37=0.8, NS; table 5.10). 
5.3.6 Effect of acute clozapine on sub-chronic PCP treatment in the 
retention trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of clozapine (1.0 - 5.0 mg/kg) to 
rats treated with sub-chronic PCP produced a significant effect on object exploration 
in the retention trial of the NOR test (F3, 38=4.1, P<0.05; figure 5.6). Planned post-
hoc comparisons showed that rats treated sub-chronically with vehicle spent 
significantly (P<0.05) more time exploring the novel object compared with the 
familiar object during the retention trial. However this significant preference for the 
novel compared to the familiar object was not observed in the sub-chronic PCP 
treated rats i.e. these rats’ spent similar amounts of time exploring both objects. 
Acute treatment with clozapine at both doses (1.0 & 5.0 mg/kg) significantly 
attenuated the sub-chronic PCP-induced impairment such that a significant (P<0.05) 
increase in the time spent exploring the novel compared with the familiar object was 
again observed. A one-way ANOVA on the total exploration times in the retention 
trial of the NOR test showed a significant effect of drug treatment (F3, 41=4.6, P<0.01; 
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table 5.10.). Post-hoc comparisons revealed a significant increase in total exploration 
time in the sub-chronic PCP treatment group that received an acute treatment with 
vehicle (P<0.01) and in the sub-chronic PCP treated group that received an acute 
treatment with clozapine (1.0 mg/kg; P<0.05). 
5.3.7 Effect of acute clozapine on sub-chronic PCP treatment on the DI in 
the NOR test in female rats 
One-way ANOVA on the DI data showed no significant effect of drug treatment on 
the rats’ ability to discriminate between the familiar and novel objects (F3, 41=0.28, 
NS; figure 5.7).  
5.3.8 Effect of acute clozapine on sub-chronic PCP treatment on the 
number of line crossings in the NOR test in female rats 
Figure 5.8 shows the effect of acute clozapine treatment in sub-chronically PCP 
treated rats on the total number of line crossings during the acquisition and retention 
trials of the NOR test. One-way ANOVA revealed no significant effect of any 
treatment on the number of line crossings (F3, 41=0.68, NS). 
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Figure 5.5 The effect of acute clozapine (c; 1.0 & 5.0 mg/kg, i.p) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on exploration time (s) of two identical objects in the 
3 min acquisition trial. Data are expressed as the mean ± S.E.M. (n=8-12 per group). 
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Figure 5.6 The effect of acute clozapine (c; 1.0 & 5.0 mg/kg, i.p.) and sub-chronic PCP 
(2.0 mg/kg, i.p, twice daily for seven days) on exploration time (s) of a familiar object 
and a novel object in the 3 min retention trial. Data are expressed as the mean ± S.E.M. 
(n=8-12 per group) *P<0.05; significant increase in time spent exploring the novel 
compared with the familiar object. 
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Figure 5.7 The effect of clozapine (c; 1.0-5.0 mg/kg, i.p) on sub-chronic PCP treatment on 
the DI in female rats. Data are expressed as the mean ± S.E.M. (n=8-12 per group). 
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Figure 5.8 The effect of acute clozapine (c; 1.0 & 5.0 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p, twice daily for seven days) on the total number of line crossings in the 
acquisition and retention trial of the NOR test in female rats. Data are expressed as ± S.E.M. 
(n=8-12 per group). 
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Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 22.1 ± 3.8 14.4 ± 2.0 
PCP 29.3 ± 3.5 29.0 ± 4.4** 
PCP + c 1.0 27.8 ± 3.0 25.2 ± 2.6* 
PCP + c 5.0 22.4 ± 3.1 19.2 ± 2.9 
 
Table 5.10 The effect of acute clozapine (c; 1.0 & 5.0 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p. twice daily for seven days) on the total exploration time in the acquisition and 
retention trial of the NOR test in female rats. Data are expressed as the mean ± S.E.M. (n=8-
12 per group). *P<0.05-**P<0.01; significant increase in total exploration time compared to 
vehicle.  
5.3.9 Effect of acute risperidone on sub-chronic PCP treatment in the 
acquisition trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of risperidone (0.05 – 0.2 mg/kg) 
to rats treated with sub-chronic PCP did not produce any significant effect on object 
exploration in the acquisition trial of the NOR test (F, 43=1.85, NS). Rats from both 
treatment groups spent similar times exploring both the objects (figure 5.9). A one-
way ANOVA showed no significant (F4, 47=1.9, NS) effect of drug treatment on the 
total exploration time in the acquisition trial of the NOR test (table 5.11). 
5.3.10 Effect of acute risperidone on sub-chronic PCP treatment in the 
retention trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of risperidone (0.05 – 0.2 mg/kg) 
to rats treated with sub-chronic PCP produced a significant effect on object 
exploration in the retention trial of the NOR test (F4, 43=4.1, P<0.01; figure 5.10). 
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Planned post-hoc comparisons showed that rats treated sub-chronically with vehicle 
spent significantly (P<0.05) more time exploring the novel objects during the 
retention trial. However, this significant preference for the novel compared to the 
familiar object was not observed in the sub-chronic PCP treated rats and also in the 
sub-chronic PCP treated rats administered with the two lowest doses of risperidone 
(0.05 & 0.1 mg/kg) i.e. these rats spent similar amounts of time exploring both 
objects. Treatment with risperidone at the highest dose (0.2 mg/kg) significantly 
attenuated the sub-chronic PCP-induced impairment such that a significant (P<0.05) 
increase in time spent exploring the novel compared with the familiar object was 
again observed. A one-way ANOVA showed no significant (F4, 47=0.5) effect of drug 
treatment on the total exploration time in the retention trial of the NOR test (table 
5.11). 
5.3.11 Effect of acute risperidone on sub-chronic PCP treatment on the 
DI in the NOR test in female rats 
One-way ANOVA on the DI data showed a significant effect of drug treatment on 
the rats’ ability to discriminate between the familiar and novel objects (F4,43=6.8, 
0.001; figure 5.11). Post-hoc analysis showed a significant (P<0.001) reduction in 
the DI of the sub-chronic PCP treated group compared to vehicle control. Sub-
chronic PCP rats treated with risperidone (0.05 & 0.1 mg/kg) also showed a 
significant (P<0.01) reduction in DI compared to vehicle control. Following 
treatment with risperidone (0.1 & 0.2 mg/kg) a significant (P<0.05-P<0.001, 
respectively) reversal of the sub-chronic PCP-induced reduction in DI was observed. 
 
173 
 
5.3.12 Effect of acute risperidone on sub-chronic PCP treatment on the 
number of line crossings in the NOR test in female rats 
Figure 5.12 shows the effect of acute risperidone treatment in sub-chronically PCP 
treated rats on the total number of line crossings during the acquisition and retention 
trials of the NOR test. One-way ANOVA revealed no significant effect of any 
treatment on the number of line crossings (F4, 47=0.58, NS). 
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Figure 5.9 The effect of acute risperidone treatment (r; 0.05-0.2 mg/kg, i.p) and sub-chronic 
PCP (2.0 mg/kg, i.p, twice daily for seven days) on exploration time (s) of two identical 
objects in the 3 min retention trial. Data are expressed as the mean ± S.E.M. (n=8-11 per 
group). 
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Figure 5.10 The effect of acute risperidone treatment (r; 0.05-0.2 mg/kg, i.p.) and sub-
chronic PCP (2.0 mg/kg, i.p, twice daily for seven days) on exploration time (s) of a familiar 
object and a novel object in the 3 min retention trial. Data are expressed as the mean ± 
S.E.M. (8-11 per group). P<0.05; significant increase in time spent exploring the novel 
compared with the familiar object. 
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Figure 5.11 The effect of risperidone (r; 0.05-0.2 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on the DI. Data are expressed as the mean ± S.E.M. 
(n=8-11 per group).  **P<0.01-***P<0.001; significant reduction in DI compared to vehicle. 
#P<0.05-P<0.001; significant reversal of the reduction in DI compared to sub-chronic PCP. 
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Figure 5.12 The effect of acute risperidone (r; 0.05-0.2 mg/kg, i.p.) and sub-chronic PCP 
(2.0 mg/kg, i.p, twice daily for seven days) on the total number of line crossings in the 
acquisition and retention trial of the NOR test in female rats. Data are expressed as mean ± 
S.E.M. (n=8-11 per group). 
 
Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 15.4 ± 2.0 13.0 ± 2.7 
PCP 19.6 ± 3.8 15.1 ± 2.7 
PCP + r 0.05 12.3 ± 2.2 13.6 ± 2.3 
PCP + r 0.1 22.7 ± 3.5 13.7 ± 2.0 
PCP + r 0.2 15.1 ± 2.4 13.0 ± 2.1 
 
Table 5.11 The effect of acute risperidone (r; 0.05-0.2 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p. twice daily for seven days)  on the total exploration time in the acquisition and 
retention trial of the NOR test in female rats . Data are expressed as the mean ± S.E.M. 
(n=8-11 per group). 
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5.3.13 Effect of acute CDP on sub-chronic PCP treatment in the 
acquisition trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of CDP (1.25 – 5.0 mg/kg) to rats 
treated with sub-chronic PCP did not produce a significant effect on object 
exploration in the acquisition trial of the NOR test (F4, 43=0.1, NS). Rats from both 
treatment groups spent similar times exploring both the objects (figure 5.13). A one 
way ANOVA on the total exploration times in the acquisition trial revealed no 
significant effect of drug treatment (F4, 47= 0.56, NS; table 5.12). 
5.3.14 Effect of acute CDP on sub-chronic PCP treatment in the retention 
trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of haloperidol (1.25 – 5.0 mg/kg) 
to rats treated with sub-chronic PCP produced a significant effect on object 
exploration in the retention trial of the NOR test (F4, 43=0.65, NS; figure 5.14). Post-
hoc comparisons showed that rats treated sub-chronically with vehicle spent 
significantly (P<0.001) more time exploring the novel objects during the retention 
trial. However this significant preference for the novel compared to the familiar 
object was not observed in the sub-chronic PCP treated rats and the sub-chronic PCP 
treated rats which were administered acute CDP i.e. these rats spent similar amounts 
of time exploring both objects. A one way ANOVA on the total exploration times in 
the retention trial revealed no significant effect of drug treatment (F 4, 47= 0.70, NS; 
table 5.11). 
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5.3.15 Effect of acute CDP on sub-chronic PCP treatment on the DI in the 
NOR test in female rats 
One-way ANOVA on the DI data showed a significant effect of drug treatment on 
the rats ability to discriminate between the familiar and novel objects (F4, 47=3.5, 
P<0.05; figure 5.15). Post-hoc analysis showed a significant reduction in the DI of 
the sub-chronic PCP treated group (P<0.05) compared to vehicle control. Sub-
chronic PCP rats treated with the CDP (2.5 & 5.0 mg/kg) also showed a significant 
(P<0.05-P<0.001, respectively) reduction in DI compared to vehicle. 
5.3.16 Effect of acute CDP on sub-chronic PCP treatment on the number 
of line crossings in the NOR test in female rats 
Figure 5.16 shows the effect of CDP treatment in sub-chronically PCP treated rats on 
the total number of line crossings during the acquisition and retention trials of the 
NOR test. One-way ANOVA revealed no significant effect of any treatment on the 
total number of line crossings (F4, 47=1.4, NS). 
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Figure 5.13 The effect of acute CDP (1.25 – 5.0 mg/kg, i.p.) and sub-chronic PCP- (2.0 
mg/kg, i.p., twice daily for seven days) on exploration time (s) of identical objects in the 
3min acquisition trial of the NOR test. Data are expressed as the mean ± S.E.M. (n=9-10 per 
group). 
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Figure 5.14 The effect of acute CDP (1.25 – 5.0 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on exploration time (s) of a familiar object and a 
novel object in the 3min retention trial. Data are expressed as the mean ± S.E.M. (n=9-10 
per group). ***P<0.001; significant difference in time spent exploring the novel compared 
with the familiar object. 
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Figure 5.15 The effect of CDP (1.25 – 5.0 mg/kg, i.p.) and sub-chronic PCP (2.0 mg/kg, 
i.p., twice daily for seven days) on the DI. Data are expressed as the mean ± S.E.M. (n=9-10 
per group). *P<0.05-***P<0.001; significant reduction in DI compared to vehicle. 
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Figure 5.16 The effect of acute CDP (1.25 – 5.0 mg/kg, i.p.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on line crossings. Data are expressed as mean ± 
S.E.M. total number of line crossings in both acquisition and retention trial in the NOR test 
(n=9-10 per group). 
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Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 31.7 ± 3.2 20.7 ± 3.3 
PCP 29.2 ± 4.8 19.0 ± 4.5 
PCP + CDP 32.9 ± 7.2 23.3 ± 3.1 
PCP + CDP 38.1 ± 4.7 16.8 ± 4.0 
PCP + CDP 40.1 ± 11.7 28.1 ± 12.6 
 
Table 5.12 The effect of acute treatment with CDP (1.25 - 5.0 mg/kg, i.p.) and sub-chronic 
PCP (2.0 mg/kg, i.p., twice daily for seven days) on the total exploration time in acquisition 
and retention trial of the NOR test in female rats. Data are expressed as the mean ± S.E.M. 
(n=9-10 per group). 
5.3.17 Effect of acute fluphenazine, fluoxetine, risperidone or modafinil 
on sub-chronic PCP treatment in the acquisition trial in the NOR test in 
female rats 
An overall two-way ANOVA revealed that administration of fluphenazine (0.2 
mg/kg), fluoxetine (5.0 mg/kg), risperidone (0.2 mg/kg) or modafinil (50 mg/kg) to 
rats treated with sub-chronic PCP did not produce a significant effect on object 
exploration in the acquisition trial of the NOR test (F5, 46=0.4, NS). Rats from both 
treatment groups spent similar times exploring both the objects (figure 5.17). A one-
way ANOVA on the total exploration times in the acquisition trial revealed no 
significant effect of drug treatment (F5, 51= 0.44, NS; table 5.13). 
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5.3.18 Effect of acute fluphenazine, fluoxetine, risperidone or modafinil 
on sub-chronic PCP treatment in the retention trial in the NOR test in 
female rats 
A two-way ANOVA revealed that administration of fluphenazine (0.2 mg/kg), 
fluoxetine (5.0 mg/kg), risperidone (0.2 mg/kg) or modafinil (50 mg/kg) to rats 
treated with sub-chronic PCP produced a significant effect on object exploration in 
the retention trial of the NOR test (F5, 46=3.9, P<0.01; figure 5.18). Planned post-hoc 
comparisons showed that rats treated sub-chronically with vehicle spent significantly 
(P<0.01) more time exploring the novel objects during the retention trial. However 
this significant preference for the novel compared to the familiar object was not 
observed in the sub-chronic PCP treated rats and the sub-chronic PCP treated rats 
which were administered acute fluphenazine and fluoxetine i.e. these rats spent 
similar amounts of time exploring both objects. Acute treatment with risperidone and 
modafinil significantly attenuated the sub-chronic PCP-induced impairment such 
that a significant (P<0.05-P<0.01) increase in time spent exploring the novel 
compared with the familiar object was again observed. A one-way ANOVA on the 
total exploration times in the retention trial revealed no significant effect of drug 
treatment (F5, 52=1.1, NS; table 5.13). 
5.3.19 Effect of acute fluphenazine, fluoxetine, risperidone or modafinil 
on sub-chronic PCP treatment on the DI in the NOR test in female rats 
A one-way ANOVA on the DI data showed a significant effect of drug treatment on 
the rats’ ability to discriminate between the familiar and novel objects (F5, 51=3.1, 
P<0.05; figure 5.19). Post-hoc analysis showed a significant reduction in the DI of 
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the sub-chronic PCP group treated with fluoxetine (P<0.01) compared to vehicle 
control.  
5.3.20 Effect of acute fluphenazine, fluoxetine, risperidone or modafinil 
on sub-chronic PCP treatment on the number of line crossings in the 
NOR test in female rats 
Figure 5.20 shows the effect of fluphenazine, fluoxetine, risperidone or modafinil 
treatment in sub-chronically PCP treated rats on the total number of line crossings 
during the acquisition and retention trials of the NOR test. One-way ANOVA 
revealed a significant effect of drug treatment on the number of line crossings (F5, 
51=4.9, P<0.01). Post-hoc analysis showed a significant (P<0.05) reduction in the 
total number of line crossings following treatment with risperidone. 
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Figure 5.17 The effect of acute fluphenazine (0.2 mg/kg, i.p.), fluoxetine (5.0 mg/kg, i.p.), 
risperidone (0.2 mg/kg, i.p.) or modafinil (50.0 mg/kg, p.o.) and sub-chronic PCP- (2.0 
mg/kg, i.p., twice daily for seven days) on exploration time (s) of identical objects in the 
3min acquisition trial of the NOR test. Data are expressed as the mean ± S.E.M. (n=8-10 per 
group). 
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Figure 5.18 The effect of acute fluphenazine (0.2 mg/kg, i.p.), fluoxetine (5.0 mg/kg, i.p.), 
risperidone (0.2 mg/kg, i.p.) or modafinil (50.0 mg/kg, p.o.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on exploration time (s) of a familiar object and a 
novel object in the 3min retention trial. Data are expressed as the mean ± S.E.M. (n=8-10 
per group). *P<0.05-**P<0.01; significant difference in time spent exploring the novel 
compared with the familiar object. 
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Figure 5.19 The effect of acute fluphenazine (0.2 mg/kg, i.p.), fluoxetine (5.0 mg/kg, i.p.), 
risperidone (0.2 mg/kg, i.p.) or modafinil (50.0 mg/kg, p.o.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on the DI. Data are expressed as the mean ± S.E.M. 
(n=8-10 per group). **P<0.01; significant reduction in DI when compared to vehicle. 
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Figure 5.20 The effect of acute fluphenazine (0.2 mg/kg, i.p.), fluoxetine (5.0 mg/kg, i.p.), 
risperidone (0.2 mg/kg, i.p.) or modafinil (50.0 mg/kg, p.o.) and sub-chronic PCP (2.0 
mg/kg, i.p., twice daily for seven days) on line crossings. Data are expressed as ± S.E.M. 
total number of line crossings in both acquisition and retention trial in the NOR test (n=8-10 
per group). *P<0.05; significant reduction in the total number of line crossings compared to 
vehicle. 
Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 29.9 ± 3.2 36.8 ± 3.9 
PCP 31.7 ± 4.7 40.0 ± 4.8 
PCP + 
fluphenazine 
28.7 ± 2.8 41.2 ± 3.1 
PCP + fluoxetine 28.3 ± 4.8 37.6 ± 6.1 
PCP + risperidone 29.0 ± 6.8 35.1 ± 6.2 
PCP + modafinil 36.3 ± 3.2 51.1 ± 7.0 
 
Table 5.13 The effect of acute fluphenazine (0.2 mg/kg, i.p.), fluoxetine (5.0 mg/kg, i.p.), 
risperidone (0.2 mg/kg, i.p.) or modafinil (50.0 mg/kg, p.o.) and sub-chronic PCP- (2.0 
mg/kg, i.p., twice daily for seven days)  on the total exploration time in acquisition and 
retention trial of the NOR test in female rats. Data are expressed as the mean ± S.E.M.  
(n=8-10 per group). 
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5.3.21 Effect of acute PNU-282987 and nicotine on sub-chronic PCP 
treatment in the acquisition trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of PNU-282987 (10 & 20 mg/kg) 
or nicotine (0.2 mg/kg) to rats treated with sub-chronic PCP did not produce any 
significant effect on object exploration in the acquisition trial of the NOR test (F4, 
59=0.2, NS). Rats from all treatment groups spent similar times exploring both the 
objects (figure 5.21). A one-way ANOVA on the total exploration times in the 
acquisition trial revealed no significant effect of drug treatment (F4, 63=1.3, NS; table 
5.14). 
5.3.22 Effect of acute PNU-282987 and nicotine on sub-chronic PCP 
treatment in the retention trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of PNU-282987 (10 & 20 mg/kg) 
or nicotine (0.2 mg/kg) to rats treated with sub-chronic PCP produced a significant 
effect on object exploration in the retention trial of the NOR test (F4, 59=10.1, 
P<0.001; figure 5.22). Planned post-hoc comparisons showed that rats treated sub-
chronically with vehicle spent significantly (P<0.001) more time exploring the novel 
objects during the retention trial. However, this significant preference for the novel 
compared to the familiar object was not observed in the sub-chronic PCP treated rats 
i.e. these rats spent similar amounts of time exploring both objects. Acute treatment 
with PNU-282987 at both doses (10 & 20 mg/kg) and nicotine (0.2 mg/kg) 
significantly attenuated the sub-chronic PCP-induced impairment such that a 
significant (P<0.01) increase in time spent exploring the novel compared with the 
familiar object was again observed. A one-way ANOVA on the total exploration 
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times in the retention trial revealed no significant effect of drug treatment (F4, 63=1.1, 
NS; table 5.14). 
5.3.23 Effect of acute PNU-282987 and nicotine on sub-chronic PCP 
treatment on the DI in the NOR test in female rats 
One-way ANOVA on the DI data showed a significant effect of drug treatment on 
the rats ability to discriminate between the familiar and novel objects (F4, 63=9.8, 
P<0.001; figure 5.23). Post-hoc analysis showed a significant reduction in the DI of 
the sub-chronic PCP treated group (P<0.01) compared to vehicle control. The sub-
chronic PCP-induced reduction in DI was significantly (P<0.05 – P<0.001) restored 
following treatment with PNU-282987 (10 & 20 mg/kg; respectively) and nicotine 
(P<0.01). 
5.3.24 Effect of acute PNU-282987 and nicotine on sub-chronic PCP 
treatment on the number of line crossings in the NOR test in female rats 
Figure 5.24 shows the effect of PNU-282987 (10 & 20 mg/kg) or nicotine (0.2 
mg/kg) treatment in sub-chronically PCP treated rats on the total number of line 
crossings during the acquisition and retention trials of the NOR test. A one-way 
ANOVA revealed no significant effect of any treatment on the number of line 
crossings (F4, 63=1.5, NS). 
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Figure 5.21 The effect of acute PNU-282987 (10 & 20 mg/kg, s.c.) and nicotine (0.2 mg/kg, 
i.p.) in rats treated sub-chronically with PCP (2.0 mg/kg, i.p., twice daily for seven days) on 
exploration time (s) of two identical objects in the 3 min acquisition trial of the NOR test. 
Data are expressed as the mean ± S.E.M. (n=10-18 per group). 
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Figure 5.22 The effect of acute PNU (10 & 20 mg/kg, s.c.) or nicotine (0.2 mg/kg, i.p.) in 
rats treated sub-chronically with PCP (2.0 mg/kg, i.p., twice daily for seven days) on 
exploration time (s) of a familiar object and a novel object in the 3 min retention trial. Data 
are expressed as the mean ± S.E.M. (n=10-18 per group). **P<0.05-***P<0.001; significant 
increase in time spent exploring the novel compared with the familiar object. 
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Figure 5.23 The effect of PNU-282987 (10 & 20 mg/kg, s.c.) and nicotine (0.2 mg/kg, i.p.) 
in rats treated sub-chronically with PCP (2.0 mg/kg, i.p., twice daily for seven days) on the 
DI. Data are expressed as the mean ± S.E.M. (n=10-18 per group). **P<0.01; significant 
reduction in DI compared to vehicle. #P<0.05- ###P<0.001; significant increase in DI 
compared to sub-chronic PCP. 
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Figure 5.24 The effect of acute PNU-282987 (10 & 20 mg/kg, s.c.) and nicotine (0.2 mg/kg, 
s.c.) in rats sub-chronically treated with PCP (2.0 mg/kg, i.p., twice daily for seven days) on 
total number of line crossings in the acquisition and retention trial in the NOR task. Data are 
expressed as mean ± s.e.m total number of line crossings (n=10-18 per group).  
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Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 38.9 ± 3.1 31.9 ± 3.6 
PCP 37.6 ± 2.5 28.7 ± 2.0 
PCP + PNU-282987 10 30.3 ± 5.1 21.1 ± 5.4 
PCP + PNU-282987 20 31.5 ± 3.5 28.5 ± 5.5 
PCP + nicotine 0.2 32.3 ± 2.5 25.2 ± 1.8 
 
Table 5.14 The effect of acute PNU-282987 (10 & 20 mg/kg, s.c.) and nicotine (0.2 mg/kg, 
s.c.) in rats sub-chronically treated with PCP (2.0 mg/kg, i.p., twice daily for seven days) on 
total exploration time (s). Data are expressed as mean ± S.E.M. (n=10-18 per group). 
 
 
5.3.25 Effect of acute PNU-120596 on sub-chronic PCP treatment in the 
acquisition trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of PNU-120596 (5-20 mg/kg) to 
rats treated with sub-chronic PCP did not produce any significant effect on object 
exploration in the acquisition trial of the NOR test (F4, 43=1.1, NS). Rats from all 
treatment groups spent similar times exploring both the objects (figure 5.25). A one-
way ANOVA on the total exploration times in the acquisition trial revealed no 
significant effect of drug treatment (F4, 47=0.4, NS; table 5.15). 
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5.3.26 Effect of acute PNU-120596 on sub-chronic PCP treatment in the 
retention trial in the NOR test in female rats 
A two-way ANOVA revealed that administration of PNU-120596 (5-20 mg/kg) to 
rats treated with sub-chronic PCP produced a significant effect on object exploration 
in the retention trial of the NOR test (F4, 43=3.4, P<0.05). Planned post-hoc 
comparisons showed that rats treated sub-chronically with vehicle spent significantly 
(P<0.05) more time exploring the novel objects during the retention trial. However, 
this significant preference for the novel compared to the familiar object was not 
observed in the sub-chronic PCP treated rats i.e. these rats spent similar amounts of 
time exploring both objects (figure 5.26). Acute treatment with PNU-120596 at 10 
mg/kg significantly attenuated the sub-chronic PCP-induced impairment such that a 
significant (P<0.05) increase in time spent exploring the novel compared with the 
familiar object was again observed. A one-way ANOVA on the total exploration 
times in the retention trial revealed no significant effect of drug treatment (F4, 47=1.8, 
NS; table 5.15). 
5.3.27 Effect of acute PNU-120596 on sub-chronic PCP treatment on the 
DI in the NOR test in female rats 
One-way ANOVA on the DI data showed a significant effect of drug treatment on 
the rats ability to discriminate between the familiar and novel objects (F4, 47=4.9, 
P<0.01; figure 5.27). Post-hoc analysis showed a significant reduction in the DI of 
the sub-chronic PCP treated group (P<0.01) compared to vehicle control. The sub-
chronic PCP-induced reduction in DI was significantly (P<0.001 - P<0.05) restored 
following treatment with PNU-120596 (10 & 20 mg/kg; respectively). 
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5.3.28 Effect of acute PNU-120596 on sub-chronic PCP treatment on the 
number of line crossings in the NOR test in female rats 
Figure 5.28 shows the effect of PNU-120596 (5-20 mg/kg) treatment in sub-
chronically PCP treated rats on the total number of line crossings during the 
acquisition and retention trials of the NOR test. A one-way ANOVA revealed no 
significant effect of any treatment on the number of line crossings (F4, 47=1.8, NS). 
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Figure 5.25 The effect of acute PNU-120596 (5.0 - 20.0 mg/kg, p.o.) in rats treated sub-
chronically with PCP (2.0 mg/kg, i.p., twice daily for seven days) on exploration time (s) of 
two identical objects in the 3 min acquisition trial of the NOR test. Data are expressed ± 
S.E.M. (n=9-10 per group). 
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Figure 5.26 The effect of acute PNU-120596 (5.0 - 20.0 mg/kg, p.o.) in rats treated sub-
chronically with PCP (2.0 mg/kg, i.p., twice daily for seven days) on exploration time (s) of 
a familiar object and a novel object in the 3 min retention trial of the NOR test. Data are 
expressed ± S.E.M. (n=9-10 per group). *P<0.05; significant increase in the time spent 
exploring the novel compared to the familiar object. 
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Figure 5.27 The effect of PNU-120596 (5 - 20 mg/kg, p.o.) in rats treated sub-chronically 
with PCP (2.0 mg/kg, i.p., twice daily for seven days) on the DI. Data are expressed as the 
mean ± S.E.M. (n=9-10 per group). **P<0.01; significant reduction in DI compared to 
vehicle. #P<0.05 - ###P<0.001; significant reversal of reduction in DI compared to sub-
chronic PCP. 
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Figure 5.28 The effect of acute PNU-120596 (5 - 20 mg/kg, p.o.) in rats sub-chronically 
treated with PCP (2.0 mg/kg, i.p., twice daily for seven days) on total number of line 
crossings in the acquisition and retention trial in the NOR task. Data are expressed as mean 
± s.e.m. total number of line crossings (n=9-10 per group).  
 
 
Treatment (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 38.0 ± 5.0 29.3 ± 5.7 
PCP 35.4 ± 4.1 32.4 ± 4.9 
PCP + PNU-120596 5 34.7 ± 5.4 29.3 ± 5.6 
PCP + PNU-120596 10 30.1 ± 3.4 23.3 ± 4.0 
PCP + PNU-120596 20 34.3 ± 2.7 23.2 ± 3.9 
 
Table 5.15 The effect of acute PNU-120596 (5-20 mg/kg, p.o.) in rats sub-chronically 
treated with PCP (2.0 mg/kg, i.p., twice daily for seven days) on the total exploration time 
(s). Data are expressed as mean ± S.E.M. (n=9-10 per group). 
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Treatments 
Doses 
tested 
(mg/kg) 
Deficit in the 
retention 
trial. Dose 
(mg/kg) 
Deficit in 
the  DI. 
Dose 
(mg/kg) 
Effect on 
line 
crossings. 
Dose 
(mg/kg) 
Effect on 
total 
exploration 
time. Dose 
(mg/kg) 
Sub-chronic 
PCP 
2.0 Yes 
Yes 
(Except 
clozapine study) 
No No 
Haloperidol 
0.05, 
0.075 
Yes 
 0.05, 0.075 
Yes  
0.05,    
0.075 
No 
 0.05, 0.075 
No 
 0.05, 0.075 
Clozapine 1, 5 
No 
 1, 5 
No  
1, 5 
No  
1, 5 
*Yes 
(retention;  
PCP, 1) 
No 5 
Risperidone 
0.05, 
0.1, 0.2 
Yes  
0.05, 0.1 
No 0.2 
Yes 
 0.05 
No 0.1, 
0.2 
No  
0.05, 0.1, 
0.2 
No  
0.05, 0.1, 
0.2 
CDP 
1.25, 
2.5, 5.0 
Yes  
1.25, 2.5, 5.0 
No 
 1.25, 2.5 
Yes 5.0 
No 
 1.25, 2.5, 
5.0 
No 
 1.25, 2.5, 
5.0 
Fluphenazine 0.2 Yes Yes No No 
Fluoxetine 5.0 Yes Yes No No 
Modafinil 50 No No No No 
PNU-282987 10, 20 No No No No 
Nicotine 0.2 No No No No 
PNU-120596 
5, 10, 
20 
Yes 
 5, 20 
No 10 
No No No 
 
Table 5.16 Summary table showing the effect of sub-chronic treatment with PCP (2.0 mg/kg, 
i.p., twice daily for seven days) and haloperidol (0.05-0.075 mg/kg), clozapine (1.0-5.0 
mg/kg), risperidone (0.05-0.2 mg/kg), CDP (1.25-5.0 mg/kg), fluphenazine (0.2 mg/kg), 
fluoxetine (5.0 mg/kg), modafinil (50 mg/kg), PNU-282987 (10 & 20 mg/kg), nicotine (0.2 
mg/kg) and PNU-120596 (5-20 mg/kg) on female rats on performance in the NOR test. 
Significant increase (*P<0.05-P<0.01) compared to the vehicle treated group. 
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5.4 Discussion 
5.4.1 Pharmacology 
The sub-chronic PCP-induced object recognition deficits presented in this chapter 
were robust and consistent, which enabled pharmacological intervention to assist in 
validation of the sub-chronic PCP impairments in the NOR test and assessment of its 
use as a test for detecting efficacy of novel targets for this aspect of cognitive 
dysfunction in schizophrenia. 
5.4.2 Haloperidol, clozapine and risperidone 
Acute administration of the classical antipsychotic haloperidol was ineffective at 
reversing the recognition memory deficit induced by sub-chronic PCP in the NOR 
test. Conversely, acute treatment with the atypical antipsychotic agents, clozapine 
and risperidone successfully restored the sub-chronic PCP-induced deficit. These 
results are in agreement with NOR studies performed in mice by Hashimoto et al 
(2005), whereby NOR deficits were induced by repeated administration of PCP and 
this deficit was significantly improved by sub-chronic administration of clozapine 
but not haloperidol. Furthermore, the atypical antipsychotic agents clozapine, 
olanzapine and ziprasidone were effective at restoring the sub-chronic PCP-induced 
deficits in the reversal learning task (Abdul-Monim et al, 2003, 2006). The ability of 
clozapine and risperidone to improve the sub-chronic PCP-induced impairments in 
recognition memory in the NOR test in the rat are in agreement with some clinical 
findings stating that clozapine and risperidone can improve certain aspects of 
cognition in certain schizophrenia patients (Meltzer & McGurk, 1999; Keefe et al, 
1999). In marked contrast to these effects, acute administration of the classical 
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agents haloperidol and chlorpromazine failed to significantly reverse the PCP-
induced cognitive impairment in reversal learning in the rat (Abdul-Monim et al, 
2006). The pharmacological binding profile of clozapine and risperidone may 
explain the pro-cognitive effects compared to the lack of effect of the classical 
agents to reverse the sub-chronic PCP-induced deficits in the NOR test. It has been 
shown that clozapine and risperidone have a high affinity for 5-HT receptors, 
particularly the 5-HT2A receptor, whereas haloperidol has low affinity for 5-HT2A 
receptors and high affinity for D2 receptors, suggesting involvement of the 5-HT2A 
receptor in cognition. Atypical antipsychotics have been shown to elevate mPFC 
dopamine levels via blockade of 5-HT2A and D2 receptors to promote 5-HT1A 
stimulation to increase dopamine release (Ichikawa et al, 2001). This increased 
dopamine release in the mPFC has been hypothesized to contribute to the ability to 
improve negative symptoms and some domains of cognition in schizophrenia 
(Moghaddam and Bunney, 1990; Kuroki et al, 1999; Meltzer and McGurk. 1999).  
The ability of the atypical antipsychotics, cognitive enhancers and novel agents but 
not the classical antipsychotics, antidepressants and anxiolytics to reverse the sub-
chronic PCP induced recognition deficits in the NOR test provide important 
predictive validity. However it is of importance to note that atypical antipsychotics 
such as clozapine, demonstrated by the clinical Antipsychotic Trials of Invention 
Effectiveness (CATIE) study showed a lack of ability compared to classical agents to 
improve the cognitive symptoms associated with schizophrenia (Lieberman, 2006; 
Keefe et al, 2007). This difference between the results obtained in this thesis and 
such clinical findings is vital. It could be argued that sub-chronic PCP in 
combination with the NOR test does not accurately represent the clinical situation, 
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given the lack of efficacy of atypical antipsychotics for improving cognitive deficits 
in schizophrenia. It is important to bear in mind that we are using animals to mimic 
an aspect of a complex human disease where patients have genetic and 
neurodevelopmental predispositions for the disorder, may have co-morbid drug 
abuse, and are commonly prescribed combinations of different pharmacological 
agents. In contrast, our rats have no genetic predisposition and no previous drug 
exposure. Instead they live in optimal conditions (lighting, noise level, humidity etc.) 
for that species with minimum stress. This makes it even harder to fully mimic a 
human disorder (particularly a psychiatric disorder) and this caveat is important to 
recognise (see Moore 2010 for a full review of this issue and Neill et al, 2010). 
5.4.3 Fluphenazine 
In agreement with the reversal learning studies (Abdul-Monim et al, 2006), the 
inability of the classical antipsychotic haloperidol to ameliorate sub-chronic PCP-
induced deficits in NOR was further established with the use of another classical 
agent fluphenazine. In the clinical setting, classical antipsychotic agents such as 
haloperidol, chlorpromazine and fluphenazine are effective at relieving the positive 
symptoms of schizophrenia and are known to exacerbate cognitive and negative 
symptomatology (Keefe et al, 1999; Meltzer et al, 1999). Further studies using 
carefully selected pharmacological agents in the sub-chronic PCP treated rats were 
conducted in order to provide further validation of the sub-chronic PCP-induced 
deficit in the NOR test.  
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5.4.4 Chlordiazepoxide 
The benzodiazepine, anxiolytic agent chlordiazepoxide which binds to the GABAA 
receptor was shown to be ineffective in this study to reverse the sub-chronic PCP-
induced impairments in NOR. The evidence available on the effect of 
benzodiazepines on cognition in patients with schizophrenia is inconclusive 
(Baandrup et al, 2011). However, clinical studies (for review see Lister, 1985) have 
shown that benzodiazepine treatment impairs cognition, particularly long-term 
episodic memory in healthy controls. A pre-clinical study in rats, looking at the 
effects of intra-perirhinal cortex injections of the benzodiazepine lorazepam 
demonstrated impairments of recognition memory (Wan et al, 2004).  Results of a 
NOR study in mice by Bertaina-Anglade (2006), provide further support for the lack 
of effect of CDP to reverse the sub-chronic PCP-induced deficit in NOR, whereby 
alprazolam and diazepam prior to the acquisition trial of the NOR test induced 
impairments in object recognition memory. 
5.4.5 Fluoxetine 
Following acute treatment with the selective serotonin re-uptake inhibitor (SSRI) 
antidepressant agent fluoxetine, no improvement of the sub-chronic PCP-induced 
cognitive deficit was observed; indeed the very poor discriminatory ability of the rats 
following fluoxetine treatment may have exacerbated the sub-chronic PCP-induced 
impairments. These results are supported by the clinical data, whereby clinically 
depressed patients exhibit SSRI-induced deficits in episodic memory (Wadsworth et 
al, 2005). Furthermore, one study has demonstrated no significant cognitive 
improvements following adjunctive treatment with the SSRI citalopram added to 
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atypical medications in patients with schizophrenia (Friedman et al, 2005). 
Conversely, fluoxetine has been shown to induce cognitive impairments (Mirrow, 
1991; Bangs, 1994) and also to improve cognition (Cassano et al, 2002; Doraiswamy 
et al, 2003) in elderly patients suffering from depression.   
5.5.6 Modafinil 
In this study, administration of the analeptic agent modafinil which is thought in part 
to exert its effects via the hypocretin/orexin system was effective in restoring the 
cognitive deficit induced by sub-chronic PCP. These results support the findings of 
Dawson et al (2010) and Goetghebeur & Dias (2009), who demonstrated a reversal 
of sub-chronic PCP-induced impairments in ability to switch attentional set by 
modafinil. Additionally, acute treatment with modafinil has been shown to 
ameliorate the PCP-induced deficit in novel object exploration (Redrobe et al, 2010). 
The pre-clinical data is further substantiated by the promising pro-cognitive effects 
of modafinil treatment in some specific groups of schizophrenia patients (see review 
by Morein-Zamir et al, 2007).  
5.5.7 Nicotine 
Acute administration of the nicotinic receptor agonist, nicotine to the sub-chronic 
PCP-treated rats was effective at restoring the object recognition deficit. There is 
extensive literature indicating nicotine’s pro-cognitive effects in brain lesion models 
of cognitive impairment (Decker et al, 1992; Grigoryan et al, 1994), and muscarinic 
and nicotine antagonist mecamylamine-induced impairments (Zarrindast et al, 1996). 
Additionally, chronic nicotine treatment has been shown to have pro-cognitive 
effects in normal rats as measured by the 5CSRTT (Amitai & Markou, 2009). 
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However, chronic nicotine treatment was ineffective in reversing the sub-chronic 
PCP-induced cognitive deficits in 5CSRTT (Amitai & Markou, 2008). In another 
study by Rushforth et al, (2010), nicotine, dose dependently reversed working 
memory deficits in the odour span test in sub-chronic ketamine treated rats.  
Research on administration of nicotine to patients with schizophrenia has shown that 
single administration improves working and declarative memory, whereas second 
administrations of nicotine are not as effective, due to tachyphylaxis (Tamminga, 
2006). Nicotinic receptors appear to modulate neurotransmitter release to improve 
cognition which suggests that the nicotinic receptor has a modulatory role with 
respect to cognition. Moreover, it is reported that schizophrenia patients are very 
heavy cigarette smokers, allegedly self medicating to alleviate side effects of 
antipsychotics, enhance the therapeutic effects of antipsychotics in alleviating the 
negative symptoms and to ameliorate the cognitive deficits associated with 
schizophrenia (Kumari & Postma, 2005). Nicotine may improve cognition by direct 
effects on attention and by interacting with the presynaptic nAChR to facilitate the 
release of ACh, dopamine, noradrenaline, glutamate, 5-HT, and GABA, 
neurotransmitters that have all been implicated in learning and memory (Samuels & 
Davis 1998; Wonnacott 1997). 
5.5.8 PNU-282987 (α7 full agonist ) 
One of the therapeutic targets identified by the MATRICS is the α7-nicotinic 
acetylcholine receptor (nAChR). Results presented in thesis show that acute 
treatment with PNU-282987, a selective full agonist of the human and rat α7 nAChR, 
improved the sub-chronic PCP-induced impairment in object recognition. There was 
no effect in the acquisition trial or on the total number of line crossings which 
201 
 
suggests specificity of PNU-282987 for the retention trial without any sedation. 
These results are supported by work undertaken in our laboratory, whereby, PNU-
282987 selectively reversed the sub-chronic PCP-induced impairments in reversal 
learning (McLean et al, 2011). This compound has previously been shown to reduce 
amphetamine induced gating deficits in PPI and also improved a scopolamine-
induced deficit in a continuous Y-maze task in mice at 10 mg/kg (Redrobe et al., 
2009). Results are further substantiated by the work of Buccafusco and Terry (2009) 
in pigtail monkeys (Macaca nemestrina), whereby the α7 nicotinic receptor agonist 
GTS-21, produced a dose-dependent attenuation of ketamine-induced decreases in 
task accuracies in a delayed matching-to-sample test (DMTS). In fact, the highest 
dose of GTS-21 completely reversed the effects of ketamine.  Also, the partial α7 
agonist, AZD0328, has been shown to improve cognitive performance in a delayed 
spatial response task using the Wisconsin General Testing Apparatus in rhesus 
macaques (Macaca mulatta) (Castner et al, 2010). 
It has been shown from post-mortem studies that schizophrenia patients have 
decreased expression of α7 nAChR at the two major sites of expression in the brain, 
the inhibitory interneurons of the hippocampus and of the nucleus reticularis thalami 
(Freedman et al, 2008). Activation of the α7 nAChR by PNU-282987 at 1 mg/kg i.v., 
induced an enhancement in amphetamine-induced theta and gamma oscillations in 
the CA3 region of the hippocampus and entorhinal cortex; these frequencies of 
oscillations and these brain regions are believed to be important for cognitive 
processing (Hajós et al, 2005; Hoffmann et al, 2005). Furthermore, studies in our 
laboratory have shown that gamma oscillations are reduced following sub-chronic 
PCP treatment in the CA3 region of the hippocampus (McLean et al, 2009). 
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5.5.9 PNU-120596 (PAM) 
Results presented in this thesis also show that the α7 positive allosteric modulator 
(PAM) PNU-120596 was effective in reversing the sub-chronic PCP-induced deficit 
in NOR, which is supported by previous work in our laboratory, showing that PNU-
120596 was successful in reversing a sub-chronic PCP-induced cognitive 
impairment in the attentional set-shifting task (McLean et al, 2011).  The pro-
cognitive effects of PNU-120596 on the sub-chronic PCP-induced recognition 
memory deficits in the NOR test are supported by a study showing that PNU-120596 
increased the potency of ACh by ~10-fold and reversed an amphetamine-induced 
deficit in auditory gating in rats (Hurst et al, 2005). PNU-120596 has also been 
reported to enhance the increase in dopamine release in the mPFC induced by 
choline and an α7 nAChR agonist (compound A; (R)-N-(1-azabicyclo[2.2.2]oct-3-
yl)(5-(2-pyridyl)thiophene-2-carboxamide); it was also shown that PNU-120596 
when administered systemically (but not locally) produced an increase in dopamine 
overflow in the mPFC in the absence of an agonist (Livingstone et al, 2009). This is 
important because the PCP-induced deficit in NOR memory is accompanied by 
impaired dopamine neurotransmission in the PFC during the retention trial of the 
task (Snigdha et al, 2008).  
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CHAPTER 6 - Investigation of NOR deficits 
produced by another animal model of schizophrenia 
symptomatology: Rats reared in social isolation 
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6.1 Introduction  
An important finding of neurodevelopment research is that the basic architecture of 
the brain is set in-utero, but the wiring of the brain is only partially complete by birth. 
Neurodevelopment continues after birth and is constantly modified by environmental 
influences, possibly the most significant factor in development is the introduction of 
stress in early life. There is a large body of evidence indicating that early 
environmental stress plays a pivotal role in the pathogenesis of psychiatric disorders 
such as schizophrenia and depression (Agid et al, 2000; Yuii et al, 2007; van OS et 
al, 2010). Isolation rearing of rats at weaning, results in a lack of the essential 
sensory information coming from social contact with cage mates. The olfactory 
information and environmental stimuli available to isolation reared rats may not be 
sufficient to drive the process of normal brain development and neurotransmitter 
function (Muchimapura & Marsden, 2004). Isolation rearing of rats is considered to 
be an environmental stressor and has been shown to consistently result in 
hyperactivity at adulthood when placed into a novel environment (Smith et al, 1997; 
Lapiz et al, 2003; Elliot & Grunberg, 2005; Bianchi et al, 2006, Marsden et al, 2011). 
This behavioural effect is undoubtedly the most robust effect of isolation rearing and 
has been shown to appear as early as 2 weeks of isolation in Hooded-Lister rats 
(Bakshi & Geyer, 1999). Isolation rearing provides a non-pharmacological method 
of inducing long-term alterations of relevance to symptomology of schizophrenia 
(Geyer et al, 1993). Prepulse inhibition of the startle reflex (PPI) is an operational 
measure of sensorimotor gating which has been shown to be disrupted in rats reared 
in isolation (Cilia et al, 2001; Varty et al, 1995). Results from earlier studies in our 
laboratory demonstrate impairments in the EDS phase of the attentional set-shifting 
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task in isolation reared rats, they required significantly more trials to reach criterion 
compared to socially housed animals; indicative of a selective deficit in set-shifting 
ability (McLean et al, 2010). Additionally, other laboratories have shown isolation 
rearing induced impairments in spatial memory and reversal learning in the Morris 
water maze (Hellemans et al, 2004; Quan et al, 2010). However, there have been 
studies to contradict these findings, for example; Wongwitdecha & Marsden (1996) 
showed that place learning and reversal learning in the Morris water maze was 
enhanced in isolation reared rats compared to socially housed controls. Bianchi and 
colleagues (2006), showed deficits in object recognition following a 1 h ITI, but not 
at a 1 min ITI in male rats reared in isolation compared to social controls. Isolation 
reared rats have been shown to exhibit an enhanced behavioural reactivity to 
dopamine agonists (Bowling and Bardo, 1994; Jones et al, 1992) which is also 
observed in schizophrenia patients (Lieberman et al, 1987). 
Isolation rearing has been shown to disrupt behaviour which is accompanied by 
alterations in neurochemistry and neuropathology associated with schizophrenia 
(Harte et al, 2006, 2007; Fone & Porkess, 2008). Rats reared in isolation have been 
shown to have increased steady-state levels of dopamine and decreased basal 
dopamine turnover which indicates reduced metabolic activity in the medial 
prefrontal cortex (Heidbreder et al, 2000). A reduction in metabolic activity in the 
prefrontal cortex is also observed in schizophrenia patients and may be indicative of 
hypofrontality (Andreasen et al 1997). Studies have demonstrated that isolated rats 
exhibit PPI deficits and reductions in parvalbumin and calbindin-immunoreactive 
cells in the hippocampus, with no significant change in calretinin. These findings 
reveal selective abnormalities of sub-populations of GABAergic interneurons in the 
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hippocampus of isolation reared rats, which resemble the neuronal deficits seen in 
this region in schizophrenia (Harte et al, 2007).   
The aim of these studies was to assess the effects of isolation rearing compared to 
socially housed controls on the cognitive performance in the NOR test following 
increasing ITI periods. Furthermore, in view of the fact that previous studies have 
demonstrated that isolation reared rats demonstrate an elevated response to 
psychotomimetic agents, the second aim was to investigate the effects of isolation 
rearing in response to acute treatment with d-amphetamine and PCP on cognitive 
performance in the NOR test. 
6.2 Materials and Methods 
6.2.1 Experimental Animals and Design 
All experiments (using cohorts 12 and 13; see table 6.1) were conducted using 
female hooded-Lister rats (Charles River, UK), obtained at weaning (21-25 days) 
and weighing between 75-100 g.  For details regarding the isolation rearing protocol, 
housing conditions and experimental timeline see section 2.1.6, 2.1.1 and figure 6.0 
respectively. 
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Experiment 
number 
Cohort 
number 
Total number of 
rats used 
Weight 
range 
during 
testing (g) 
Experiment, ITI 
duration or 
compound tested 
(mg/kg) 
1 12 
n=20 isolates; 
n=30 socials 
220-260 
Locomotor activity 
(60 min test) 
2 12 
n=10 isolates; 
n=10 socials 
220-260 1 min ΙΤΙ 
3 12 
n=10 isolates; 
n=10 socials 
220-260 1 h ΙΤΙ 
4 12 
n=10 isolates; 
n=10 socials 
220-260 3.5 h ITI 
5 12 
n=10 isolates; 
n=10 socials 
220-260 4 h ITI 
6 12 
n=10 isolates; 
n=10 socials 
220-260 5 h ITI 
7 12 
n=10 isolates; 
n=10 socials 
220-260 6 h ITI 
8 12 
n=20 isolates; 
n=20 socials 
240-280 
PCP  
(lower doses; 0.5-1.5) 
9 12 
n=16 isolates; 
n=16 socials 
240-280 PCP (higher dose; 2.0) 
10 12 n=16 socials 190-225 PCP (repeat; 0.5) 
11 13 
n=10 isolates; 
n=10 socials 
240-280 d-amph (0.25-0.75) 
 
Table 6.1 Details of the rats used in these studies. 
 
 
Timeline of the isolation rearing studies 
                         
Day 
           
 
 
      1                      91            92-105             111-132                 139             146-167 
Rats isolated  LMA         NOR              NOR PCP          NOR PCP       NOR d-amph    
 PND 21-25                    Differential ITIs   (lower doses)     (high dose) 
   (3 weeks)            (4 weeks)              (1 day)            (4 weeks)    
 
Figure 6.0 Timeline showing days after isolation on which behavioural tests were conducted. 
LMA: Locomotor Activity in a novel environment, NOR: Novel Object Recognition. The 
repeat study for PCP (0.5 mg/kg) is not included in timeline as the experiment was 
performed in a separate cohort of rats (i.e. cohort 13). 
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6.2.2 NOR testing (social v isolates; differential ITI, experiment 2-6) 
Both groups of rats were habituated and tested in the NOR apparatus as previously 
described (see section 2.1.4) and a range of ITIs were used (1 min, 1, 3.5, 4, 5 and 6 
h; see table 6.2). These ITIs were selected and based upon previous data from our 
laboratory, which showed that group housed rats were able to discriminate between 
the novel and familiar up to an ITI of 3 h (Sutcliffe, et al, 2007). The isolation reared 
group rats were tested up to 4 h ITI and the group housed rats were tested up to an 
ITI of 6 h. The duration of ITI experiments were separated by at least 7 days and due 
to the small total number of animals available for the isolation rearing ITI study, rats 
were tested twice and the study took 2 weeks to complete. For the ITI study, a within 
subjects design would have been ideal, however the time available using the NOR 
apparatus was limited.   
 Social Isolates 
Experiment 
& order 
ITI 
Initial 
number of 
rats 
Number of 
rats excluded 
Initial 
number of 
rats 
Number of rats 
excluded 
2 1 min 10 0 10 0 
3 1 h 10 0 10 0 
4 3.5 h 10 0 10 0 
5 4 h 10 0 10 0 
6 5 h 10 0   
7 6 h 10 0   
 
Table 6.2 The number of rats excluded from from each housing group (social and isolates) 
during the differential ITI’s (1 min- 6h) selected for use in this NOR study. 
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6.2.3 NOR testing (social v isolates; acute PCP, experiment 8) 
In this experiment a within subjects experimental design was used. Both groups of 
rats were administered vehicle (0.9% saline, i.p.) or PCP (0.5-1.5 mg/kg, i.p.), 30 
min prior to NOR testing in a volume of 1 ml/kg, calculated as the base equivalent 
weight (see table 6.1 for doses). Due to lack of efficacy of the first dose range of 
PCP to produce a NOR deficit in the socially reared rats, a second separate 
experiment was carried out in the social rats using a higher dose of PCP (2 mg/kg; 
see table 6.4). 
Experiment 8 
Dose of 
PCP 
(mg/kg) 
Social Isolates 
Initial 
number of 
rats 
Number of rats 
excluded 
Initial 
number of 
rats 
Number of rats 
excluded 
Veh 20 0 20 0 
0.5 20 0 20 0 
1.0 20 0 20 0 
1.5 20 0 20 0 
 
Table 6.3 The number of rats excluded from each housing group (social and isolates) in the 
NOR study following acute administration of PCP (0.5-1.5 mg/kg, i.p.), or vehicle (0.9% 
saline, i.p.). 
 
6.2.4 NOR testing (social v isolates; acute PCP, experiment 9) 
Both groups of rats were administered vehicle (0.9% saline, i.p.) or PCP (2.0 mg/kg, 
i.p.), 30 min prior to NOR testing in a volume of 1 ml/kg, calculated as the base 
equivalent weight (see table 6.4 for doses). 
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Experiment 9 
Dose of PCP 
(mg/kg) 
Social Isolates 
Initial 
number of 
rats 
Number of 
rats excluded 
Initial 
number of 
rats 
Number of rats 
excluded 
Veh 8 0 8 0 
2.0 8 0 8 0 
 
Table 6.4 The number of rats excluded from each housing group (social and isolates) in the 
NOR study following acute administration of PCP (2.0 mg/kg, i.p.), or vehicle (0.9% saline, 
i.p.). 
 
6.2.5 NOR testing (social v isolates; acute PCP, experiment 10). 
It was demonstrated in chapter 4 (summary table 4.15) that acute treatment with PCP 
(0.5-1.5 mg/kg) induced an NOR deficit in socially reared female rats. However, 
studies in this chapter showed there was a lack of efficacy of acute PCP (0.5-1.5 
mg/kg) to induce a deficit in the NOR test in the socially reared rats. It is unclear as 
to why there was a lack of efficacy of acute PCP to induce a cognitive deficit at the 
lower doses (i.e. 0.5-1.5 mg/kg). Therefore, the lowest dose of acute PCP was 
selected to be re-tested since this had previously been shown to induce a cognitive 
deficit in socially reared female rats (see chapter 4). Both groups of rats were 
administered vehicle (0.9% saline, i.p.) or PCP (0.5 mg/kg, i.p.), 30 min prior to 
NOR testing in a volume of 1 ml/kg, calculated as the base equivalent weight (see 
table 6.5 for doses). 
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Experiment 10 
Dose of PCP 
(mg/kg) 
Social Isolates 
Initial 
number of 
rats 
Number of 
rats excluded 
Initial 
number of 
rats 
Number of rats 
excluded 
0 8 0 8 0 
0.5 8 0 8 0 
 
 
Table 6.5 The number of rats excluded from each housing group (social and isolates) in the 
NOR study following acute administration of PCP (0.5 mg/kg, i.p.), or vehicle (0.9% saline, 
i.p.).  
 
6.2.6 NOR testing (social v isolates; acute d-amph, experiment 11). 
In this experiment a within subject experimental design was used, both groups of rats 
were administered vehicle (0.9% saline, i.p.) or d-amph (0.25-0.75 mg/kg, i.p.), 30 
min prior to NOR testing in a volume of 1 ml/kg, calculated as the base equivalent 
weight (see table 6.6 for doses).  
Experiment 11 
Dose of d-
amph (mg/kg) 
Socials Isolates 
Initial 
number of 
rats 
Number of 
rats excluded 
Initial 
number of 
rats 
Number of rats 
excluded 
0 10 0 10 2 
0.25 10 0 10 2 
0.5 10 0 10 2 
0.75 10 0 10 2 
 
Table 6.6 The number of rats excluded from each housing group (social and isolates) in the 
NOR study following acute administration of d-amphetamine (0.25-0.75 mg/kg, i.p.), or 
vehicle (0.9% saline, i.p.). 
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6.2.7 NOR apparatus 
For details regarding NOR apparatus see section 2.1.4. 
6.2.8 NOR testing 
For details regarding NOR testing see section 2.1.5. 
6.2.9 Statistical analysis 
All data are expressed as the mean ± S.E.M. For the NOR experiments, exploration 
data were analysed by a two-way ANOVA or a repeated measures two-way ANOVA. 
This detected the main effect of variable ITI, main effect of the task (exploration of 
both objects) and the interaction between variable ITI and the two trials (acquisition 
and retention). Planned comparisons using a post-hoc Student’s t-test was carried out 
to compare the time spent exploring the novel and familiar objects. 
Discrimination index, total exploration time and line crossing data was analysed by a 
one-way ANOVA, followed by a post-hoc Dunnett’s t-test. 
6.3 Results 
6.3.1 Effect of rearing conditions in response to a novel environment 
Figure 6.1 shows the effect of housing conditions in response to a novel environment. 
An independent samples Student’s t-test revealed a significant (P<0.05) increase in 
LMA response to a novel environment in isolation-reared rats compared to social 
controls. 
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Figure 6.1 The response to a novel environment in rats reared socially and in isolation. Data 
are expressed as the mean ± S.E.M. (n=20 per group). *P<0.05; significant increase in LMA 
in the isolates compared to social controls. 
 
6.3.2 Effect of increasing the ITI on social controls in the acquisition trial 
of the NOR test in female rats 
A two-way ANOVA revealed a significant interaction between object exploration 
and ITI in the acquisition trial of the NOR test (F5, 51 =2.54, P<0.05). However, rats 
from all ITI groups spent similar times exploring both the objects (figure 6.2). A 
one-way ANOVA on the total exploration time revealed a significant effect (F5, 
56=2.74, P<0.05).  Post-hoc analysis showed a significant (P<0.01) reduction in the 
time spent exploring the identical objects at 6 h ITI when compared to the 1 min ITI 
(table 6.7). 
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6.3.3 Effect of ITI on social controls in the retention trial of the NOR test 
in female rats  
An overall two-way ANOVA revealed a significant interaction between object 
exploration and ITI in the retention trial of the NOR test (F5, 51=4.7; P<0.01). 
Planned post-hoc comparisons revealed that rats spent significantly more time 
exploring the novel objects during the retention trial at ITIs of 1 min  (P<0.001), 1 h 
(P<0.001), 3.5 h; (P<0.01) and 4 h (P<0.01) but not at 5 h and 6 h (figure 6.3). This 
significant preference for the novel object compared to the familiar object was not 
observed in the rats from the 5 h and 6 h ITI groups i.e. these rats spent similar 
amount of time exploring both objects. Analysis of the total exploration of the 
objects in the retention trial by a one-way ANOVA revealed a significant effect of 
ITI (F5, 56=2.54, P<0.05; table 6.7). However, planned post-hoc analysis failed to 
reveal any individual significant differences in total exploration time in the retention 
trial when compared to the 1 min ITI. 
6.3.4 Effect of ITI duration on the DI in social controls in the NOR test in 
female rats 
One-way ANOVA on the DI data showed no significant effect of increasing the ITI 
duration on the rats’ ability to discriminate between the familiar and novel objects 
(F5, 56=1.63, NS; figure 6.4). There was a marked trend in reduction of DI; however 
this failed to reach statistical significance. Planned post-hoc analysis failed to reveal 
any individual significant differences in DI. 
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6.3.5 Effect of ITI duration on the line crossings in social controls in the 
NOR test in female rats 
Figure 6.5 shows the effect of increasing the ITI duration on the total number of line 
crossings of the rats during the acquisition and retention trials of the NOR test. One-
way ANOVA revealed no significant differences when compared to the 1 min ITI 
(F5, 56=0.42, NS). 
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Figure 6.2 The effect of social rearing conditions on exploration of two identical objects in 
the 3 min acquisition trial prior to ITIs of 1 min, 1 h, 3.5 h, 4 h, 5 h and 6 h in the NOR test 
in female rats. Data are shown as mean ± S.E.M. (n=8-10 per group).  
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Figure 6.3 The effect of social rearing conditions on exploration of a novel and a familiar 
object following ITIs of 1 min, 1 h, 3.5 h, 4 h, 5 h and 6 h during the 3 min retention trial in 
the NOR test in female rats. Data are shown as mean ± S.E.M (n=8-10 per group). 
**P<0.01-***P<0.001; significant increase in time spent exploring the novel compared with 
the familiar object. 
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Figure 6.4 The effect of increasing the ITI duration on the DI in the NOR test in female rats 
reared in social groups. Data are expressed as the mean ± S.E.M. (n=10 per group). 
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Figure 6.5 The effect of increasing the ITI duration on the total number of line crossings in 
the acquisition and retention trials of the NOR test in female rats reared in social groups. 
Data are expressed as the mean ± S.E.M. (n=10 per group). 
 
 
ITI 
Total exploration time (s) 
Acquisition trial Retention trial 
1 min 34.2 ± 4.7 20.8 ± 2.1 
1 h 25.8 ± 2.6 20.7 ± 2.2 
3.5 h 26.0 ± 2.5 24.7 ± 5.4 
4  h 24.1 ± 3.7 19.8 ± 3.2 
5 h 26.4 ± 2.5 10.3 ± 2.6 
6 h 18.5 ± 1.2** 14.0 ± 2.2 
 
Table 6.7 The effect of increasing the ITI duration on the total exploration time in social 
controls in the acquisition and retention trials of the NOR test in female rats. Data are 
expressed as the mean ± S.E.M. (n=10 per group). **P<0.01; significant reduction in total 
object exploration time compared to the 1 min ITI. 
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6.3.6 Effect of ITI duration on the acquisition trial of the NOR test in 
female rats reared in isolation 
A two-way ANOVA revealed no significant interaction between object exploration 
and ITI in the acquisition trial of the NOR test (F3, 36=0.40, NS). Rats from all ITI 
groups spent similar times exploring both the objects (figure 6.6). A one-way 
ANOVA on the total exploration time revealed a significant effect (F3, 39=5.05, 
P<0.01).  Planned post-hoc analysis showed significant reductions in the time spent 
exploring the identical objects at 1 h ITI (P<0.05), 3.5 h ITI (P<0.01) and 4 h ITI 
(P<0.01) when compared to the 1 min ITI (table 6.8).  
6.3.7 Effect of ITI duration on the retention trial of the NOR test in 
female rats reared in isolation 
An overall two-way ANOVA revealed a significant interaction between object 
exploration and ITI in the retention trial of the NOR test (F3, 36=11.12, P<0.001). 
Planned post-hoc comparisons revealed that rats spent significantly more time 
exploring the novel object during the retention trial at ITIs of 1 min (P<0.001) and 1 
h (P<0.001) but not following ITIs of 3.5 h and 4 h (figure 6.7). A one-way ANOVA 
on the total time spent exploring both the novel and familiar objects in the retention 
trial revealed a significant effect (F3, 39=5.01, P<0.01). However, planned post-hoc 
analysis showed no significant effect in the time spent exploring the novel and 
familiar objects following all ITIs (1 h, 3.5 h and 4 h) when compared to the 1 min 
ITI (table 6.8). 
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6.3.8 Effect of ITI duration on the DI in the NOR test in female rats 
reared in isolation 
One-way ANOVA on the DI data showed no significant effect of increasing the ITI 
duration on the rats’ ability to discriminate between the familiar and novel objects 
(F3, 39=0.67, NS). 
6.3.9 Effect of ITI duration on the total number of line crossings in the 
NOR test in female rats reared in isolation 
Figure 6.9 shows the effect of increasing the ITI duration on total number of line 
crossings of the rats during the acquisition and retention trials in the NOR test. One-
way ANOVA revealed no significant differences when compared to the 1 min ITI 
(F3, 39=0.93, NS). 
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Figure 6.6 The effect of isolation rearing conditions on exploration of two identical objects 
in the 3 min acquisition trial prior to the ITIs of 1 min, 1 h, 3.5 h and 4 h in the NOR test in 
female rats. Data are shown as mean ± S.E.M. (n=10 per group). 
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Figure 6.7 The effect of isolation rearing conditions on exploration of a novel and a familiar 
object following ITIs of 1 min, 1 h, 3.5 h and 4 h during the 3 min retention trial in the NOR 
test in female rats. Data are shown as mean ± S.E.M. (n=10 per group). ***P<0.001; 
significant increase in time spent exploring the novel compared with the familiar object. 
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Figure 6.8 The effect of increasing the ITI duration on the DI in the NOR test in female rats 
reared in isolation. Data are expressed as the mean ± S.E.M. (n=10 per group). 
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Figure 6.9 The effect of increasing the ITI duration on the total number of line crossings in 
the acquisition and retention trials of the NOR test in female rats reared in isolation. Data are 
expressed as the mean ± S.E.M. (n=10 per group). 
 
ITI 
Total exploration time (s) 
Acquisition trial Retention trial 
1 min 35.9  ± 4.9 20.2 ± 3.0 
1 h 23.6 ± 3.5* 26.5 ± 4.9 
3.5 h 20.7 ± 2.4** 12.7 ± 3.1 
4  h 18.3 ± 1.4** 9.5 ± 1.7 (P=0.1) 
 
Table 6.8 The effect of increasing the ITI duration on the total exploration time in the 
acquisition and retention trials of the NOR test in female rats reared in isolation. Data are 
expressed as the mean ± S.E.M. (n=10 per group). *P<0.05-**P<0.01; significant reduction 
in the total object exploration time compared to the 1 min ITI. 
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6.3.10 Effect of acute PCP treatment (0.5-1.5 mg/kg) in the acquisition 
trial in female rats housed in social groups 
A two-way ANOVA revealed that acute treatment with PCP did not produce a 
significant effect on object exploration in the acquisition trial of the NOR test (F3, 
57=1.29, NS). Rats from all treatment groups spent similar times exploring both the 
objects (figure 6.10). A one-way ANOVA on the total time spent exploring both 
identical objects in the acquisition trial revealed no significant effect of PCP 
treatment (F3, 57=0.83, NS; table 6.9).  
6.3.11 Effect of acute PCP treatment (0.5-1.5 mg/kg) in the retention trial 
in female rats housed in social groups 
An overall two-way ANOVA revealed that treatment with acute PCP did not 
produce a significant effect on object exploration in the retention trial of the NOR 
test (F3, 57=0.89, NS; figure 6.11). Planned post-hoc analysis revealed that vehicle 
control rats had a significant preference for the novel compared with the familiar 
object, (P<0.01). This preference in the vehicle treated rats for the novel object was 
also observed in all the PCP treated rats at all of the doses tested (0.5–1.5 mg/kg), i.e. 
these rats spent significantly (P<0.01-P<0.05) more time exploring the novel object 
compared to the familiar object. A one-way ANOVA on the total time spent 
exploring both the novel and familiar objects in the retention trial revealed no 
significant effect of PCP treatment (F3, 57=1.08, NS; table 6.9). 
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6.3.12 Effect of acute PCP treatment (0.5-1.5 mg/kg) on the DI in female 
rats housed in social groups 
A one-way ANOVA revealed no significant effect of PCP treatment on the DI (F3, 
57=2.2, NS). Subsequent planned post-hoc analysis revealed a near significant 
(P=0.09) reduction in DI following treatment with PCP at 1.5 mg/kg when compared 
to vehicle control (figure 6.12). 
6.3.13 Effect of acute PCP treatment (0.5-1.5mg/kg) on the total number 
of line crossings in female rats housed in social groups 
A one-way ANOVA revealed no significant effect of PCP treatment on the total 
number of line crossings (F3, 57=0.48, NS; figure 6.13). 
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Figure 6.10 The effect of acute PCP (0.5-1.5 mg/kg, i.p) and 0.9% saline (veh, i.p) on the 
exploration of two identical objects in the 3 min acquisition trial in the NOR test in female 
rats housed in social groups. Data are shown as mean ± S.E.M. (n=20 per group). 
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Figure 6.11 The effect of acute PCP (0.5-1.5 mg/kg, i.p) and 0.9% saline (veh, i.p) on the 
time (s) spent exploring a familiar and novel object in the 3 min retention trial in female rats 
housed in social groups. Data are shown as mean ± S.E.M. (n=20 per group). *P<0.05-
**P<0.01; significant increase in the time (s) spent exploring the novel compared with the 
familiar object. 
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Figure 6.12 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p) and 0.9% 0.9% 
saline (veh, i.p) on the DI in the NOR test in female rats housed in social groups. Data are 
expressed as the mean ± S.E.M. (n=20 per group). P=0.09; approaching significant reduction 
in DI compared to the vehicle control. 
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Figure 6.13 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p) and 0.9% saline 
(veh, i.p)  on the total number of line crossings in the acquisition and retention trials of the 
NOR test in female rats housed in social groups. Data are expressed as the mean ± S.E.M. 
(n=20 per group). 
 
Treatment Total exploration time (s) 
PCP (mg/kg) Acquisition trial Retention trial 
Veh 26.4  ± 2.6 22.9 ± 3.2 
0.5 23.1 ± 3.2 19.2 ± 2.4 
1.0 20.4 ± 3.9 24.1 ± 2.6 
1.5 25.3 ± 4.1 19.8  ± 2.7 
 
Table 6.9 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p) and 0.9% 0.9% saline 
(veh, i.p) on the total exploration time in the acquisition and retention trials of the NOR test 
in female rats reared in social groups. Data are expressed as the mean ± S.E.M (n= 20 per 
group).  
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6.3.14 Effect of acute PCP treatment (2.0 mg/kg) in the acquisition trial in 
female rats housed in social groups 
Since there was no effect of PCP (0.5–1.5 mg/kg) to induce a deficit in object 
recognition memory a higher dose of PCP (2.0 mg/kg) was tested.  A two-way 
ANOVA revealed that acute treatment with PCP (2.0 mg/kg) did not produce a 
significant effect on object exploration in the acquisition trial of the NOR test (F1, 
14=3.22, NS). Rats from both treatment groups spent similar times exploring both the 
objects (figure 6.14). An independent Student’s t-test on the total time spent 
exploring identical objects in the acquisition trial showed no significant effect of 
PCP treatment (table 6.10). 
6.3.15 Effect of acute PCP treatment (2.0 mg/kg) in the retention trial in 
female rats housed in social groups 
An overall two-way ANOVA revealed that treatment with acute PCP did not 
produce any significant effect on object exploration in the retention trial of the NOR 
test (F1, 14=1.27, NS; figure 6.15). However, planned post-hoc analysis revealed that 
vehicle control rats had a significant preference for the novel compared with the 
familiar object (P<0.05), this preference was not observed following treatment with 
PCP at 2.0 mg/kg. An independent Student’s t-test on the total time spent exploring 
the objects in the retention trial showed no significant effect of PCP treatment (table 
6.10). 
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6.3.16 Effect of acute PCP treatment (2.0 mg/kg) on the DI in female rats 
housed in social groups 
An independent samples Student’s t-test revealed a significant (P<0.05) decrease in 
the DI compared to vehicle control rats following acute treatment with PCP (2.0 
mg/kg; figure 6.16). 
6.3.17 Effect of acute PCP treatment (2.0 mg/kg) on the total number of 
line crossings in female rats housed in social groups 
An independent samples Student’s t-test revealed no significant effect of acute 
treatment with PCP (2.0 mg/kg) on the total number of line crossings in the 
acquisition and retention trials of the NOR test (figure 6.17). 
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Figure 6.14 The effect of acute PCP (2.0 mg/kg, i.p.) and 0.9% saline (veh, i.p.) on 
exploration of two identical objects in the 3 min acquisition trial in a NOR test in female rats 
housed in social groups. Data are shown as mean ± S.E.M. (n=8 per group). 
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Figure 6.15 The effect of acute PCP administration (2.0 mg/kg, i.p) and 0.9% saline (veh, 
i.p.) on time (s) spent exploring a familiar and novel object in the 3 min retention trial of the 
NOR test in female rats housed in social groups. Data are shown as mean ± S.E.M. (n=8 per 
group). *P<0.05; significant difference between the time spent exploring the familiar 
compared with the novel object. 
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Figure 6.16 The effect of acute treatment with PCP (2.0 mg/kg, i.p) and 0.9% saline (veh, 
i.p.) on the DI in the NOR test in female rats housed in social groups. Data are expressed as 
the mean ± S.E.M. (n=8 per group). *P<0.05; significant reduction in DI compared with 
vehicle. 
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Figure 6.17 The effect of acute treatment with PCP (2.0 mg/kg, i.p) and 0.9% saline (veh, 
i.p.) on the total number of line crossings in the acquisition and retention trials of the NOR 
test in female rats housed in social groups. Data are expressed as the mean ± S.E.M. (n=8 
per group). 
 
Socials Total exploration time (s) 
PCP (mg/kg) Acquisition trial Retention trial 
Veh 16.7 ± 2.1 20.9 ± 3.5 
2.0 29.9 ± 7.0 (P=0.09) 32.3 ± 6.7 (P=0.1) 
 
Table 6.10 The effect of acute treatment with PCP (2.0 mg/kg, i.p) and 0.9% saline (veh, i.p) 
on the total exploration time (s) in the acquisition and retention trials of the NOR test in 
female rats housed in social groups. Data are expressed as the mean ± S.E.M. (n=8 per 
group). 
 
 
6.3.18 Effect of acute PCP treatment (0.5 mg/kg) in the acquisition trial in 
female rats housed in social groups 
Previously in chapter 4, socially reared female rats were sensitive to the object 
recognition deficit induced by acute PCP at all the doses tested (0.5-2.0 mg/kg). 
However, due to the lack of effect of PCP (0.5–1.5 mg/kg) to induce a deficit in 
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object recognition memory in this study (cohort 12), a repeat experiment in a 
separate group of rats (cohort 13) was performed; to determine the effects of acute 
PCP in socially reared rats at 0.5 mg/kg. 
A two-way ANOVA revealed that acute treatment with PCP (0.5 mg/kg) did not 
produce a significant effect on object exploration in the acquisition trial of the NOR 
test (F1, 14=0.24, NS). Rats from both treatment groups spent similar times exploring 
both the objects (figure 6.18). An independent Student’s t-test on the total time spent 
exploring identical objects in the acquisition trial showed no significant effect of 
PCP treatment (table 6.11). 
6.3.19 Effect of acute PCP treatment (0.5 mg/kg) in the retention trial in 
female rats housed in social groups 
An overall two-way ANOVA revealed that acute treatment with PCP (0.5 mg/kg) 
produced a significant effect on object exploration in the retention trial of the NOR 
test (F1, 14=16.4, P<0.01; figure 6.19). Planned post-hoc analysis revealed that 
vehicle control rats had a significant preference for the novel compared with the 
familiar object (P<0.01), this preference was not observed following treatment with 
PCP at 0.5 mg/kg. An independent Student’s t-test showed a significant (P<0.05) 
decrease in total exploration time following PCP treatment in the retention trial 
(table 6.11). 
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6.3.20 Effect of acute PCP treatment (0.5 mg/kg) on the DI in female rats 
housed in social groups 
An independent samples Student’s t-test revealed a significant (P<0.01) decrease in 
the DI compared to vehicle control rats following acute treatment with PCP (0.5 
mg/kg; figure 6.20). 
6.3.21 Effect of acute PCP treatment (0.5 mg/kg) on the total number of 
line crossings in female rats housed in social groups 
An independent samples Student’s t-test revealed no significant effect of acute 
treatment with PCP (0.5 mg/kg) on the total number of line crossings in the 
acquisition and retention trials of the NOR test (figure 6.21). 
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Figure 6.18 The effect of acute PCP (0.5 mg/kg, i.p) and 0.9% saline (veh, i.p) 
administration on the exploration of two identical objects in the 3 min acquisition trial of the 
NOR test in female rats housed in social groups. Data are shown as mean ± S.E.M. (n=8 per 
group). 
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Figure 6.19 The effect of acute PCP administration (0.5 mg/kg, i.p) and 0.9% saline (veh, 
i.p)  on time (s) spent exploring a familiar and a novel object in the 3 min retention trial of 
the NOR test in female rats housed in social groups. Data are shown as mean ± S.E.M. (n=8 
per group). **P<0.01; significant increase in time (s) spent exploring the novel compared 
with the familiar object. 
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Figure 6.20 The effect of acute treatment with PCP (0.5 mg/kg, i.p.) and 0.9% saline (veh, 
i.p) on the DI in the NOR test in female rats housed in social groups. Data are expressed as 
the mean ± S.E.M. (n=8 per group). *P<0.01; significant reduction in DI compared with 
vehicle. 
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Figure 6.21 The effect of acute treatment with PCP (0.5 mg/kg, i.p.) and 0.9% saline (veh, 
i.p.) on the total number of line crossings in the acquisition and retention trials in the NOR 
test in female rats housed in social groups. Data are expressed as the mean ± S.E.M. (n=8 
per group). 
 
Socials Total exploration time (s) 
PCP (mg/kg) Acquisition trial Retention trial 
Veh 33.4 ± 5.9 42.9  ± 6.7 
0.5 35.4 ± 8.9 22.5  ± 4.2 * 
 
Table 6.11 The effect of acute treatment with PCP (0.5 mg/kg, i.p.) and 0.9% saline (veh, 
i.p.)  on the total exploration time (s) in the acquisition and retention trials of the NOR test in 
female rats housed in social groups. Data are expressed as the mean ± S.E.M. (n=8 per 
group). *P<0.05; significant reduction in total exploration time compared to vehicle. 
 
6.3.22 Effect of acute PCP treatment (0.5-1.5 mg/kg) in the acquisition 
trial in female rats reared in isolation 
A two-way ANOVA revealed that acute treatment with PCP did not produce any 
significant effect on object exploration in the acquisition trial of the NOR test (F3, 
57=1.10, NS). Rats from all treatment groups showed similar times exploring both the 
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objects (figure 6.22). A one-way ANOVA on the total time spent exploring both 
identical objects in the acquisition trial revealed no significant effect (F3, 57=2.08, NS; 
figure 6.12).  
6.3.23 Effect of acute PCP treatment (0.5-1.5mg/kg) in the retention trial 
in female rats reared in isolation 
An overall two-way ANOVA revealed that treatment with PCP produced a near 
significant effect on object exploration in the retention trial of the NOR test (F3, 
57=152.77, P=0.05; figure 6.23). Planned post-hoc analysis revealed that vehicle 
control rats had a significant preference for the novel compared with the familiar 
object, (P<0.01). This preference in the vehicle treated rats for the novel object was 
also observed in all the PCP treated rats at all of the doses tested (0.5–1.5 mg/kg), i.e. 
these rats spent significantly (P<0.01-P<0.05) more time exploring the novel object 
compared to the familiar object. A one-way ANOVA on the total time spent 
exploring both the novel and familiar objects in the retention trial revealed no 
significant effect of PCP treatment (F3, 57=0.79, NS; table 6.12).  
6.3.24 Effect of acute PCP treatment (0.5-1.5 mg/kg) on the DI in female 
rats reared in isolation 
A one-way ANOVA revealed no significant effect of PCP treatment on the DI (F3, 
57=2.2, NS; figure 6.24). 
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6.3.25 Effect of acute PCP treatment (0.5-1.5 mg/kg) on the total number 
of line crossings in female rats reared in isolation 
A one-way ANOVA revealed a significant effect of PCP treatment on the total 
number of line crossings in the acquisition and retention trials of the NOR test (F3, 
57=3.78, P<0.05; figure 6.25). Planned post-hoc analysis revealed a significant 
(P<0.05) increase in the total number of line crossings following treatment with the 
lowest dose of PCP (0.5 mg/kg) when compared with vehicle control. 
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Figure 6.22 The effect acute treatment with PCP (0.5-1.5 mg/kg, i.p.) and 0.9% saline (veh, 
i.p) on exploration of two identical objects in the 3 min acquisition trial of the NOR test in 
female rats housed in isolation. Data are shown as mean ± S.E.M. (n=20 per group). 
 
 
236 
 
Veh 0.5 1.0 1.5
0
10
20
30
Dose (mg/kg)
Novel
Familiar
**
**
**
*
The effect of acute PCP in isolates: Retention trial
E
x
p
lo
r
a
ti
o
n
 t
im
e
 (
s)
 
 
 
Figure 6.23 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p) and 0.9% saline 
(veh, i.p.) on the time (s) spent exploring a familiar and a novel object in the 3 min retention 
trial in female rats housed in isolation. Data are shown as mean ± S.E.M. (n=20 per group). 
*P<0.05-P<0.01; significant increase in the time spent exploring the novel compared with 
the familiar object. 
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Figure 6.24 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p) and 0.9% saline 
(veh, i.p.) on the DI in the NOR test in female rats housed in isolation. Data are expressed as 
the mean ± S.E.M. (n=20 per group). 
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Figure 6.25 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p) and 0.9% saline 
(veh, i.p.)  on the total number of line crossings in the acquisition and retention trials of the 
NOR test in female rats reared in isolation. Data are expressed as the mean ± S.E.M. (n=20 
per group). P<0.05; significant increase in line crossings when compared to the vehicle 
control group. 
 
 
PCP (mg/kg) 
Total exploration time (s) 
Acquisition trial Retention trial 
Veh 27.2 ± 3.3 21.2 ± 2.6 
0.5 32.3 ± 3.8 23.7 ± 2.9 
1.0 27.7 ± 4.3 27.2 ± 3.3 
1.5 21.9 ± 2.9 32.3 ± 3.8 
 
Table 6.12 The effect of acute treatment with PCP (0.5-1.5 mg/kg, i.p.) and 0.9% saline 
(veh, i.p.) on the total exploration time (s) in the acquisition and retention trials in the NOR 
test in female rats reared in isolation. Data are expressed as the mean ± S.E.M. (n= 20 per 
group).  
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6.3.26 Effect of acute PCP treatment (2.0 mg/kg) in the acquisition trial in 
female rats housed in isolation 
A two-way ANOVA revealed that acute treatment with PCP (2.0 mg/kg) did not 
produce any significant effect on object exploration in the acquisition trial of the 
NOR test (F1, 14=1.23, NS). Rats from both treatment groups spent similar times 
exploring both the objects (figure 6.26). An independent Student’s t-test on the total 
time spent exploring identical objects in the acquisition trial showed no significant 
effect of PCP treatment (table 6.13). 
6.3.27 Effect of acute PCP treatment (2.0 mg/kg) in the retention trial in 
female rats housed in isolation 
An overall two-way ANOVA revealed that acute treatment with PCP produced a 
significant effect on object exploration in the retention trial of the NOR test (F1, 
14=100.0, P<0.001; figure 6.27). Post-hoc analysis revealed that vehicle control rats 
had a significant preference for the novel compared with the familiar object (P<0.05) 
this preference was not observed following treatment with PCP at 2.0 mg/kg. An 
independent Student’s t-test on the total time spent exploring the objects in the 
retention trial showed no significant effect of PCP treatment (table 6.13). 
6.3.28 Effect of acute PCP treatment (2.0 mg/kg) on the DI in female rats 
housed in isolation 
An independent samples Student’s t-test revealed a significant (P<0.05) decrease in 
the DI compared to vehicle control rats following acute treatment with PCP (2.0 
mg/kg; figure 6.28) 
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6.3.29 Effect of acute PCP treatment (0.5 mg/kg) on the total number of 
line crossings in female rats housed in isolation 
An independent samples Student’s t-test showed no significant effect of acute PCP 
treatment on the total number of line crossings compared to vehicle control rats 
(figure 6.29). 
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Figure 6.26 The effect acute treatment with PCP (2.0 mg/kg, i.p.) and 0.9% saline (veh, i.p.) 
on exploration of two identical objects in the 3 min acquisition trial in the NOR test in 
female rats housed in isolation. Data are shown as mean ± S.E.M. (n=8 per group). 
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Figure 6.27 The effect of acute PCP administration (2.0 mg/kg, i.p.) and 0.9% saline (veh, 
i.p.) on the time (s) spent exploring a familiar and novel object in the 3 min retention trial in 
the NOR test in female rats housed in isolation. Data are shown as mean ± S.E.M. (n=8 per 
group). *P<0.05; significant increase in time spent exploring the novel compared with 
familiar object. 
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Figure 6.28 The effect of acute treatment with PCP (2.0 mg/kg, i.p.) and 0.9% saline (veh, 
i.p.) on the DI in the NOR test in female rats housed in isolation. Data are expressed as the 
mean ± S.E.M. (n=8 per group). *P<0.05; significant reduction in DI compared with vehicle. 
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Figure 6.29 The effect of acute treatment with PCP (2.0 mg/kg, i.p.) and 0.9% saline (veh, 
i.p.) on the total number of line crossings in the acquisition and retention trials of the NOR 
test in female rats housed in isolation. Data are expressed as the mean ± S.E.M. (n=8 per 
group). 
 
Isolates Total exploration time (s) 
PCP (mg/kg) Acquisition trial Retention trial 
Veh 20.9 ± 2.1 23.3 ± 3.5 
2.0 27.5 ± 5.6 29.4 ± 3.9 
 
Table 6.13 The effect of acute treatment with PCP (2.0  mg/kg, i.p) and 0.9% saline (veh, i.p) 
on the total exploration time in the acquisition and retention trials of the NOR test in female 
rats housed in isolation. Data are expressed as the mean ± S.E.M. (n=8 per group). 
 
6.3.30 Effect of acute d-amph treatment (0.25-0.75 mg/kg) in the 
acquisition trial in female rats housed in social groups 
A two-way ANOVA revealed that acute treatment with d-amph did not produce a 
significant effect on object exploration in the acquisition trial of the NOR test (F3, 
21=0.39, NS). Rats from all treatment groups spent similar times exploring both the 
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objects (figure 6.30). Analysis of the total object exploration time in the acquisition 
trial by a one-way ANOVA revealed a significant effect of drug treatment (F3, 
21=7.93, P<0.01). Post-hoc analysis showed that all doses of d-amph (0.5 - 0.75 
mg/kg) significantly (P<0.05-P<0.001) reduced the total exploration time of the 
identical objects when compared to vehicle control (table 6.14). 
6.3.31 Effect of acute d-amph treatment (0.25-0.75 mg/kg) in the retention 
trial female rats housed in social groups 
A two-way ANOVA revealed that treatment with d-amph produced a significant 
effect on object exploration (figure 6.31) in the retention trial of the NOR test (F3, 
21=3.6, P<0.05). Further planned post-hoc analysis showed that rats treated with 
vehicle control and the lowest dose of d-amph (0.25 mg/kg) had a significant 
(P<0.05 and P<0.01, respectively) preference for the novel compared with the 
familiar object. This significant preference in the vehicle treated rats for the novel 
object was not observed in the rats treated with higher doses of d-amph (0.5 - 0.75 
mg/kg), i.e. these rats spent similar amounts of time exploring both objects. Analysis 
of the total exploration time of the objects in the retention trial by a one-way 
ANOVA revealed no significant effect (F3, 21=1.33, NS). Post-hoc analysis on the 
observed reduction in total exploration time following treatment with the highest 
dose of d-amph (0.75 mg/kg) failed to reach significance (P=0.15) when compared 
to vehicle (table 6.14). 
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6.3.32 Effect of acute d-amph treatment (0.25-0.75 mg/kg) on the DI in 
female rats housed in social groups 
One-way ANOVA on the DI data showed a significant effect of d-amph treatment 
(F3, 21=4.02, P<0.05; figure 6.32). Further post-hoc analysis of the DI showed that the 
highest dose of d-amph (0.75 mg/kg) induced a significant (P<0.05) reduction in DI 
when compared to vehicle control. 
6.3.33 Effect of acute d-amph treatment (0.25-0.75 mg/kg) on the total 
number of line crossings in female rats housed in social groups 
Figure 6.33 shows the effect of acute d-amph treatment on total number of line 
crossings of the rats during the acquisition and retention trials of the NOR test. One-
way ANOVA revealed a significant effect of d-amph on total number of line 
crossings (F3, 21=10.4, P<0.001). Further post-hoc analysis of the total number of line 
crossings revealed that the two highest doses of d-amph (0.5 and 0.75 mg/kg) 
induced a significant (P<0.01 and P<0.001 respectively) increase in the number of 
line crossings. 
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Figure 6.30 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p.) on exploration of two identical objects in the 3 min acquisition trial of the 
NOR test in female rats housed in social groups. Data are shown as mean ± S.E.M. (n=8 per 
group). 
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Figure 6.31 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p.) on time (s) spent exploring a familiar and a novel object in the 3 min 
retention trial in female rats housed in social groups. Data are shown as mean ± S.E.M. (n=8 
per group). *P<0.05-**P<0.01; significant increase in the time (s) spent exploring the novel 
compared with the familiar object. 
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Figure 6.32 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p) on the DI in the NOR test in female rats housed in social groups. Data are 
expressed as the mean ± S.E.M. (n=8 per group). *P<0.05; significant reduction in DI 
compared with vehicle. 
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Figure 6.33 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p) and 0.9% 
saline (veh, i.p.) on the total number of line crossings in the acquisition and retention trials 
of the NOR test in female rats housed  in social groups. Data are expressed as the mean ± 
S.E.M. (n=8 per group). **P<0.01-**P<0.001; significant increase compared to vehicle 
control. 
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Socials Total exploration time (s) 
d-amph 
(mg/kg) 
Acquisition trial Retention trial 
Veh 25.7 ± 1.9 21.9 ± 3.2 
0.25 16.1 ± 2.5 * 15.3 ± 2.6 
0.5 13.6 ± 2.1 ** 14.4 ± 4.0 
0.75 11.5 ± 1.9 *** 13.2  ±2.8 (P=0.15) 
 
Table 6.14 The effect of acute treatment with d-amph (0.5-0.75 mg/kg, i.p.) and 0.9% saline 
(veh, i.p.) on the total number of line crossings in the acquisition and retention trials of the 
NOR test in female rats housed in social groups. Data are expressed as the mean ± S.E.M. 
(n=8 per group). *P<0.05-***P<0.001; significant reduction in the total exploration time 
when compared to vehicle control. 
 
6.3.34 Effect of acute d-amph treatment (0.25-0.75 mg/kg) in the 
acquisition trial in female rats housed in isolation 
A two-way ANOVA revealed that treatment with d-amph did not produce any 
significant effect on object exploration in the acquisition trial of the NOR test (F3, 
21=1.6, NS). Rats from all treatment groups spent similar times exploring both 
objects (figure 6.34). Analysis of the total exploration time in the acquisition trial by 
a one-way ANOVA revealed no significant effect (F3, 21=1.47, NS). However, 
planned post-hoc analysis showed that the highest dose of d-amph (0.75 mg/kg) 
significantly (P<0.05) reduced the total exploration time of the identical objects 
when compared to vehicle control (table 6.15). 
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6.3.35 Effect of acute d-amph treatment (0.25-0.75 mg/kg) in the retention 
trial female rats housed in isolation 
A two-way ANOVA revealed that treatment with d-amph produced a significant 
effect on object exploration in the retention trial of the NOR test (F3, 21=3.06, 
P<0.05). Planned post-hoc comparisons revealed that rats spent significantly (P<0.05) 
more time exploring the novel object during the retention trial in the vehicle control 
group only (figure 6.35).  This significant preference in the vehicle treated rats for 
the novel object was not observed in the rats treated with all doses of d-amph (0.25-
0.75 mg/kg), i.e. these rats spent similar amount of time exploring both objects. 
Analysis of the total exploration time in the retention trial by a one-way ANOVA 
revealed a significant effect of drug treatment (F3, 21=4.64, P<0.05). Post-hoc 
analysis showed that the highest doses of d-amph (0.5 and 0.75 mg/kg) significantly 
(P<0.05 and P<0.01, respectively) reduced the total exploration time of the objects in 
the retention phase when compared to vehicle control (table 6.15). 
6.3.36 Effect of acute d-amph treatment (0.25-0.75 mg/kg) on the DI in 
female rats housed in isolation 
One-way ANOVA on the DI data showed no significant effect of d-amph treatment 
(F3, 21=1.33, NS; figure 6.36). 
6.3.37 Effect of acute d-amph treatment (0.25-0.75 mg/kg) on the total 
number of line crossings in female rats housed in isolation 
Figure 6.37 shows the effect of d-amph treatment on total number of line crossings 
of the rats during the acquisition and retention trials in the NOR test. One-way 
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ANOVA revealed a significant effect of d-amph on line crossings (F3, 21=8.14, 
P<0.01). Further post-hoc analysis of the total line crossings revealed that all the 
doses of d-amph (0.25 - 0.75 mg/kg) induced a significant (P<0.01 - P<0.001) 
increase in number of line crossings compared to vehicle. 
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Figure 6.34 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p) on the exploration of two identical objects in the 3 min acquisition trial in 
the NOR test in female rats housed in isolation. Data are shown as mean ± S.E.M. (n=8 per 
group). 
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Figure 6.35 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p.) on the time (s) spent exploring a familiar and a novel object in the 3 min 
retention trial in female rats housed in isolation. Data are shown as mean ± S.E.M. (n=8 per 
group). *P<0.05; significant increase in the time spent exploring the novel compared with 
the familiar object. 
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Figure 6.36 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p.) on the DI in the NOR test in female rats housed in isolation. Data are 
expressed as the mean ± S.E.M. (n=8 per group). 
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Figure 6.37 The effect of acute treatment with d-amph (0.25-0.75 mg/kg, i.p.) and 0.9% 
saline (veh, i.p.) on the total number of line crossings in the acquisition and retention trials 
of the NOR test in female rats housed in isolation. Data are expressed as the mean ± S.E.M. 
(n=8 per group). **P<0.01-***P<0.001; significant increase the line crossings when 
compared to vehicle control. 
 
Isolates Total exploration time (s) 
d-amph 
(mg/kg) 
Acquisition trial Retention trial 
Veh 24.6 ± 3.3 30.5 ± 6.2 
0.25 18.3 ± 4.3 18.1 ± 4.9 
0.5 15.4 ± 2.9 11.5 ± 2.5 * 
0.75 13.4 ± 2.0 * 11.5 ± 2.4 ** 
 
Table 6.15 The effect of acute treatment with d-amph (0.5-0.75 mg/kg, i.p.) and 0.9% saline 
(veh, i.p) on the total number of line crossings in the acquisition and retention trials of the 
NOR test in female rats housed in isolation. Data are expressed as the mean ± S.E.M. (n=8 
per group). *P<0.05-**P<0.01; significant reduction in total exploration time when 
compared to vehicle control. 
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Housing 
conditions 
LMA 
response to 
novel 
environment 
Onset of 
deficit in 
the 
retention 
trial 
Deficit 
in the 
DI 
 
Effect of 
ITI on 
line 
crossings 
Effect of ITI on 
total 
exploration time 
Isolates *Yes 3.5 h 
No 
(trend; 
NS) 
No 
# (acquisition; 
1h, 3.5h & 4h cf.  
1 min) 
Socials No 5 h 
No 
(trend; 
NS) 
No 
# (acquisition; 
6h cf. 1 min) 
 
Table 6.16 Summary table showing the effect of differential ITIs on the performance in the 
NOR test in female rats raised in isolation or in social groups. Significant (*P<0.05) 
increase in LMA in the isolates when compared to the social control group.  Significant 
decrease (#P<0.05-P<0.01) compared to 1 min ITI. 
 
Treatment 
 
Doses 
tested 
(mg/kg) 
Effective 
in the 
retention 
trial. 
Dose 
(mg/kg) 
Deficit in 
the DI. 
Dose 
(mg/kg) 
Effect on 
line 
crossings. 
Dose 
(mg/kg) 
Effect on total 
exploration. 
Dose (mg/kg) 
Acute 
PCP 
0.5, 
1.0, 1.5 
No 
1.5; 
P=0.09, 
NS 
No No 
Acute 
PCP 
(higher 
dose) 
2.0 Yes 
Yes 
 2.0 
No 
* (Acquisition; 
P=0.09. Retention; 
P=0.1) 
Acute 
PCP 
(repeat) 
0.5 Yes 
Yes 
 0.5 
No No 
Acute        
d-amph 
0.25, 
0.5, 
0.75 
Yes           
0.5, 0.75 
Yes  
0.75 
*0.5, 075 
# (Acquisition; 0.25, 
0.5 0.75, retention; 
0.75 P=0.15) 
 
 
Table 6.17 Summary table showing the effect of acute treatment with PCP (0.5-2.0 mg/kg or 
d-amph (0.25-0.75 mg/kg) on female rats raised in social groups on performance in the NOR 
test. Significant decrease# or increase* (P<0.05-P<0.001) compared to the vehicle treated 
group. 
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Treatment 
 
Doses 
tested 
(mg/kg) 
Deficit in 
the 
retention 
trial. Dose 
(mg/kg) 
Deficit in    
the  DI. 
Dose (mg/kg) 
Effect on 
line 
crossings. 
Dose (mg/kg) 
Effect on  
total 
exploration. 
Dose (mg/kg) 
Acute PCP 0.5, 
1.0, 1.5 
No No *0.5 No 
Acute PCP 
(higher 
dose) 
2.0 Yes Yes  No No 
Acute         
d-amph 
0.25, 
0.5, 
0.75 
Yes         
0.25, 0.5, 
0.75 
No 
*0.25, 0.5,  
0.75 
#(acquisition; 
0.75, 
retention; 0.5, 
0.75) 
 
Table 6.18 Summary table showing the effect of acute treatment with PCP (0.5-2.0 mg/kg or 
d-amph (0.25-0.75 mg/kg) on female rats raised in isolation on performance in the NOR test. 
Significant decrease# or increase* (P<0.05-P<0.001) compared to the vehicle treated group. 
 
 
6.6 Discussion 
6.6.1 LMA in a novel environment 
Results demonstrate that isolation rearing induced an enhanced locomotor reactivity 
to a novel environment (LMA box) compared to socially housed controls. The 
isolated rats were more active compared to the social controls when comparing the 
mean locomotor counts over a 60 min period. These results are supported by many 
studies into the effects of isolation rearing (Phillips et al, 1994; Hall et al, 1998; 
Lapiz et al, 2000; Fabricius et al 2011; review by Fone and Porkess, 2008) and 
indicate that isolated rats show a differential habituation response to a novel 
environment. The rationale behind measuring the rat’s locomotor activity response to 
a novel environment, prior to behavioural experimentation and subsequent drug 
administration was to ensure the efficacy of the isolation procedure. Hyperactivity 
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response to a novel environment induced by isolation rearing has been shown to be 
dependent on dopaminergic function (Burns et al, 1994), and indicates that isolation 
rearing of rats induces an alteration of the mesolimbic dopamine system. 
6.6.2 Socials and isolates; Differential ITI 
In this study, there was no effect of rearing conditions on the acquisition trial or on 
line crossings following any ITI which suggests specificity of effects in the NOR test. 
However there were reductions in the total exploration time in the acquisition trial in 
the socially reared and to a greater extent in the isolation reared rats which could be 
explained as an exploratory habituation effect of repeated (twice) testing of the rats.  
Work carried out in our laboratory has previously shown that female rats reared in 
social groups can discriminate between novel and familiar objects when the ITI is 3 
h, but were unable to discriminate at 4 h (Sutcliffe et al, 2007). However, in the 
present study, female rats reared in social groups were successful at discriminating 
between the novel and familiar object at a greater ITI of 4 h and incapable of 
discriminating at 5 h. The rats were supplied for the studies by two different 
companies (Harlan & Charles River) which may explain the difference in the 
discriminatory abilities of the rats in these two studies. In contrast, the rats reared in 
isolation were only successful at discriminating between novel and familiar objects 
up to an ITI of 1 h, but were not capable of discriminating between the novel and 
familiar objects at 3.5 h, indicating an impairment in object recognition memory in 
rats reared in isolation. A previous study into the effects of isolation rearing in NOR 
using male Hooded-Lister rats showed deficits in their ability to discriminate 
between the novel and familiar objects following at 1 h ITI (Bianchi et al, 2006). 
Studies in our laboratory have previously shown that male rats can discriminate 
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between the novel and familiar objects up to an ITI of 30 min and are unable to 
discriminate between the novel and familiar objects following an ITI of 1h. This 
difference in discriminatory ability of male and female isolation reared rats may be 
explained by evidence showing that in general female rats are superior at 
discriminating between the novel and familiar objects at longer ITIs (Sutcliffe et al, 
2007).  
6.6.3 Isolation rearing; acute PCP 
The first dose range (0.5-1.5 mg/kg) of acute PCP when administered to socially 
reared rats failed to produce an object recognition memory deficit, albeit a reduction 
in the DI was observed, when compared to vehicle controls, but this failed to reach 
statistical significance (P=0.09). The lack of effect of acute PCP to produce an object 
recognition impairment was unusual, unexpected and contradicted the results from 
chapter 4, which clearly showed that acute PCP treatment induced an object 
recognition memory deficit at all the doses tested (0.5-1.5 mg/kg). The female rats 
used in chapter 4 had a lighter bodyweight (g), and were younger than the social 
controls used in this study. It was therefore decided to test a higher dose of PCP (2 
mg/kg) in the same cohort of rats (cohort 12), and to re-test the lowest dose of PCP 
(0.5 mg/kg) in a new cohort of younger and lighter (g) social controls (cohort 13). 
This time, both treatments resulted in clear object recognition memory deficits. The 
differences in bodyweight and age may provide some explanation for the lack of 
consistency in the results obtained following treatment with acute PCP in the 
separate cohorts of rats. In the isolation reared rats, acute PCP treatment did not 
affect exploration levels in the acquisition trial and failed to induce an object 
recognition deficit as measured in the retention trial at all of the doses tested. 
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However, there was a small but significant increase in the total number of line 
crossings following administration of the lowest dose of PCP (0.5 mg/kg), which 
may suggest that acute treatment with PCP at this dose is inducing hyperactivity. As 
with the social control rats, a higher dose of PCP (2 mg/kg) was tested in the 
isolation reared rats and a clear object recognition deficit was observed in the 
absence of any non specific drug effects in the acquisition trial, line crossings and 
total exploration time. The apparent lack of sensitivity of the isolation reared rats to 
the object recognition deficits induced by PCP in the social controls is not supported 
by previous studies in our laboratory, whereby the identical doses of acute PCP 
impaired reversal task performance of the reversal learning task in social and 
isolation reared rats (Abdul-Monim, et al, 2003). It is not clear why the isolation 
reared rats were less sensitive to the acute PCP-induced recognition memory 
impairments than socially reared controls in the NOR test. However, acute PCP 
treatment enhances dopamine in the mPFC (Jentsch et al, 1997; Balla et al, 2003; 
Kalinichev et al, 2008) and isolation rearing induces a reduction of dopamine 
turnover and function in the mPFC (Heidbreder et al, 2000; Muira et al, 2002; Fone 
& Porkess, 2008).  Acute treatment with PCP could enhance the dopamine function 
in the mPFC back to control levels, but not induce a hyperdopaminergic state, thus 
sparing the isolation reared rats from the cognitive impairments observed in the 
social controls. The mPFC is a region known to be important for cognition 
(Goldman-Rakic et al, 2000) and is connected to the perirhinal cortex via excitatory 
projections (Aspergis-schoute et al, 2006). Conversely, the recognition deficits 
induced by acute PCP treatment in social control rats may be explained by acute PCP 
inducing a hyperdopaminergic state with levels of dopamine above the optimum 
levels for cognition. The optimum levels of dopamine required for performance in 
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the NOR test follows an inverted U-shape and reflects the Yerkes-Dodson law 
(Kimberg et al, 2001). 
6.6.4 Isolation rearing; acute d-amphetamine 
Object recognition impairments were observed following the administration of d-
amphetamine to both social and isolation reared rats. However, isolation reared rats 
exhibited object recognition deficits at a lower dose of d-amphetamine compared to 
social controls, indicating an enhanced sensitivity to the cognitive impairment effects 
of the isolation reared rats to d-amphetamine. Additionally, both groups of rats 
demonstrated enhanced total number of line crossings following treatment with d-
amphetamine, signifying a lack of specificity of the cognitive impairment induced by 
d-amphetamine. Conversely, only the isolation reared rats showed increased line 
crossings at a lower dose of d-amphetamine, indicating an enhanced sensitivity to the 
locomotor stimulant effects of d-amphetamine. Furthermore, the effect of d-
amphetamine to induce recognition deficits in the NOR test is confounded by the 
reduced total exploration time of the objects. These results are in agreement with 
previous work carried out in our laboratory (Smith et al, 1997) and other laboratories 
(Jones et al, 1990; 1992), demonstrating that isolation reared rats have an enhanced 
response to the d-amphetamine in terms of increased locomotor activity, although 
there are some conflicting reports (Bowling & Bardo 1994). Both groups of rats 
demonstrated decreased total exploration time of the objects in the acquisition and 
retention trials following treatment with d-amphetamine, further substantiating the 
lack of specificity of the cognitive impairment induced by acute d-amphetamine in 
the NOR test. Reversal learning studies in our laboratory have shown that 
administration of d-amphetamine to socially reared rats selectively impairs the 
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performance of an operant reversal-learning task an effect which was subsequently 
reversed by the administration of the D2 receptor antagonist haloperidol. (Idris et al, 
2005). Microdialysis studies have shown that acute administration of d-amphetamine 
elevates dopamine levels in the mPFC (Pehek, 1999), thus inducing a 
hyerdopaminergic state which may account for the recognition memory deficits 
observed in the NOR test. 
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CHAPTER 7 - Investigation of psychotomimetic-
induced deficits in another test of cognitive function 
impaired in psychiatric disorders: Working memory 
using the 16-holeboard maze   
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7.1 Introduction 
Working memory deficits are one of the most robust and measurable cognitive 
deficits observed in schizophrenia patients and their relatives (Goldman-Rakic, 1994; 
Barch, 2005, Lee & Park, 2005). Evidence for the role of the prefrontal cortex in 
working memory comes from pre-clinical and clinical studies such as human 
neuropsychological, brain lesion, functional brain imaging studies and lesion studies 
in the primate (Perlstein et al, 2001). The role of the prefrontal cortex in 
schizophrenia comes from studies that demonstrate poor performance of patients on 
tasks that are sensitive to frontal lobe damage such as the WCST (van der Does & 
van den Bosch, 1992) and delayed response tasks (Park & Holzman, 1992; Carter et 
al, 1996). Furthermore, schizophrenia patients showed a physiological deficit in 
activation of the right dorsolateral prefrontal cortex under task performance of the 
“n-back” sequential letter working memory task when compared to healthy controls 
(Perlstein et al, 2001). 
Primarily the holeboard has previously been used to assess altered exploratory 
activity and anxiety and not spatial learning and memory (Rogers et al, 1999; 
Casarrubea et al, 2010). However, there have been a number of studies reported 
using the holeboard maze for measuring experimental manipulations on learning and 
memory in mice and rats (Oades and Isaacson, 1978; Kuc et al, 2006).  A large 
variety of measures can be assessed using the holeboard maze (see review by van der 
Staay et al, 2012). The working memory measure has been calculated in a variety of 
ways, for results shown in this thesis, working memory score is calculated as: 
rewarded hole visits/ total hole visits (see chapter 2, section 2.1.8.4.2).  
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Selected pharmacological agents and specific brain lesions have been shown to 
disrupt learning and memory on the holeboard maze. Studies by Kuc and colleagues 
(2006) established that the muscarinic antagonist scopolamine at 0.1 and 1.0 mg/kg 
significantly increased the working memory score i.e. the mice performed worse 
compared to controls.  
The cone field test is a variant of the holeboard maze which instead of holes, has 16 
cones upon which small cups hold the food rewards (van der Staay et al, 1990). A 
study by Blokland et al (1998) demonstrated impairments in working memory 
following treatment with d-amphetamine in the cone field test. Furthermore, deficits 
in working memory were observed in the cone field test following treatment with 
scopolamine, which were reversed by the acetylcholinesterase inhibitor metrifonate 
(van der Staay & Bouger, 2005). In another study, a significant increase in the 
number of working memory errors was observed following a repeated (once daily for 
14-days) dosing regimen with the NMDA receptor antagonist MK801 in a modified 
version of the holeboard maze (Rujescu et al, 2006). 
It has been shown that deactivation of the medial prefrontal cortex with muscimol 
selectively impairs working memory in a delayed alternation task in the rat (Yoon et 
al, 2008). Additionally, lesions of the prelimbic and infralimbic but not the medial 
prefrontal cortex region of the frontal cortex has been shown to induce profound 
impairments in working memory in a delayed non-matching-to-sample test in the rat 
(Kesner et al, 1996). Delayed discrimination tasks have also revealed to important 
role for the prefrontal cortex. For example, lesions of the prefrontal cortex have been 
shown to impair performance in a delayed alternation task (Joel et al, 1997; Sanchez-
Santed et al, 1997).  The effect of prefrontal cortex lesions has not been assessed 
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using the holeboard maze. However, lesions of the hippocampus, a brain region also 
implicated in working memory and schizophrenia, resulted in increased working 
memory errors in a 16-holeboard maze in the rat (Oades, 1981). Working memory 
on the holeboard maze is not only impaired after direct lesions of the hippocampus, 
but also lesions of the hippocampal afferents (van der Staay et al, 1989). 
The aim of this study was to determine the effects of acute treatment with 
psychotomimetic agents d-amph, PCP and the muscarinic antagonist scopolamine on 
working memory score in the 16-holeboard maze. Furthermore, the cognitive effects 
of the sub-chronic PCP dosing regimen were evaluated in this paradigm to detect 
impairments in working memory score.  
7.2 Materials and methods 
7.2.1 Experimental Animals and Design 
Studies used two cohorts (cohort 16 & 17) of adult (n=28; 200-245g) female hooded-
Lister rats (Harlan, UK), details are shown in tables 7.1 & 7.2. For housing 
conditions see section 2.1.1 and for information regarding the drugs used in this 
study see table 7.3, 7.4 and 2.2. For the sub-chronic PCP dosing regimen see section 
2.1.3. 
Experiment 
number 
Cohort 
number 
Total number of 
rats used 
Weight 
range (g) 
Compound tested 
and dose (mg/kg) 
1 1 16 200-245 PCP 2.0 
2 1 16 200-245 d-amph 0.75 
3 1 16 200-245 Scopolamine 0.25 
 
Table 7.1 Details of the rats used in the acute studies. 
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Experiment 
number 
Cohort 
number 
Total number of 
rats used 
Weight 
range (g) 
Compound tested and 
dose (mg/kg) 
4 2 12 210-245 Sub-chronic PCP 2.0 
 
Table 7.2 Details of the rats used in the sub-chronic PCP studies. 
 
7.2.2 Drugs 
The individual experiments (1-3) were separated by 1 week, rats were tested three 
times and the study took 3 weeks to complete. 
In experiment 1, rats were randomly assigned to receive either an acute injection of 
PCP (2.0 mg/kg, i.p.) or vehicle (0.9% saline, i.p.). In experiment 2, rats were 
randomly assigned to receive either an acute injection of d-amph (0.75 mg/kg, i.p.) 
or vehicle (0.9 % saline, i.p.) and in experiment 3, rats were again randomly assigned 
to receive scopolamine (0.25 mg/kg, i.p.) or vehicle (0.9 % saline, i.p.). All 
compounds were administered 30 min prior to testing on the 16-holeboard maze (see 
table 2.2).  The doses of PCP and d-amph used in this study were chosen based upon 
previous studies whereby similar doses of PCP (1.5 mg/kg) and d-amph (0.75 mg/kg) 
induced a psychotomimetic reversal learning deficit in rats (McLean et al, 2010). 
The dose of scopolamine was chosen based on a study whereby scopolamine (0.2 
mg/kg) impaired NOR in young (3-6 mths old), male Wistar rats (Vannucchi et al, 
1997). 
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Experiment 
number 
Acute 
Treatment 
Dose 
(mg/kg) 
Dose volume 
(ml/kg) 
Initial 
number 
of rats 
Number 
of rats 
excluded 
1 Vehicle 0 1 8 0 
1 PCP 2.0 1 8 0 
 
2 Vehicle 0 1 8 0 
2 d-amph 0.75 1 8 0 
 
3 Vehicle 0 1 8 0 
3 Scopolamine 0.25 1 8 0 
 
Table 7.3 The acute treatments and number of rats in each treatment group. 
 
In experiment 4, a total of 12 rats were randomly assigned to receive either vehicle 
(n=6; 0.9% saline twice a day, i.p.) or PCP (n=6; 2mg/kg twice a day, i.p.) in a 
volume of 1 ml/kg for 7 days. Subsequently, animals were given a 7-day drug free 
period prior to 16-holeboard maze testing. Training data is not shown for cohort 17 
as it was almost identical to the training data generated from cohort 16.  
Experiment 
number 
Treatment Dose (mg/kg) 
Initial 
number of 
rats 
Number of 
rats 
excluded 
4 Veh 0 6 0 
4 PCP 2.0 6 0 
 
Table 7.4 The dose of sub-chronic PCP and number of rats in each treatment group. 
 
7.2.3 16-Holeboard Maze apparatus 
For details regarding the apparatus, see section 2.1.8.1. 
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7.2.4 16-Holeboard Maze protocol 
For details regarding the protocol, see section 2.1.8.3. 
7.2.5 Statistical analysis 
For details regarding the statistical analysis, see section 2.1.8.5. 
7.3 Results 
7.3.1 Effect of daily training sessions on WMS in the 16-holeboard maze 
in female rats 
A one-way ANOVA revealed that daily training sessions had a significant (F8, 
143=10.2, P<0.001) effect on the WMS in the 16-hole board maze. Planned post-hoc 
comparisons showed a significant increase in WMS on days 3 (P<0.05), 4 (P<0.01) 
and 5-9 (P<0.001) when compared to day 1 (figure 7.1). 
7.3.2 Effect of daily training sessions on latency to complete the task in 
the 16-holeboard maze in female rats 
A one-way ANOVA revealed that daily training sessions had a significant (F8, 
143=37.7, P<0.001) effect on latency to complete the task in the 16-holeboard maze. 
Planned post-hoc comparisons showed a significant decrease in latency on days 4-9 
(P<0.001) compared to day 1 (figure 7.2). 
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Figure 7.1 The effect of daily training sessions on WMS in the 16-holeboard maze. Data are 
expressed as the mean of 10 trials per day over 9-days ± S.E.M.. (n=16). *P<0.05-
***P<0.001; significant increase in WMS compared to day 1. 
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Figure 7.2 The effect of daily training sessions on latency to complete the task (i.e. collect 
all 4 food pellets) in the 16-holeboard maze. Data are expressed as the mean of 10 trials per 
day over 9-days ± S.E.M. (n=16). ***P<0.001; significant decrease in latency to complete 
the task compared to day 1. 
266 
 
7.3.3 Effect of acute PCP on WMS in the 16-holeboard maze in female 
rats 
A two-way ANOVA revealed that acute administration of PCP (2.0 mg/kg) to rats 
produced an overall significant effect on WMS in the 16-holeboard maze (F1, 14=57.7, 
P<0.001; figure 7.3). Further planned post-hoc Student’s t-test analysis revealed a 
significant reduction in WMS in the PCP treated rats compared to vehicle controls in 
trials 1 & 3 (P<0.001), 4 (P<0.05), 5 (P<0.01) and 6-9 (P<0.05). 
7.3.4 Effect of acute PCP on latency to complete the task in the 16-hole 
board maze in female rats 
A two-way ANOVA revealed that acute administration of PCP (2.0 mg/kg) to rats 
produced an overall significant effect on latency to complete the task in the 16-
holeboard maze (F1.14=9.7, P<0.01; figure 7.4). Further planned post-hoc Student’s t-
test analysis revealed a significant increase in latency to complete the task in the PCP 
treated rats compared to vehicle controls in trials 1 (P<0.001), 4 (P<0.05) and 9 
(P<0.05). 
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Figure 7.3 The effect of acute treatment with PCP (2 mg/kg, i.p.) on WMS over 10 trials in 
the 16-holeboard maze. Data are expressed as mean ± S.E.M. (n=8). *P<0.05-P<0.001; 
significant reduction in WMS compared to vehicle control. 
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Figure 7.4 The effect of acute treatment with PCP (2 mg/kg, i.p.) on latency to complete the 
task (i.e. collect all 4 food pellets) over the 10 trials on the 16-holeboard maze. Data are 
expressed as mean ± S.E.M. (n=8). *P<0.05-***P<0.001; significant increase in latency to 
complete the task compared to vehicle control. 
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7.3.5 Effect of acute d-amph on WMS in the 16-holeboard maze in female 
rats 
A two-way ANOVA revealed that acute administration of d-amph (0.75 mg/kg) to 
rats produced an overall significant effect on WMS in the 16-holeboard maze (F1, 
14=20.1, P<0.01; figure 7.5). Further planned post-hoc Student’s t-test analysis 
revealed a significant reduction in WMS in the d-amph treated rats compared to 
vehicle control in trials 6-8 (P<0.05) and 10 (P<0.001). 
7.3.6 Effect of acute d-amph on latency to complete the task in the 16-
holeboard maze in female rats 
A two-way ANOVA revealed that acute administration of d-amph (0.75 mg/kg) to 
rats produced an overall significant effect on latency to complete the task in the 16-
holeboard maze (F1.14=43.9, P<0.001; figure 7.6). Further planned post-hoc Student’s 
t-test analysis revealed a significant increase in latency to complete the task in the d-
amph treated rats compared to vehicle controls in trials 1-3 and 5 (P<0.05), 6 
(P<0.01), 8 (P<0.05), 9-10 (P<0.01). 
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Figure 7.5 The effect of acute treatment with d-amph (0.75 mg/kg, i.p.) on WMS over 10 
trials in the 16-holeboard maze. Data are expressed as mean ± S.E.M. (n=8). *P<0.05-
P<0.001; significant reduction in WMS compared to vehicle control. 
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Figure 7.6 The effect of acute treatment with d-amph (0.75 mg/kg, i.p.) on latency to 
complete the task (i.e. collect all 4 food pellets) over the 10 trials on the 16-holeboard maze. 
Data are expressed as mean ± S.E.M. (n=8). *P<0.05-**P<0.01; significant increase in 
latency to complete the task compared to vehicle control. 
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7.3.7 Effect of acute scopolamine on WMS in the 16-holeboard maze in 
female rats 
A two-way ANOVA revealed that acute administration of scopolamine (0.25 mg/kg) 
to rats produced an overall significant effect on WMS in the 16-holeboard maze (F1, 
14=20.3, P<0.001; figure 7.7). Further planned post-hoc Student’s t-test analysis 
revealed a significant reduction in WMS in the scopolamine treated rats compared to 
vehicle control in trials 1 (P<0.05), 2-4 (P<0.01), 5 (P<0.001), 7 (P<0.01), 9 and 10 
(P<0.05). 
7.3.8 Effect of acute scopolamine on latency to complete the task in the 
16-hole board maze in female rats 
A two-way ANOVA revealed that acute administration of scopolamine (0.25 mg/kg) 
to rats produced an overall significant effect on latency to complete the task in the 
16-holeboard maze (F1.14=47.1, P<0.001; figure 7.8). Further planned post-hoc 
Student’s t-test analysis revealed a significant increase in latency to complete the 
task in the scopolamine treated rats compared to vehicle controls in trials 2 (P<0.01), 
3 (P<0.05), 4 (P<0.01) 5 and 6 (P<0.05), 7 (P<0.01), and 9 (P<0.05). 
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Figure 7.7 The effect of acute treatment with scopolamine (0.25 mg/kg, i.p.) on WMS over 
10 trials in the 16-holeboard maze. Data are expressed as mean ± S.E.M. (n=8).  *P<0.05-
***P<0.001; significant reduction in WMS compared to vehicle control. 
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Figure 7.8 The effect of acute treatment with scopolamine (0.25 mg/kg, i.p.) on latency to 
complete the task (i.e. collect all 4 food pellets) over the 10 trials on the 16-holeboard maze. 
Data are expressed as mean ± S.E.M. (n=8). *P<0.05-**P<0.01; significant increase in 
latency compared to vehicle control. 
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7.3.9 Effect of sub-chronic PCP-treatment on WMS in the 16-holeboard 
maze in female rats 
A two-way ANOVA revealed that sub-chronic PCP treatment produced an overall 
significant effect on WMS in the 16-holeboard maze (F1, 10=9.3, P<0.05; figure 7.9). 
Further planned post-hoc Student’s t-test analysis revealed a significant reduction in 
WMS in the sub-chronic PCP treated rats compared to vehicle controls in trials 1 
(P<0.01), 6, 8 and 9 (P<0.05). 
7.3.10 Effect of acute sub-chronic PCP-treatment on latency to complete 
the task in the 16-hole board maze in female rats 
A two-way ANOVA revealed that sub-chronic PCP treatment produced an overall 
significant effect on latency to complete the task in the 16-holeboard maze (F1.10=8.8, 
P<0.05; figure 7.10). Further planned post-hoc Student’s t-test analysis revealed a 
significant increase in latency to complete the task in the sub-chronic PCP treated 
rats compared to vehicle controls in trials 1 (P<0.01), 4 (P<0.05) and 5 (P<0.01). 
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Figure 7.9 The effect sub-chronic PCP treatment (2mg/kg i.p. twice daily for 7-days) on 
WMS over 10 trials in the 16-holeboard maze. Data are expressed as mean ± S.E.M. (n=6). 
*P<0.05-**P<0.01; significant reduction in WMS compared to vehicle control. 
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Figure 7.10 The effect sub-chronic PCP treatment (2mg/kg i.p. twice a day for 7-days 
followed by a 7-day drug free washout period) on latency to complete the task (i.e. collect 
all 4 food pellets) over the 10 trials in the 16-holeboard maze. Data are expressed as mean ± 
S.E.M. (n=6). *P<0.05-**P<0.01; significant increase in latency compared to vehicle control.  
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Treatments 
Number of trials showing 
a deficit in the WM S 
Increase in latency to 
complete the task (time s) 
Acute PCP 8/10 trials (*-***) 3/10 trials(*-***) 
Acute d-amph 4/10 trials (*-***) 8/10 trials (*-***) 
Acute scopolamine 8/10 trials (*-***) 7/10 trials (*-**) 
Sub-chronic PCP 4/10 trials (*-**) 4/10 trials (*-**) 
 
Table 7.5 Summary table showing the effect of acute treatment with PCP, d-amph, 
scopolamine and sub-chronic PCP in female rats performance in the NOR test. *P<0.05-
***P<0.001; significant deficit in WMS compared to vehicle control. *P<0.05-***P<0.001; 
significant increase in the latencey to complete the task. 
 
7.4 Discussion 
7.4.1 16-Holeboard maze 
Studies demonstrate that daily training sessions to find the food rewards on the 16-
holeboard maze increased the working memory score (WMS) compared to training 
day 1, which demonstrates the ability of the rats to learn the location of the 4 food 
rewards in the 16-holeboard maze and their ability to utilise their spatial working 
memory to remember which food rewards had already been eaten and not to re-visit 
these previously visited food rewarded holes. In addition, repeated daily training 
sessions on the 16-holeboard maze was seen to reduce the latency to find and eat the 
4 food pellets during the training sessions compared to training day 1, which again 
provides further evidence of the ability of the rats to learn the test.  
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7.4.2 Acute PCP, d-amphetamine, scopolamine 
Acute treatment with PCP was shown to impair the WMS throughout the test (8/10 
trials), demonstrating a powerful effect of acute PCP to produce a cognitive 
impairment in the 16-holeboard maze. Latency to complete the task was generally 
increased following acute treatment with PCP and reached significance at 3/10 trials. 
This increase in latency is probably due to the rats making more errors and is a 
secondary consequence of the increased WMS observed in the acute PCP treated rats. 
It cannot be ignored that the reduction in latency to complete the task could be 
explained by a direct decrease in locomotor activity. Nevertheless, this is unlikely 
since acute PCP has been shown to increase locomotor activity in rats, usually at 
higher doses than used in this study (Javitt et al, 1997). However, the dose of PCP 
used in this study was selected based on the results in chapter 4 whereby, PCP at a 
dose of 2 mg/kg induced object recognition deficits in the absence of an increase in 
locomotor activity. The impairments in WMS following acute treatment with d-
amphetamine were observed in 4/10 trials. The pattern of WMS impairment in the d-
amphetamine treated rats differed from the overall general impairment observed in 
the acute PCP treated rats, such that WMS impairments following acute 
administration of d-amphetamine were only seen in the later trials (trials 6-8, 10). 
However, the increase in latency to complete the task induced by acute d-
amphetamine treatment was observed in 8/10 trials, an effect that was evenly 
distributed throughout the 10 trials. In contrast to the acute PCP treated rats, the 
increase in latency to complete the task following acute d-amphetamine treatment is 
likely to be affected by the locomotor stimulant effect; since the dose of 0.5 mg/kg 
increased line crossings in the NOR test in chapter 4. Furthermore, it is widely 
276 
 
accepted that d-amphetamine is a powerful enhancer of locomotor acivity (Antoniou 
et al, 1998; Frey et al, 2006). 
Administration of scopolamine induced deficits in WMS in 8/10 trials in the 16-
holeboard maze. The pattern of WMS impairment over the 10 trials was different to 
those observed following acute treatment with PCP and d-amphetamine. The 
increased latency to complete the task was observed somewhat uniformly throughout 
the 10 trials of the 16-holeboard maze test and most likely is a result of the increased 
number of errors producing a reduction in the WMS, which has a secondary effect 
on latency to complete the task. Previous studies provide further support, showing 
that scopolamine-induced increases in locomotor activity in mice on the COGITAT 
hole-board system which is a modified automated version of the hole-board maze, 
decreased attention and resulted in a higher number of non-baited hole inspections 
(Post et al, 2011). Scopolamine induced memory deficits are related to reduced 
cholinergic activity through blockade of muscarinic receptors and studies in the 
clinic have shown that scopolamine induces working memory impairments in man 
(Thomas et al, 2008) and rodent (see review by Klinkenburg & Blokland, 2010).  
Scopolamine has been shown to increase locomotor activity at 0.56 mg/kg (Sipos et 
al, 1999), somewhat higher than the dose tested in this study. Nevertheless, we 
cannot rule out the possibility of non-specific locomotor effects of acute 
scopolamine in the 16-holeboard maze. The reduction in the scopolamine induced 
WMS observed in these studies is supported by numerous studies demonstrating 
increases in working memory errors in the 8-arm radial maze following acute 
treatment with  scopolamine (Watts et al, 1981; Wang & Tang, 1998; Olsen & Cero, 
2010).  
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7.4.2 Sub-chronic PCP 
Following treatment with sub-chronic PCP, WMS deficits were observed in 4/10 
trials, latency to complete the task increased in 3/10 trials. Sub-chronic PCP 
treatment did not affect the total number of line crossings in the NOR test. Therefore, 
it is unlikely that the increase in latency to complete the trials following treatment 
with sub-chronic PCP, in the hole board maze, is a direct locomotor effect of PCP 
and more likely to be secondary effect of the decrease in WMS. The reduction in the 
WMS induced by sub-chronic PCP is supported by Jentsch and Taylor (2001) who 
have demonstrated that rats display impairments in spatial working memory in the T-
maze following sub-chronic PCP treatment. Furthermore, studies using a non-
delayed 4-arm baited radial maze have reported working memory impairments in 
male Sprague-Dawley rats after 14 day treatment regimen of PCP (Noda et al, 2000). 
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CHAPTER 8 - General Discussion 
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8.1 General discussion 
The work presented in this thesis investigates the NOR test as a potential paradigm 
for studying recognition memory in the rat. Initial pilot studies were carried out to 
provide validation initially this involved determination of innate preference for 
various different objects and then the effect of altering the inter-trial-interval was 
studied. Behavioural manipulations and psychotomimetic dosing regimens were 
performed in an attempt to induce cognitive impairments of relevance to psychiatric 
disorders, especially schizophrenia. Further studies aimed to attenuate the sub-
chronic PCP-induced recognition memory deficits with a series of carefully selected 
pharmacological agents in an attempt to provide further understanding of the 
pharmacological mechanisms involved in the sub-chronic PCP induced cognitive 
deficit in the NOR test. Additional studies were carried out into the 16-holeboard 
maze as a potential paradigm for studying working memory which is impaired in 
many neurological and psychiatric disorders e.g. schizophrenia and Alzheimer’s 
disease. A summary of all the results presented in this thesis from the individual 
chapters are shown in tables 3.3, 3.9, 4.13, 4.14, 4.15, 4.16, 5.16, 6.16, 6.17, 6.18 
and 7.5. 
Hooded-Lister rats were selected for use in all the studies, since these animals have 
been found to be superior when compared to other rat strains in a simple a simple T-
maze task (Deacon & Rawlings, 2006). Additionally, in our laboratory female 
hooded-Lister rats have consistently been shown to learn quickly and perform 
reliably in various cognitive tasks (see review by Neill et al, 2010). The preliminary 
work in this thesis concentrated on the development of a suitable testing protocol for 
the NOR paradigm. 
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The importance of pilot studies prior to behavioural research work is paramount, 
undertaking careful initial studies allow the parameters of a paradigm to be adjusted 
and the observed animal behaviour fully understood. One of the main advantages of 
conducting pilot studies is that they give advance warning about where the main 
research project could fail, or whether proposed methods and measurement tools or 
instruments are inappropriate or too complicated (Festing & Altman, 2004). 
The main findings of this thesis are summarised below: 
(1) In summary, the results of the object preference studies in chapter 3 highlight the 
importance of undertaking preliminary pilot studies. It was vital to determine the 
object preference of both sub-chronic PCP treated rats and not just controls since one 
of the core feature of the thesis was to investigate the effect of sub-chronic PCP 
treatment in the NOR test. The results demonstrated a preference for the wood cone 
in both sub-chronic PCP and vehicle control treated rats, furthermore a significant 
increase in total exploration time of the wood cone was observed in the sub-chronic 
PCP treated rats when all the total exploration times were pooled from the series of 
object preference experiments. If this preliminary study had not been carried out, the 
entire data set where we used the wooden cone would have been fundamentally 
flawed. 
(2) It could be hypothesised that sub-chronic PCP-induced recognition memory 
deficits observed after a short ITI such as 1 min in the NOR test may be attributed to 
impaired attention processes. Impaired attention in the NOR test would manifest as a 
decreased ability of the rats to encode information in the acquisition trial. However, 
it is unlikely that sub-chronic PCP-induced deficits in NOR are solely attributed to a 
lack of attention since the total exploration time in the acquisition and retention trials 
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in the sub-chronic PCP-treated groups of rats are not lower compared to control 
groups.  
(3) A series of experiments was performed to determine if the recognition memory 
deficits observed in the sub-chronic PCP treated rats following the short 1 min ITI 
were as a result of disruption in the ability of the rats to encode the information 
(identical objects) in the acquisition trial. Therefore, if rats were unable to encode the 
information in the acquisition trial, any recognition deficits observed following sub-
chronic PCP treatment could not be attributed to memory impairment. Results 
suggest that following a 0 or 1 min ITI, i.e. if rats remain in the NOR box whilst the 
acquisition objects (two identical objects) were carefully exchanged for the retention 
trial objects (familiar and novel objects), sub-chronic PCP treated rats were able to 
discriminate between the novel and familiar object. These animals are therefore 
successful in encoding the information presented in the acquisition trial. Furthermore, 
it was discovered that the sub-chronic PCP-induced deficit in recognition memory in 
the NOR test during the short ITIs (0 – 1 min) may be in part due to distraction. For 
example, the sub-chronic PCP treated rats only demonstrated object recognition 
deficits when they were either removed from the NOR test box by an experimenter 
or remained in the NOR test box with a distracter object for the duration of the ITI. 
These careful pilot studies are vital components to the overall infrastructure in 
developing and validating a behavioural paradigm.  
(4) Based on the pilot study results in chapter 3, acute treatment with PCP (0.5-5.0 
mg/kg) and d-amph (0.1-2.5 mg/kg) were examined for their ability to induce 
cognitive deficits in both male and female rats in the NOR test (chapter 4). Results 
showed that that acute treatment with d-amph and PCP induces recognition deficits 
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in the NOR test with lower sensitivity in male compared to female rats, clearly 
signifying a gender difference in the PCP and d-amph–induced impairments in 
cognition. Sub-chronic PCP treatment induces recognition deficits in both sexes of 
rats, but more pronounced sub-chronic PCP-induced NOR deficits were observed in 
female rats. 
(5) The effect of isolation rearing on performance in the NOR test was examined in 
chapter 6. The principal findings show that rats reared in social groups exhibit an 
enhanced capacity to discriminate between novel and familiar objects at a longer ITI 
in the NOR test than rats reared in isolation. Furthermore, rats reared in isolation 
were less sensitive to the acute PCP-induced recognition memory deficits and more 
sensitive to the acute d-amph-induced recognition memory deficits when compared 
to social controls in the NOR test. 
(6) The results from chapter 5 show that sub-chronic PCP-induced cognitive deficits 
observed in the NOR test were successfully reversed by the atypical antipsychotic 
agents clozapine and risperidone, the cognitive enhancing agents modafinil and 
nicotine, the novel agents α7 nAChR agonist PNU-282987 and the α7 PAM PNU-
120986. Furthermore, the sub-chronic PCP-induced cognitive deficits in NOR were 
not reversed by the classical antipsychotic agents haloperidol and fluphenazine, the 
benzodiazepine anxiolytic agent CDP or the SSRI antidepressant agent fluoxetine. 
(7) In chapter 7, the 16-holeboard maze was selected to examine the acute and sub-
chronic effects of PCP, acute treatment with d-amph or the muscarinic receptor 
antagonist scopolamine. Results demonstrate that acute treatment with d-amph, PCP 
and scopolamine induce robust reductions in working memory score in the holeboard 
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maze. In addition, sub-chronic PCP treatment also produced reductions in working 
memory score in this paradigm. 
There has been a surge of interest in the NOR test by psychologists and 
neuroscientists in the last decade. The NOR test is a very simple, non-rewarded 1-
trial test, requires little habituation, involves no training and experiments using this 
paradigm can be completed rapidly (Silvers et al, 2007). The NOR test utilises the 
rats’ innate preference for novelty and measures the rats' ability to recognise a novel 
object within its environment. The unconditioned preference of rats and mice for the 
novel object is an indication that an account of the familiar object exists in the 
memory. The NOR test involves memory for a familiar object and detection and 
processing of information about a novel object. The ITI-delay/pharmacological 
dependent decrease in recognition memory results from a decay in memory of the 
familiar object. The novel object needs to be detected and encoded whereas the 
familiar object will need to be updated and reconsolidated after delay intervals or 
other manipulations (Ennaceur, 2010). 
There has been much discussion over the type of memory that is measured using the 
NOR test (Ennaceur, 2010; Antunes & Biala, 2011) and it has been described as 
measuring working memory (Ennaceur & Delacour, 1987), episodic memory 
(Bertaina-Angalade et al, 2011), and novelty preference (Gaskin et al, 2003). 
Episodic memory is described as the ability remember an event in time and place i.e. 
what-where-when, however the 1-trial NOR test only measures what- (Le Cozannet 
et al, 2010). Assessing the temporal aspect of an episode is very challenging. A 
novelty preference test infers the rats may have a generic reaction of familiarity in 
the absence of a specific recollection of the memory of the familiar object. It is now 
284 
 
agreed that the NOR test is not a working memory test because the objects are 
apparently not encoded for the explicit purpose to achieve an ongoing task (Ennaceur, 
2010). 
In all experiments (chapter 1-6) using sub-chronic PCP treated rats, a robust 
recognition memory deficit in the retention trial was observed in the NOR test. Non-
specific effects in the acquisition trial, line-crossings and total object exploration 
time were not observed following treatment with sub-chronic PCP in the NOR test. 
On the contrary, non-specific effects were observed following acute treatment with 
PCP and d-amph in the NOR test. Furthermore, results in chapter 4 demonstrate that 
male rats were insensitive to the acute PCP induced NOR deficits observed in female 
rats. However, male rats demonstrated sensitivity to the sub-chronic PCP induced 
NOR deficits. Both male and female rats demonstrated NOR deficits following acute 
treatment with d-amph, however, lower doses of d-amph induced NOR deficits in the 
female rats. These results provide evidence that sub-chronic PCP dosing regimen is 
superior to acute PCP treatment in producing NOR deficits in both sexes of rats. The 
possible reasons for the sex differences in the effects of PCP and d-amph are 
discussed in chapter 4. Since schizophrenia is generally shown to be more prevalent 
in males compared to female patients (Nicole et al, 1992), the sub-chronic PCP 
treatment regimen demonstrates better face validity compared to acute PCP 
treatment. Overall this suggests that the NOR test is a sensitive paradigm with ability 
to assess the sub-chronic PCP induced recognition memory deficits. The sub-chronic 
PCP-induced recognition deficits measured by the NOR test provide good face 
validity for the cognitive deficits associated with schizophrenia on the basis that 
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schizophrenia patients demonstrate impairments in a 2D-visual object recognition 
task (Tek et al, 2002). 
In an attempt to provide further validation of and to explore the reliability of the 
NOR test to detect cognitive deficits associated with schizophrenia, it was important 
to assess object recognition memory in isolation reared rats; another model with 
translational relevance to some of the core symptoms of schizophrenia. Results are 
consistent with previous studies (Bianchi et al, 2006) demonstrating that isolation 
rearing of rats from weaning produced ITI dependent deficits in NOR when 
compared to social controls i.e. isolation reared rats could discriminate between 
novel and familiar objects up to ITIs of 3.5 h compared to 5 h in the social controls. 
The NOR deficits induced by isolation rearing were not comparable to the sub-
chronic PCP-induced recognition deficits following a much shorter ITI of 1 min. A 
study by Jones et al (1990) may help to explain these differences; isolation reared 
rats were less susceptible to disruptions such as reduction in stimulus lights or the 
introduction of distracting stimulus during the acquisition of a conditional visual 
discrimination task. Therefore, the lack of NOR deficit observed in the isolation 
reared rats following a 1 min ITI could be explained by the resistance to distraction 
during the ITI; an opposite effect is observed following sub-chronic PCP treatment. 
Additionally, it may be suggested that sub-chronic PCP may induce greater 
neurophysiological disruptions compared to isolation rearing in rats and therefore 
demonstrate more powerful object recognition deficits in the NOR test. 
An essential feature of an animal model of a human disease is the predictive validity. 
The predictive validity of any cognitive test will be limited by the quality of the 
rodent model and the degree to which they reproduce the biological basis of the 
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cognitive impairments associated with the disease state being modelled.  Therefore, 
if the NOR test is to be classed as an important screening paradigm then it is 
imperative that the NOR test can detect compounds that demonstrate efficacy in the 
clinic and not generate false positives by detecting compounds that would not show 
efficacy in the clinic. Many genetic, pharmacological and environmental 
manipulations, thought to model aspects of cognitive dysfunction associated with 
schizophrenia have demonstrated impairments in the NOR test. Importantly, a 
number of pharmacological agents of relevance to therapy of schizophrenia have 
been shown the restore the cognitive deficits (see review by Lyon et al, 2011). 
 In chapter 5, a selection of agents with diverse pharmacology and mechanisms of 
action were selected to elucidate the potential of the sub-chronic PCP-induced 
cognitive deficit measured in the NOR test as a useful preclinical model for detection 
of novel pro-cognitive agents for the treatment of cognitive impairments in 
schizophrenia. Results in chapter 5 reveal that atypical agent’s clozapine and 
risperidone but not the classical antipsychotic agent’s haloperidol and fluphenazine 
were effective in reversing the sub-chronic PCP-induced impairment. These data are 
consistent with some studies in the clinic (Keefe et al, 2007). Unfortunately, the 
CATIE study which compared four atypical antipsychotics to the classical agent 
perphenazine in over 1400 schizophrenia patients revealed that, although all drugs 
improved cognition minimally, no difference between atypicals and classical 
antipsychotics with respect to cognition was observed. The wake promoting agent 
modafinil licensed to treat the symptoms of narcolepsy has demonstrated some 
positive results in enhancing performance in several domains of cognition but can 
also exacerbate the positive symptoms in some schizophrenia patients (see review by 
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Morein-Zamir et al, 2007). Results presented in this thesis demonstrate that 
modafinil was effective at restoring the sub-chronic PCP-induced cognitive deficit in 
the NOR test which provides support for the clinical data and the predictive validity 
for the combination of the NOR test and sub-chronic PCP treatment regimen. 
Furthermore, additional predictive validity was demonstrated when the SSRI 
fluoxetine, licensed to treat depression and the anxiolytic, benzodiazepine 
chlordiazepoxide were ineffective in ameliorating the NOR deficits induced by sub-
chronic PCP. Negative controls were used to confirm that the sub-chronic PCP 
treatment regimen in combination with the NOR test is not detecting any unrelated 
effects and therefore minimises the risk of detecting false positives in the future. The 
results in this thesis outline the importance of assessing the effects of negative 
controls when validating animal models of human disease. 
The α7-nAChR receptor has been selected as a most important target for drug 
development by the MATRICS initiative (Decker et al, 2008).  In clinical trials, 
nicotine and the selective α7-nicotinic receptor agonists have produced the most 
convincing improvements cognition in schizophrenia patients (see review by Lyons 
et al, 2011).  Furthermore, adjunct treatment with galantamine a positive allosteric 
modulator of the α7-nicotinic receptor and AChE inhibitor have been shown to 
improve the negative and cognitive symptoms of schizophrenia (Schilstrom et al, 
2007), although few studies measured visual memory. Unfortunately, despite these 
initial positive findings, subsequent results with galantamine have been mixed (Gray 
& Roth, 2007).  PNU-120596, a selective positive allosteric modulator of the α7-
nicotinic receptor has demonstrated efficacy to improve sub-chronic PCP-induced 
cognitive deficits in attentional set-shifting; an animal model selected by the TURNS 
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initiative as a test that can be used to determine the problem solving deficits 
described in the MATRICS cognitive battery (McLean et al, 2011). Results from 
data presented in this thesis show that both activation and modulation of the α7-
nicotinic receptor by PNU-282987 and PNU-120596 improve the sub-chronic PCP-
induced deficit in NOR.  These data are supported by the recent phase 2b clinical 
trials, whereby the α7-nicotinic receptor agonist; EVP-6124 demonstrated efficacy to 
improve cognition in schizophrenia patients (Watertown, 2011). This demonstrates 
that alleviation of the sub-chronic PCP-induced NOR deficit in rats may have some 
useful predictive validity for detecting novel targets with efficacy for cognition in 
schizophrenia. 
Overall, it can be seen that some improvements in cognition have been reported in 
clinical trials using compounds that can also improve the recognition memory 
deficits in the NOR test observed following sub-chronic PCP treatment. The clinical 
improvements in cognition observed in schizophrenia patients following treatment 
with the same compounds that were efficacious to improve the sub-chronic PCP-
induced recognition deficits presented in this thesis are generally smaller. 
Unfortunately, the full reversal of the sub-chronic PCP-induced recognition memory 
deficits observed in the NOR test by acute treatment with some pharmacological 
agents, is not mirrored in the clinic. It is currently believed that exposure to a 
combination of risk genes and environmental factors early in life can, in the future, 
lead to the development of schizophrenia. It is therefore unlikely that 
pharmacological animal models, especially in the rat which are neurobiologically 
different from humans, can be expected to fully recapitulate all of the salient features 
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of a human mental illness and have perfect correspondence with respect to individual 
behavioral symptoms (Nestler & Hyman, 2010). 
Working memory dysfunction has emerged as the core cognitive domain of 
schizophrenia and other disorders. The preliminary results from this thesis suggest 
that the 16-holeboard maze may be a useful tool in measuring working memory 
deficits associated with schizophrenia.  The working memory aspect of this food 
rewarded paradigm holds information that is only relevant within a specific trial, 
such as a list of locations that have already been visited. To obtain a high working 
memory score in the 16-holeboard maze the rats must process the temporal context 
associated with an event i.e. “what happened and when did it happen” and remember 
which holes have already been visited in attempt to negotiate the spatial working 
memory aspect of this test. Acute administration of scopolamine, PCP, d-amph and 
sub-chronic PCP treatment resulted in the rats forgetting which food rewarded holes 
they had already visited, therefore, rats returned to empty, previously visited food-
baited holes. These impairments were expressed as reductions in working memory 
scores compared to controls. These initial studies may imply face validity of the 16-
holeboard maze to detect the working memory impairments observed in 
schizophrenia. 
8.2 Limitation of the NOR test 
The moderately low exploration times sometimes observed can reduce the value of 
the data obtained in the NOR test which may impact on drug effects in the retention 
trial. It has been suggested that using a low level of food deprivation may increase 
the amount of exploration during the test (see review by Lyon et al, 2011).  
290 
 
However, making these changes to the testing protocol will invariably introduce new 
problems. Food deprivation is a mild stressor and has been indicated to exert various 
effects on brain neurotransmitters and increase the levels of the dopamine metabolite 
3, 4-dihydroxyphenylacetic acid in the mPFC (Carlson et al, 1987).  Furthermore, 
behaviours and exploration levels of rats in the NOR test can be variable; this is 
because the test relies on the spontaneous behaviour of the rats to explore the novel 
and familiar objects.  
In the pharmacology section (chapter 5), careful single dose selections were made 
based on previous studies in our laboratory and the available literature. However, 
single dose pharmacology is not ideal and is a limitation of the test. If animal 
numbers had allowed, it would have been preferable to test full dose ranges of all 
compounds. 
8.3 Future studies using the NOR test 
Detailed in-vivo microdialysis studies would allow a better understanding of the 
neurotransmitter alterations following sub-chronic PCP treatment during the NOR 
test. Furthermore, the examination of neurotransmitter levels in rats during the 
restoration of sub-chronic PCP induced recognition memory deficits by various 
pharmacological agents would provide valuable information on the mechanism of 
action of the potential pro-cognitive agents. 
Since the effects of pro-cognitive compounds provide complete restoration of sub-
chronic PCP-induced recognition memory deficits, it would be very useful to 
develop a recognition memory deficit in the NOR test that was more difficult to 
reverse. This could be achieved by combining two separate procedures that are 
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known to induce cognitive deficits of relevance to schizophrenia; sub-chronic PCP 
treatment and prefrontal cortex lesions (Schwabe et al, 2006). 
8.4 Limitations of the 16-holeboard maze 
The somewhat small differences in working memory scores between control and 
drug–induced reductions in working memory scores means the available window of 
improvement is narrow. This is a limitation of the test and would need addressing if 
pharmacological reversals of impairments were to be detected and measured i.e. if 
the test was to be used routinely to detect novel cognitive enhancers. The number 
and pattern of baited holes could be increased in attempt to make the test more 
difficult and thus induce more errors. However, this would probably increase the 
training time to attain a high WMS baseline.   
8.5 Future studies using the 16-holeboard maze. 
Further pilot and validation studies are necessary to provide evidence for the 
predictive validity of the 16-holeboard maze. As in the NOR experiments presented 
in this thesis, pharmacological agents that have demonstrated positive effects on 
working memory in schizophrenia patients would need to be assessed to provide the 
necessary evidence to determine the predictive validity of the test.   
Learning of the 16-holeboard test has been shown to be dependent on the 
hippocampus, hippocampal afferents and VTA (Oades et al, 1981, 1982), however, 
specific brain lesion studies would be important to determine which region is 
involved in the sub-chronic PCP-induced working memory deficits following the 
training period of the test. 
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8.6 Conclusions 
Results from the data presented in this thesis demonstrate the importance of carrying 
out preliminary validation studies and shows the processes that contribute towards 
increasing the validity of animal tests of cognition. The initial analysis of 
behavioural parameters revealed that there was an object preference with the wooden 
block being preferred, explored more than any other object. Clearly if we had not 
carried out this preliminary experiment, and used this object, some of our data would 
have been biased. Initial studies also showed that sub-chronic PCP treated rats 
successfully encoded object information in the acquisition trial and that males were 
less sensitive to the impairments in recognition memory induced by acute d-
amphetamine, acute PCP and most importantly for these studies, by the sub-chronic 
PCP treatment regimen compared with females. The data suggest that the sub-
chronic PCP dosing regime in female rats is superior in mimicking the cognitive 
deficits observed in schizophrenia, compared to acute treatments with d-
amphetamine and PCP. Further validation demonstrated the ability of the NOR test 
to detect isolation rearing induced-recognition memory deficits, which is another 
model of relevance to schizophrenia symptomatology. 
Pharmacological studies using both positive and negative controls are vitally 
important when validating an animal model. Results demonstrated that sub-chronic 
PCP in combination with the NOR test induces recognition memory deficits that are 
highly robust, reproducible with ability to detect compounds that show some clinical 
efficacy to improve cognition in schizophrenia patients and importantly does not 
detect agents that do not have efficacy to improve cognition. These results suggest 
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that the sub-chronic PCP deficits in the NOR test has the potential to predict the 
clinical response to potential novel pro-cognitive enhancers. 
 It is essential when detecting the efficacy of potential cognitive enhancers that 
differential domains of cognitive impairments related to schizophrenia can be 
measured, NOR only measures visual recognition memory. With further validation, 
the 16-holeboard maze may provide a useful tool to assess the working memory 
deficits associated with schizophrenia. 
In summary, the sub-chronic PCP dosing regimen in female Hooded-Lister rats can 
mimic certain cognitive deficits of schizophrenia. When used in combination with 
the NOR test and the 16-holeboard maze, this provides a relatively valid animal 
model of recognition and working memory. Further studies are clearly required to 
refine the PCP model and to explore further behavioural tests of cognition in order to 
encompass all the domains affected in this and other disorders. 
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